The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
Laboratory tests for evaluating the individual's clotting mechanism.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.
Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
A fibrin-stabilizing plasma enzyme (TRANSGLUTAMINASES) that is activated by THROMBIN and CALCIUM to form FACTOR XIIIA. It is important for stabilizing the formation of the fibrin polymer (clot) which culminates the coagulation cascade.
The time required by whole blood to produce a visible clot.
Activated form of factor XI. In the intrinsic pathway, Factor XI is activated to XIa by factor XIIa in the presence of cofactor HMWK; (HIGH MOLECULAR WEIGHT KININOGEN). Factor XIa then activates factor IX to factor IXa in the presence of calcium.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
The natural enzymatic dissolution of FIBRIN.
Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
Agents that cause clotting.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
Activated form of factor IX. This activation can take place via the intrinsic pathway by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X.
Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.
Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
Activated form of factor XII. In the initial event in the intrinsic pathway of blood coagulation, kallikrein (with cofactor HIGH MOLECULAR WEIGHT KININOGEN) cleaves factor XII to XIIa. Factor XIIa is then further cleaved by kallikrein, plasmin, and trypsin to yield smaller factor XII fragments (Hageman-Factor fragments). These fragments increase the activity of prekallikrein to kallikrein but decrease the procoagulant activity of factor XII.
Agents that prevent clotting.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
Any liquid used to replace blood plasma, usually a saline solution, often with serum albumins, dextrans or other preparations. These substances do not enhance the oxygen- carrying capacity of blood, but merely replace the volume. They are also used to treat dehydration.
Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III.
Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C.
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
A hereditary deficiency of blood coagulation factor XI (also known as plasma thromboplastin antecedent or PTA or antihemophilic factor C) resulting in a systemic blood-clotting defect called hemophilia C or Rosenthal's syndrome, that may resemble classical hemophilia.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
An absence or reduced level of blood coagulation factor XII. It normally occurs in the absence of patient or family history of hemorrhagic disorders and is marked by prolonged clotting time.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Activated form of factor VIII. The B-domain of factor VIII is proteolytically cleaved by thrombin to form factor VIIIa. Factor VIIIa exists as a non-covalent dimer in a metal-linked (probably calcium) complex and functions as a cofactor in the enzymatic activation of factor X by factor IXa. Factor VIIIa is similar in structure and generation to factor Va.
Formation and development of a thrombus or blood clot in the blood vessel.
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
Activated form of factor V. It is an essential cofactor for the activation of prothrombin catalyzed by factor Xa.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
A cell surface glycoprotein of endothelial cells that binds thrombin and serves as a cofactor in the activation of protein C and its regulation of blood coagulation.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
Found in various tissues, particularly in four blood-clotting proteins including prothrombin, in kidney protein, in bone protein, and in the protein present in various ectopic calcifications.
The most common mineral of a group of hydrated aluminum silicates, approximately H2Al2Si2O8-H2O. It is prepared for pharmaceutical and medicinal purposes by levigating with water to remove sand, etc. (From Merck Index, 11th ed) The name is derived from Kao-ling (Chinese: "high ridge"), the original site. (From Grant & Hackh's Chemical Dictionary, 5th ed)
The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.
A method of tissue ablation and bleeding control that uses ARGON plasma (ionized argon gas) to deliver a current of thermocoagulating energy to the area of tissue to be coagulated.
A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)
Hemorrhagic and thrombotic disorders that occur as a consequence of inherited abnormalities in blood coagulation.
Absence or reduced levels of PROTHROMBIN in the blood.
Hemorrhagic and thrombotic disorders resulting from abnormalities or deficiencies of coagulation proteins.
A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease.
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A nutritional condition produced by a deficiency of VITAMIN K in the diet, characterized by an increased tendency to hemorrhage (HEMORRHAGIC DISORDERS). Such bleeding episodes may be particularly severe in newborn infants. (From Cecil Textbook of Medicine, 19th ed, p1182)
A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.
A family of snakes comprising three subfamilies: Azemiopinae (the mountain viper, the sole member of this subfamily), Viperinae (true vipers), and Crotalinae (pit vipers). They are widespread throughout the world, being found in the United States, Central and South America, Europe, Asia and Africa. Their venoms act on the blood (hemotoxic) as compared to the venom of elapids which act on the nervous system (neurotoxic). (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, pp333-36)
Transglutaminases catalyze cross-linking of proteins at a GLUTAMINE in one chain with LYSINE in another chain. They include keratinocyte transglutaminase (TGM1 or TGK), tissue transglutaminase (TGM2 or TGC), plasma transglutaminase involved with coagulation (FACTOR XIII and FACTOR XIIIa), hair follicle transglutaminase, and prostate transglutaminase. Although structures differ, they share an active site (YGQCW) and strict CALCIUM dependence.
The use of green light-producing LASERS to stop bleeding. The green light is selectively absorbed by HEMOGLOBIN, thus triggering BLOOD COAGULATION.
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
Bleeding or escape of blood from a vessel.
A 3.5 per cent colloidal solution containing urea-cross-linked polymerized peptides. It has a molecular weight of approximately 35,000 and is prepared from gelatin and electrolytes. The polymeric solution is used as a plasma expander.
The rate dynamics in chemical or physical systems.
Proteins prepared by recombinant DNA technology.
Procedures using an electrically heated wire or scalpel to treat hemorrhage (e.g., bleeding ulcers) and to ablate tumors, mucosal lesions, and refractory arrhythmias. It is different from ELECTROSURGERY which is used more for cutting tissue than destroying and in which the patient is part of the electric circuit.
A family of ark shell mollusks, in the class BIVALVIA. They have soft bodies with platelike GILLS enclosed within two shells hinged together.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin.
An autosomal recessive characteristic or a coagulation disorder acquired in association with VITAMIN K DEFICIENCY. FACTOR VII is a Vitamin K dependent glycoprotein essential to the extrinsic pathway of coagulation.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Physiologically inactive substances that can be converted to active enzymes.
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
Endogenous peptides present in most body fluids. Certain enzymes convert them to active KININS which are involved in inflammation, blood clotting, complement reactions, etc. Kininogens belong to the cystatin superfamily. They are cysteine proteinase inhibitors. HIGH-MOLECULAR-WEIGHT KININOGEN; (HMWK); is split by plasma kallikrein to produce BRADYKININ. LOW-MOLECULAR-WEIGHT KININOGEN; (LMWK); is split by tissue kallikrein to produce KALLIDIN.
Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes.
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
A peptidohydrolytic enzyme that is formed from PREKALLIKREIN by FACTOR XIIA. It activates FACTOR XII; FACTOR VII; and PLASMINOGEN. It is selective for both ARGININE and to a lesser extent LYSINE bonds. EC 3.4.21.34.
Limbless REPTILES of the suborder Serpentes.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
Enzymes that catalyze the joining of two molecules by the formation of a carbon-carbon bond. These are the carboxylating enzymes and are mostly biotinyl-proteins. EC 6.4.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
A thrombin receptor subtype that couples to HETEROTRIMERIC GTP-BINDING PROTEINS resulting in the activation of a variety of signaling mechanisms including decreased intracellular CYCLIC AMP, increased TYPE C PHOSPHOLIPASES and increased PHOSPHOLIPASE A2.
A plant genus of the family MORACEAE. Puag-haad extract, from A. lakoocha, contains STILBENES and related 4-substituted RESORCINOLS.
Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.
GLYCOSPHINGOLIPIDS with a sulfate group esterified to one of the sugar groups.
Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent.
Activated form of FACTOR XIII, a transglutaminase, which stabilizes the formation of the fibrin polymer (clot) culminating the blood coagulation cascade.
Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits.
Amidines substituted with a benzene group. Benzamidine and its derivatives are known as peptidase inhibitors.
An arthropod subclass (Xiphosura) comprising the North American (Limulus) and Asiatic (Tachypleus) genera of horseshoe crabs.
Elements of limited time intervals, contributing to particular results or situations.
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
A family of proteinase-activated receptors that are specific for THROMBIN. They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. Activation of thrombin receptors occurs through the proteolytic action of THROMBIN, which cleaves the N-terminal peptide from the receptor to reveal a new N-terminal peptide that is a cryptic ligand for the receptor. The receptors signal through HETEROTRIMERIC GTP-BINDING PROTEINS. Small synthetic peptides that contain the unmasked N-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.
Venoms from snakes of the subfamily Crotalinae or pit vipers, found mostly in the Americas. They include the rattlesnake, cottonmouth, fer-de-lance, bushmaster, and American copperhead. Their venoms contain nontoxic proteins, cardio-, hemo-, cyto-, and neurotoxins, and many enzymes, especially phospholipases A. Many of the toxins have been characterized.
Proteins synthesized by organisms belonging to the phylum ARTHROPODA. Included in this heading are proteins from the subdivisions ARACHNIDA; CRUSTACEA; and HORSESHOE CRABS. Note that a separate heading for INSECT PROTEINS is listed under this heading.
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
A fused four ring compound occurring free or combined in galls. Isolated from the kino of Eucalyptus maculata Hook and E. Hemipholia F. Muell. Activates Factor XII of the blood clotting system which also causes kinin release; used in research and as a dye.
Inflammation of a vein associated with a blood clot (THROMBUS).
Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.
Hormones produced by invertebrates, usually insects, mollusks, annelids, and helminths.
The sum of the weight of all the atoms in a molecule.
Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.
Solutions or mixtures of toxic and nontoxic substances elaborated by snake (Ophidia) salivary glands for the purpose of killing prey or disabling predators and delivered by grooved or hollow fangs. They usually contain enzymes, toxins, and other factors.
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
A family of soil bacteria. It also includes some parasitic forms.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
The process whereby PLATELETS adhere to something other than platelets, e.g., COLLAGEN; BASEMENT MEMBRANE; MICROFIBRILS; or other "foreign" surfaces.
A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.
Arginine derivative which is a substrate for many proteolytic enzymes. As a substrate for the esterase from the first component of complement, it inhibits the action of C(l) on C(4).
A class of receptors that are activated by the action of PROTEINASES. The most notable examples are the THROMBIN RECEPTORS. The receptors contain cryptic ligands that are exposed upon the selective proteolysis of specific N-terminal cleavage sites.
Venoms from SNAKES of the viperid family. They tend to be less toxic than elapid or hydrophid venoms and act mainly on the vascular system, interfering with coagulation and capillary membrane integrity and are highly cytotoxic. They contain large amounts of several enzymes, other factors, and some toxins.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
An infant born at or after 42 weeks of gestation.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
A genus of snakes of the family VIPERIDAE. It is distributed in West Pakistan, most of India, Burma, Ceylon, Thailand, southeast China, Taiwan, and a few islands of Indonesia. It hisses loudly when disturbed and strikes with great force and speed. Very prolific, it gives birth to 20-60 young. This viper is the leading cause of snakebite in India and Burma. (Moore: Poisonous Snakes of the World, 1980, p127)
Poisonous animal secretions forming fluid mixtures of many different enzymes, toxins, and other substances. These substances are produced in specialized glands and secreted through specialized delivery systems (nematocysts, spines, fangs, etc.) for disabling prey or predator.
Substances that display the physical properties of ELASTICITY and VISCOSITY. The dual-nature of these substances causes them to resist applied forces in a time-dependent manner.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
The formation or presence of a blood clot (THROMBUS) within a vein.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Linear polymers in which orthophosphate residues are linked with energy-rich phosphoanhydride bonds. They are found in plants, animals, and microorganisms.
A genus of venomous snakes of the subfamily Crotalinae. Twelve species of this genus are found in North and Central America and Asia. Agkistrodon contortrix is the copperhead, A. piscivorus, the cottonmouth. The former is named for its russet or orange-brown color, the latter for the white interior of its mouth. (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, p336; Moore, Poisonous Snakes of the World, 1980, p75)
A clinical condition resulting from repeated physical and psychological injuries inflicted on a child by the parents or caregivers.
Extracellular vesicles generated by the shedding of CELL MEMBRANE blebs.
Important modulators of the activity of plasminogen activators. The inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
A genus of poisonous snakes of the VIPERIDAE family. About 50 species are known and all are found in tropical America and southern South America. Bothrops atrox is the fer-de-lance and B. jararaca is the jararaca. (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, p336)
Proteins and peptides found in SALIVA and the SALIVARY GLANDS. Some salivary proteins such as ALPHA-AMYLASES are enzymes, but their composition varies in different individuals.
A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
The coagulation of tissue by an intense beam of light, including laser (LASER COAGULATION). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, hemorrhages, and malignant and benign neoplasms. (Dictionary of Visual Science, 3d ed)
A genus of leguminous shrubs or trees, mainly tropical, yielding useful compounds such as ALKALOIDS and PLANT LECTINS.
The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA.
A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
The study of fluid channels and chambers of tiny dimensions of tens to hundreds of micrometers and volumes of nanoliters or picoliters. This is of interest in biological MICROCIRCULATION and used in MICROCHEMISTRY and INVESTIGATIVE TECHNIQUES.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
A deficiency or absence of FIBRINOGEN in the blood.
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.
A sulfated pentosyl polysaccharide with heparin-like properties.
A product formed from skin, white connective tissue, or bone COLLAGEN. It is used as a protein food adjuvant, plasma substitute, hemostatic, suspending agent in pharmaceutical preparations, and in the manufacturing of capsules and suppositories.
OXIDOREDUCTASES which mediate vitamin K metabolism by converting inactive vitamin K 2,3-epoxide to active vitamin K.
A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Laboratory and other services provided to patients at the bedside. These include diagnostic and laboratory testing using automated information entry.
A group of simple proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish. Protamines contain very few kinds of amino acids. Protamine sulfate combines with heparin to form a stable inactive complex; it is used to neutralize the anticoagulant action of heparin in the treatment of heparin overdose. (From Merck Index, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p692)
Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
The degree of similarity between sequences of amino acids. This information is useful for the analyzing genetic relatedness of proteins and species.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
A group of substances similar to VITAMIN K 1 which contains a ring of 2-methyl-1,4-naphthoquinione and an isoprenoid side chain of varying number of isoprene units. In vitamin K 2, each isoprene unit contains a double bond. They are produced by bacteria including the normal intestinal flora.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
A foul-smelling diamine formed by bacterial decarboxylation of lysine.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A salt used to replenish calcium levels, as an acid-producing diuretic, and as an antidote for magnesium poisoning.
A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
Family of calcium- and phospholipid-binding proteins which are structurally related and exhibit immunological cross-reactivity. Each member contains four homologous 70-kDa repeats. The annexins are differentially distributed in vertebrate tissues (and lower eukaryotes) and appear to be involved in MEMBRANE FUSION and SIGNAL TRANSDUCTION.
The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
A deficiency of blood coagulation FACTOR XIII or fibrin stabilizing factor (FSF) that prevents blood clot formation and results in a clinical hemorrhagic diathesis.
Two-phase systems in which one is uniformly dispersed in another as particles small enough so they cannot be filtered or will not settle out. The dispersing or continuous phase or medium envelops the particles of the discontinuous phase. All three states of matter can form colloids among each other.
Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein.
Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.
A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Peptides composed of between two and twelve amino acids.
Control of bleeding during or after surgery.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.
Established cell cultures that have the potential to propagate indefinitely.
Chemical groups containing the covalent disulfide bonds -S-S-. The sulfur atoms can be bound to inorganic or organic moieties.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. (1/3556)

Assembly of ternary thrombin-heparin-fibrin complexes, formed when fibrin binds to exosite 1 on thrombin and fibrin-bound heparin binds to exosite 2, produces a 58- and 247-fold reduction in the heparin-catalyzed rate of thrombin inhibition by antithrombin and heparin cofactor II, respectively. The greater reduction for heparin cofactor II reflects its requirement for access to exosite 1 during the inhibitory process. Protection from inhibition by antithrombin and heparin cofactor II requires ligation of both exosites 1 and 2 because minimal protection is seen when exosite 1 variants (gamma-thrombin and thrombin Quick 1) or an exosite 2 variant (Arg93 --> Ala, Arg97 --> Ala, and Arg101 --> Ala thrombin) is substituted for thrombin. Likewise, the rate of thrombin inhibition by the heparin-independent inhibitor, alpha1-antitrypsin Met358 --> Arg, is decreased less than 2-fold in the presence of soluble fibrin and heparin. In contrast, thrombin is protected from inhibition by a covalent antithrombin-heparin complex, suggesting that access of heparin to exosite 2 of thrombin is hampered when ternary complex formation occurs. These results reveal the importance of exosites 1 and 2 of thrombin in assembly of the ternary complex and the subsequent protection of thrombin from inhibition by heparin-catalyzed inhibitors.  (+info)

Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. (2/3556)

BACKGROUND: Coronary endothelial dysfunction after brief ischemia-reperfusion (IR) remains a clinical problem. We investigated the role of heparin and N-acetylheparin, a nonanticoagulant heparin derivative, in modulating coronary endothelial function after IR injury, with an emphasis on defining the role of the nitric oxide (NO)-cGMP pathway in the heparin-mediated effect. METHODS AND RESULTS: Male mongrel dogs were surgically instrumented, and the effects of both bovine heparin and N-acetylheparin on coronary endothelial vasomotor function, expressed as percent change from baseline flow after acetylcholine challenge, were studied after 15 minutes of regional ischemia of the left anterior descending artery (LAD) followed by 120 minutes of reperfusion. In dogs treated with placebo (saline), coronary vasomotor function was significantly (P+info)

Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases. (3/3556)

Archetypal members of the chymotrypsin family of serine proteases, such as trypsin, chymotrypsin, and elastase, exhibit relatively broad substrate specificity. However, the successful development of efficient proteolytic cascades, such as the blood coagulation and fibrinolytic systems, required the evolution of proteases that displayed restricted specificity. Tissue-type plasminogen activator (t-PA), for example, possesses exquisitely stringent substrate specificity, and the molecular basis of this important biochemical property of t-PA remains obscure. Previous investigations of related serine proteases, which participate in the blood coagulation cascade, have focused attention on the residue that occupies position 192 (chymotrypsin numbering system), which plays a pivotal role in determining both the inhibitor and substrate specificity of these enzymes. Consequently, we created and characterized the kinetic properties of new variants of t-PA that contained point mutations at position 192. These studies demonstrated that, unlike in coagulation serine proteases, Gln-192 does not contribute significantly to the substrate or inhibitor specificity of t-PA in physiologically relevant reactions. Replacement of Gln-192 with a glutamic acid residue did, however, decrease the catalytic efficiency of mature, two-chain t-PA toward plasminogen in the absence of a fibrin co-factor.  (+info)

Age-related changes in blood coagulation and fibrinolysis in mice fed on a high-cholesterol diet. (4/3556)

To investigate the pathogenesis of hyperlipidemia-induced atherosclerosis, we examined age-dependent changes in platelet activity, blood coagulation and fibrinolysis in susceptibility to a high cholesterol diet (HCD) feeding in male ICR mice. Pretreatment of platelet-rich-plasma from HCD feeding mice for 3 days with epinephrine (300 microM) resulted in a marked enhancement of adenosine 5'-diphosphate (ADP: 0.1 microM) or collagen (0.7 microgram/ml)-stimulated aggregation compared with the same in control mice. Yohimbine as alpha 2-adrenergic blocker antagonized these aggregations in a dose-dependent manner. A significant increase in plasma total cholesterol and VLDL (very low-density lipoprotein)-LDL (low-density lipoprotein)-cholesterol and the liver/body weight ratio was observed in mice fed on HCD for 3 months (3-month HCD mice). In the early phase of this experiment, a significant increase in fibrinogen was observed. In the middle phase, increases in the activity of antithrombin III (ATIII) and alpha 2-plasmin inhibitor (alpha 2-Pl) followed. Plasminogen content gradually decreased in both normal diet and HCD mice throughout the experiment. The activity of plasminogen activator inhibitor (PAI) decreased in 3-month HCD mice. Morphological observation of the aortic arch from 3-month HCD mice revealed apparent atheromatous plaques not seen in control mice. These results suggest that 3-month HCD mice can be a convenient hyperlipidemia-induced atherosclerotic model and the changes in platelet activity, coagulation and fibrinolysis in the early phase may be a cause of pathologic changes in this model.  (+info)

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. (5/3556)

Plasminogen activator inhibitor type-1 (PAI-1) is a major physiological inhibitor of fibrinolysis, with its plasma levels correlating with the risk for myocardial infarction and venous thrombosis. The regulation of PAI-1 transcription by endothelial cells (ECs), a major source of PAI-1, remains incompletely understood. Adipocytes also produce PAI-1, suggesting possible common regulatory pathways between adipocytes and ECs. Peroxisomal proliferator-activated receptor-gamma (PPAR)gamma is a ligand-activated transcription factor that regulates gene expression in response to various mediators such as 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2) and oxidized linoleic acid (9- and 13-HODE). The present study tested the hypotheses that human ECs express PPARgamma and that this transcriptional activator regulates PAI-1 expression in this cell type. We found that human ECs contain both PPARgamma mRNA and protein. Immunohistochemistry of human carotid arteries also revealed the presence of PPARgamma in ECs. Bovine ECs transfected with a PPAR response element (PPRE)-luciferase construct responded to stimulation by the PPARgamma agonist 15d-PGJ2 in a concentration-dependent manner, suggesting a functional PPARgamma in ECs. Treatment of human ECs with 15d-PGJ2, 9(S)-HODE, or 13(S)-HODE augmented PAI-1 mRNA and protein expression, whereas multiple PPARalpha activators did not change PAI-1 levels. Introduction of increasing amounts of a PPARgamma expression construct in human fibroblasts enhanced PAI-1 secretion from these cells in proportion to the amount of transfected DNA. Thus, ECs express functionally active PPARgamma that regulates PAI-1 expression in ECs. Our results establish a role for PPARgamma in the regulation of EC gene expression, with important implications for the clinical links between obesity and atherosclerosis.  (+info)

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. (6/3556)

The small molecule direct thrombin inhibitor L-374,087 was characterized across species in an in vitro activated partial thromboplastin clotting time (aPTT) assay and in vivo in rhesus monkey and dog thrombosis models. In vitro in rhesus, dog, and human plasma, L-374,087 concentrations eliciting 2-fold increases in aPTT were 0.25, 1.9, and 0.28 microM, respectively. In anesthetized rhesus monkeys, 300 microgram/kg bolus plus 12 microgram/kg/min and 300 microgram/kg bolus plus 30 microgram/kg/min L-374,087 i.v. infusions significantly reduced jugular vein thrombus extension, with both regimens limiting venous thrombus extension to 2-fold that of baseline thrombus mass compared with a 5-fold extension observed in the vehicle control group. Antithrombotic efficacy in the rhesus with the lower-dose regimen was achieved with 2.3- to 2.4-fold increases in aPTT and prothrombin time. In a conscious instrumented dog model of electrolytic vessel injury, the oral administration of two 10 mg/kg L-374,087 doses 12 h apart significantly reduced jugular vein thrombus mass, reduced the incidence of and delayed time to occlusive coronary artery thrombosis, and significantly reduced coronary artery thrombus mass and ensuing posterolateral myocardial infarct size. Antithrombotic efficacy in the dog was achieved with 1.6- to 2.0-fold increases in aPTT at 1 to 6 h after oral dosing with L-374,087. These results indicate significant antithrombotic efficacy against both venous and coronary arterial thrombosis with L-374,087 with only moderate elevations in aPTT or prothrombin time. The oral efficacy of L-374,087 characterizes this compound as a prototype for the further development of orally active direct thrombin inhibitors.  (+info)

Risk of clot formation in femoral arterial sheaths maintained overnight for neuroangiographic procedures. (7/3556)

BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the presence of blood clots in femoral arterial sheaths maintained after cerebral angiography and the effect of heparinized saline on clot formation. METHODS: Twenty-three sheaths were evaluated in 18 patients. Sheaths were maintained for 14 to 80 hours (average, 33 hours; median, 24 hours). After the sheaths were removed, they were vigorously flushed with 60 mL of normal saline and the number and size of clots found in each sheath were recorded. Additionally, patients' age, catheter size, presence of heparin, amount of time the sheath was kept in the artery, and patients' coagulation status were recorded. RESULTS: Clots were found in 17 (74%) of the 23 sheaths. Ten catheters had continuous heparin drip, of which seven (70%) sustained clots. Of the 13 sheaths without heparin, 10 sustained clots (77%). The difference was not statistically significant. The average number of clots was 2.2, and the maximal length of clots ranged from 0.5 to 105 mm. No thromboembolic complications associated with sheath placement were encountered in our patient population. CONCLUSION: Blood clots are present in the vast majority of intraarterial sheaths maintained after cerebral angiography. These clots constitute a risk of thromboembolic complications in the event of repeat angiography. Sheath exchange should be considered before obtaining repeat cerebral angiograms.  (+info)

Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. (8/3556)

BACKGROUND: Routine coagulation tests do not necessarily reflect haemostasis in vivo in cirrhotic patients, particularly those who have bleeding varices. Thrombelastography (TEG) can provide a global assessment of haemostatic function from initial clot formation to clot dissolution. AIM: To evaluate TEG changes in cirrhotic patients with variceal bleeding and their association with early rebleeding. PATIENTS/METHODS: Twenty cirrhotic patients with active variceal bleeding had serial TEG and routine coagulation tests daily for seven days. The TEG variables before the day of rebleeding (n = 6) were compared with those of patients without rebleeding (n = 14). RESULTS: Baseline characteristics of the rebleeding and non-rebleeding groups were comparable apart from a higher incidence of uncontrolled infection on the day of rebleeding in the rebleeding group (p = 0.007). The patients in the rebleeding group were more hypocoagulable before the day of rebleeding as shown by longer r (42 v 24 mm, p < 0.001) and k (48 v 13 mm, p < 0.001) and smaller a (12 v 38 degrees, p < 0.001) compared with the mean of daily results of the non-rebleeding group. Routine coagulation tests, however, showed no significant differences between the two groups. CONCLUSION: The results of serial TEG measurements suggest that hypocoagulability may be associated with early rebleeding in cirrhotic patients.  (+info)

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Blood coagulation factors, also known as clotting factors, are a group of proteins that play a crucial role in the blood coagulation process. They are essential for maintaining hemostasis, which is the body's ability to stop bleeding after injury.

There are 13 known blood coagulation factors, and they are designated by Roman numerals I through XIII. These factors are produced in the liver and are normally present in an inactive form in the blood. When there is an injury to a blood vessel, the coagulation process is initiated, leading to the activation of these factors in a specific order.

The coagulation cascade involves two pathways: the intrinsic and extrinsic pathways. The intrinsic pathway is activated when there is damage to the blood vessel itself, while the extrinsic pathway is activated by tissue factor released from damaged tissues. Both pathways converge at the common pathway, leading to the formation of a fibrin clot.

Blood coagulation factors work together in a complex series of reactions that involve activation, binding, and proteolysis. When one factor is activated, it activates the next factor in the cascade, and so on. This process continues until a stable fibrin clot is formed.

Deficiencies or abnormalities in blood coagulation factors can lead to bleeding disorders such as hemophilia or thrombosis. Hemophilia is a genetic disorder that affects one or more of the coagulation factors, leading to excessive bleeding and difficulty forming clots. Thrombosis, on the other hand, occurs when there is an abnormal formation of blood clots in the blood vessels, which can lead to serious complications such as stroke or pulmonary embolism.

Blood coagulation tests, also known as coagulation studies or clotting tests, are a series of medical tests used to evaluate the blood's ability to clot. These tests measure the functioning of various clotting factors and regulatory proteins involved in the coagulation cascade, which is a complex process that leads to the formation of a blood clot to prevent excessive bleeding.

The most commonly performed coagulation tests include:

1. Prothrombin Time (PT): Measures the time it takes for a sample of plasma to clot after the addition of calcium and tissue factor, which activates the extrinsic pathway of coagulation. The PT is reported in seconds and can be converted to an International Normalized Ratio (INR) to monitor anticoagulant therapy.
2. Activated Partial Thromboplastin Time (aPTT): Measures the time it takes for a sample of plasma to clot after the addition of calcium, phospholipid, and a contact activator, which activates the intrinsic pathway of coagulation. The aPTT is reported in seconds and is used to monitor heparin therapy.
3. Thrombin Time (TT): Measures the time it takes for a sample of plasma to clot after the addition of thrombin, which directly converts fibrinogen to fibrin. The TT is reported in seconds and can be used to detect the presence of fibrin degradation products or abnormalities in fibrinogen function.
4. Fibrinogen Level: Measures the amount of fibrinogen, a protein involved in clot formation, present in the blood. The level is reported in grams per liter (g/L) and can be used to assess bleeding risk or the effectiveness of fibrinogen replacement therapy.
5. D-dimer Level: Measures the amount of D-dimer, a protein fragment produced during the breakdown of a blood clot, present in the blood. The level is reported in micrograms per milliliter (µg/mL) and can be used to diagnose or exclude venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

These tests are important for the diagnosis, management, and monitoring of various bleeding and clotting disorders. They can help identify the underlying cause of abnormal bleeding or clotting, guide appropriate treatment decisions, and monitor the effectiveness of therapy. It is essential to interpret these test results in conjunction with a patient's clinical presentation and medical history.

Disseminated Intravascular Coagulation (DIC) is a complex medical condition characterized by the abnormal activation of the coagulation cascade, leading to the formation of blood clots in small blood vessels throughout the body. This process can result in the consumption of clotting factors and platelets, which can then lead to bleeding complications. DIC can be caused by a variety of underlying conditions, including sepsis, trauma, cancer, and obstetric emergencies.

The term "disseminated" refers to the widespread nature of the clotting activation, while "intravascular" indicates that the clotting is occurring within the blood vessels. The condition can manifest as both bleeding and clotting complications, which can make it challenging to diagnose and manage.

The diagnosis of DIC typically involves laboratory tests that evaluate coagulation factors, platelet count, fibrin degradation products, and other markers of coagulation activation. Treatment is focused on addressing the underlying cause of the condition while also managing any bleeding or clotting complications that may arise.

Blood coagulation disorders, also known as bleeding disorders or clotting disorders, refer to a group of medical conditions that affect the body's ability to form blood clots properly. Normally, when a blood vessel is injured, the body's coagulation system works to form a clot to stop the bleeding and promote healing.

In blood coagulation disorders, there can be either an increased tendency to bleed due to problems with the formation of clots (hemorrhagic disorder), or an increased tendency for clots to form inappropriately even without injury, leading to blockages in the blood vessels (thrombotic disorder).

Examples of hemorrhagic disorders include:

1. Hemophilia - a genetic disorder that affects the ability to form clots due to deficiencies in clotting factors VIII or IX.
2. Von Willebrand disease - another genetic disorder caused by a deficiency or abnormality of the von Willebrand factor, which helps platelets stick together to form a clot.
3. Liver diseases - can lead to decreased production of coagulation factors, increasing the risk of bleeding.
4. Disseminated intravascular coagulation (DIC) - a serious condition where clotting and bleeding occur simultaneously due to widespread activation of the coagulation system.

Examples of thrombotic disorders include:

1. Factor V Leiden mutation - a genetic disorder that increases the risk of inappropriate blood clot formation.
2. Antithrombin III deficiency - a genetic disorder that impairs the body's ability to break down clots, increasing the risk of thrombosis.
3. Protein C or S deficiencies - genetic disorders that lead to an increased risk of thrombosis due to impaired regulation of the coagulation system.
4. Antiphospholipid syndrome (APS) - an autoimmune disorder where the body produces antibodies against its own clotting factors, increasing the risk of thrombosis.

Treatment for blood coagulation disorders depends on the specific diagnosis and may include medications to manage bleeding or prevent clots, as well as lifestyle changes and monitoring to reduce the risk of complications.

Thromboplastin is a substance that activates the coagulation cascade, leading to the formation of a clot (thrombus). It's primarily found in damaged or injured tissues and blood vessels, as well as in platelets (thrombocytes). There are two types of thromboplastin:

1. Extrinsic thromboplastin (also known as tissue factor): This is a transmembrane glycoprotein that is primarily found in subendothelial cells and released upon injury to the blood vessels. It initiates the extrinsic pathway of coagulation by binding to and activating Factor VII, ultimately leading to the formation of thrombin and fibrin clots.
2. Intrinsic thromboplastin (also known as plasma thromboplastin or factor III): This term is used less frequently and refers to a labile phospholipid component present in platelet membranes, which plays a role in the intrinsic pathway of coagulation.

In clinical settings, the term "thromboplastin" often refers to reagents used in laboratory tests like the prothrombin time (PT) and activated partial thromboplastin time (aPTT). These reagents contain a source of tissue factor and calcium ions to initiate and monitor the coagulation process.

Factor Xa is a serine protease that plays a crucial role in the coagulation cascade, which is a series of reactions that lead to the formation of a blood clot. It is one of the activated forms of Factor X, a pro-protein that is converted to Factor Xa through the action of other enzymes in the coagulation cascade.

Factor Xa functions as a key component of the prothrombinase complex, which also includes calcium ions, phospholipids, and activated Factor V (also known as Activated Protein C or APC). This complex is responsible for converting prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Inhibitors of Factor Xa are used as anticoagulants in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. These drugs work by selectively inhibiting Factor Xa, thereby preventing the formation of the prothrombinase complex and reducing the risk of clot formation.

Prothrombin time (PT) is a medical laboratory test that measures the time it takes for blood to clot. It's often used to evaluate the functioning of the extrinsic and common pathways of the coagulation system, which is responsible for blood clotting. Specifically, PT measures how long it takes for prothrombin (a protein produced by the liver) to be converted into thrombin, an enzyme that converts fibrinogen into fibrin and helps form a clot.

Prolonged PT may indicate a bleeding disorder or a deficiency in coagulation factors, such as vitamin K deficiency or the use of anticoagulant medications like warfarin. It's important to note that PT is often reported with an international normalized ratio (INR), which allows for standardization and comparison of results across different laboratories and reagent types.

Factor VII, also known as proconvertin, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor VII is synthesized in the liver and is activated when it comes into contact with tissue factor, which is exposed when blood vessels are damaged. Activated Factor VII then activates Factor X, leading to the formation of thrombin and ultimately a fibrin clot.

Inherited deficiencies or dysfunctions of Factor VII can lead to an increased risk of bleeding, while elevated levels of Factor VII have been associated with an increased risk of thrombosis (blood clots).

Partial Thromboplastin Time (PTT) is a medical laboratory test that measures the time it takes for blood to clot. It's more specifically a measure of the intrinsic and common pathways of the coagulation cascade, which are the series of chemical reactions that lead to the formation of a clot.

The test involves adding a partial thromboplastin reagent (an activator of the intrinsic pathway) and calcium to plasma, and then measuring the time it takes for a fibrin clot to form. This is compared to a control sample, and the ratio of the two times is calculated.

The PTT test is often used to help diagnose bleeding disorders or abnormal blood clotting, such as hemophilia or disseminated intravascular coagulation (DIC). It can also be used to monitor the effectiveness of anticoagulant therapy, such as heparin. Prolonged PTT results may indicate a bleeding disorder or an increased risk of bleeding, while shortened PTT results may indicate a hypercoagulable state and an increased risk of thrombosis.

Factor X is a protein that is essential for blood clotting, also known as coagulation. It is an enzyme that plays a crucial role in the coagulation cascade, which is a series of chemical reactions that lead to the formation of a blood clot. Factor X is activated by one of two pathways: the intrinsic pathway, which is initiated by damage to the blood vessels, or the extrinsic pathway, which is triggered by the release of tissue factor from damaged cells. Once activated, Factor X converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Inherited deficiencies in Factor X can lead to bleeding disorders, while increased levels of Factor X have been associated with an increased risk of thrombosis or blood clots. Therefore, maintaining appropriate levels of Factor X is important for the proper balance between bleeding and clotting in the body.

Prothrombin is a protein present in blood plasma, and it's also known as coagulation factor II. It plays a crucial role in the coagulation cascade, which is a complex series of reactions that leads to the formation of a blood clot.

When an injury occurs, the coagulation cascade is initiated to prevent excessive blood loss. Prothrombin is converted into its active form, thrombin, by another factor called factor Xa in the presence of calcium ions, phospholipids, and factor Va. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a stable clot.

Prothrombin levels can be measured through a blood test, which is often used to diagnose or monitor conditions related to bleeding or coagulation disorders, such as liver disease or vitamin K deficiency.

Factor IX is also known as Christmas factor, which is a protein that plays a crucial role in the coagulation cascade, a series of chemical reactions that leads to the formation of a blood clot. It is one of the essential components required for the proper functioning of the body's natural blood-clotting mechanism.

Factor IX is synthesized in the liver and activated when it comes into contact with an injured blood vessel. Once activated, it collaborates with other factors to convert factor X to its active form, which then converts prothrombin to thrombin. Thrombin is responsible for converting fibrinogen to fibrin, forming a stable fibrin clot that helps stop bleeding and promote healing.

Deficiencies in Factor IX can lead to hemophilia B, a genetic disorder characterized by prolonged bleeding and an increased risk of spontaneous bleeding. Hemophilia B is inherited in an X-linked recessive pattern, meaning it primarily affects males, while females serve as carriers of the disease. Treatment for hemophilia B typically involves replacing the missing or deficient Factor IX through infusions to prevent or manage bleeding episodes.

Thromboelastography (TEG) is a viscoelastic method used to assess the kinetics of clot formation, clot strength, and fibrinolysis in whole blood. It provides a global assessment of hemostasis by measuring the mechanical properties of a clot as it forms and dissolves over time. The TEG graph displays several parameters that reflect the different stages of clotting, including reaction time (R), clot formation time (K), angle of clot formation (α), maximum amplitude (MA), and percentage lysis at 30 minutes (LY30). These parameters can help guide transfusion therapy and inform decisions regarding the management of coagulopathy in various clinical settings, such as trauma, cardiac surgery, liver transplantation, and obstetrics.

Factor VIIa is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor VIIa is the activated form of factor VII, which is normally activated by tissue factor (TF) when there is damage to the blood vessels. Together, TF and Factor VIIa convert Factor X to its active form, Factor Xa, which then converts prothrombin to thrombin, leading to the formation of a fibrin clot.

In summary, Factor VIIa is an important protein in the coagulation cascade that helps to initiate the formation of a blood clot in response to injury.

Thrombin is a serine protease enzyme that plays a crucial role in the coagulation cascade, which is a complex series of biochemical reactions that leads to the formation of a blood clot (thrombus) to prevent excessive bleeding during an injury. Thrombin is formed from its precursor protein, prothrombin, through a process called activation, which involves cleavage by another enzyme called factor Xa.

Once activated, thrombin converts fibrinogen, a soluble plasma protein, into fibrin, an insoluble protein that forms the structural framework of a blood clot. Thrombin also activates other components of the coagulation cascade, such as factor XIII, which crosslinks and stabilizes the fibrin network, and platelets, which contribute to the formation and growth of the clot.

Thrombin has several regulatory mechanisms that control its activity, including feedback inhibition by antithrombin III, a plasma protein that inactivates thrombin and other serine proteases, and tissue factor pathway inhibitor (TFPI), which inhibits the activation of factor Xa, thereby preventing further thrombin formation.

Overall, thrombin is an essential enzyme in hemostasis, the process that maintains the balance between bleeding and clotting in the body. However, excessive or uncontrolled thrombin activity can lead to pathological conditions such as thrombosis, atherosclerosis, and disseminated intravascular coagulation (DIC).

Factor XIII, also known as fibrin stabilizing factor, is a protein involved in the clotting process of blood. It is a transglutaminase enzyme that cross-links fibrin molecules to form a stable clot. Factor XIII becomes activated during the coagulation cascade, and its activity helps strengthen the clot and protect it from premature degradation by proteolytic enzymes. A deficiency in Factor XIII can lead to a bleeding disorder characterized by prolonged bleeding after injury or surgery.

Whole Blood Coagulation Time (WBCT) is not a standard term used in medical literature. However, I believe you may be referring to "bleeding time" or "coagulation time" which are tests used to evaluate the function of the blood's clotting system.

Bleeding time is a measure of how long it takes for bleeding to stop after a small cut is made in the skin. It helps assess the function of the platelets and the smaller blood vessels.

Coagulation time, on the other hand, measures the time it takes for a larger clot to form in whole blood. This test is not commonly used in clinical practice.

It's important to note that these tests have largely been replaced by more specific coagulation tests, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), which provide more detailed information about the different components of the clotting system.

Factor XIa is a serine protease enzyme that plays a crucial role in blood coagulation. It is formed through the activation of Factor XI, which is one of the key components in the intrinsic pathway of the coagulation cascade. The activation of Factor XI to Factor XIa occurs via either autoactivation or through the action of thrombin. Once activated, Factor XIa can cleave and activate Factor IX, leading to the formation of Factor IXa, which further amplifies the coagulation cascade.

In summary, Factor XIa is a vital enzyme in the blood coagulation process, contributing to the formation of a stable fibrin clot that helps prevent excessive bleeding during injury or trauma.

Factor VIII is a protein in the blood that is essential for normal blood clotting. It is also known as antihemophilic factor (AHF). Deficiency or dysfunction of this protein results in hemophilia A, a genetic disorder characterized by prolonged bleeding and easy bruising. Factor VIII works together with other proteins to help form a clot and stop bleeding at the site of an injury. It acts as a cofactor for another clotting factor, IX, in the so-called intrinsic pathway of blood coagulation. Intravenous infusions of Factor VIII concentrate are used to treat and prevent bleeding episodes in people with hemophilia A.

Fibrinolysis is the natural process in the body that leads to the dissolution of blood clots. It is a vital part of hemostasis, the process that regulates bleeding and wound healing. Fibrinolysis occurs when plasminogen activators convert plasminogen to plasmin, an enzyme that breaks down fibrin, the insoluble protein mesh that forms the structure of a blood clot. This process helps to prevent excessive clotting and maintains the fluidity of the blood. In medical settings, fibrinolysis can also refer to the therapeutic use of drugs that stimulate this process to dissolve unwanted or harmful blood clots, such as those that cause deep vein thrombosis or pulmonary embolism.

Blood coagulation factor inhibitors are substances that interfere with the normal blood clotting process by inhibiting the function of coagulation factors. These inhibitors can be either naturally occurring or artificially produced.

Naturally occurring coagulation factor inhibitors include antithrombin, protein C, and tissue factor pathway inhibitor (TFPI). These inhibitors play a crucial role in regulating the coagulation cascade and preventing excessive clot formation.

Artificially produced coagulation factor inhibitors are used as therapeutic agents to treat thrombotic disorders. Examples include direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran, which selectively inhibit specific coagulation factors (factor Xa or thrombin).

Additionally, there are also antibodies that can act as coagulation factor inhibitors. These include autoantibodies that develop in some individuals and cause bleeding disorders such as acquired hemophilia A or antiphospholipid syndrome.

Coagulants are substances that promote the process of coagulation or clotting. They are often used in medical settings to help control bleeding and promote healing. Coagulants work by encouraging the formation of a clot, which helps to stop the flow of blood from a wound or cut.

There are several different types of coagulants that may be used in medical treatments. Some coagulants are naturally occurring substances, such as vitamin K, which is essential for the production of certain clotting factors in the body. Other coagulants may be synthetic or semi-synthetic compounds, such as recombinant activated factor VII (rFVIIa), which is used to treat bleeding disorders and prevent excessive bleeding during surgery.

Coagulants are often administered through injection or infusion, but they can also be applied topically to wounds or cuts. In some cases, coagulants may be used in combination with other treatments, such as compression or cauterization, to help control bleeding and promote healing.

It is important to note that while coagulants can be helpful in controlling bleeding and promoting healing, they can also increase the risk of blood clots and other complications. As a result, they should only be used under the guidance and supervision of a qualified healthcare professional.

Antithrombin III is a protein that inhibits the formation of blood clots (thrombi) in the body. It does this by inactivating several enzymes involved in coagulation, including thrombin and factor Xa. Antithrombin III is produced naturally by the liver and is also available as a medication for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to and neutralizing excess clotting factors in the bloodstream, thereby reducing the risk of clot formation.

Hemostasis is the physiological process that occurs to stop bleeding (bleeding control) when a blood vessel is damaged. This involves the interaction of platelets, vasoconstriction, and blood clotting factors leading to the formation of a clot. The ultimate goal of hemostasis is to maintain the integrity of the vascular system while preventing excessive blood loss.

Protein C is a vitamin K-dependent protease that functions as an important regulator of coagulation and inflammation. It is a plasma protein produced in the liver that, when activated, degrades clotting factors Va and VIIIa to limit thrombus formation and prevent excessive blood clotting. Protein C also has anti-inflammatory properties by inhibiting the release of pro-inflammatory cytokines and reducing endothelial cell activation. Inherited or acquired deficiencies in Protein C can lead to an increased risk of thrombosis, a condition characterized by abnormal blood clot formation within blood vessels.

Fibrinogen is a soluble protein present in plasma, synthesized by the liver. It plays an essential role in blood coagulation. When an injury occurs, fibrinogen gets converted into insoluble fibrin by the action of thrombin, forming a fibrin clot that helps to stop bleeding from the injured site. Therefore, fibrinogen is crucial for hemostasis, which is the process of stopping bleeding and starting the healing process after an injury.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the activation of Factor X to Factor Xa, which is a critical step in the coagulation cascade.

When blood vessels are damaged, the coagulation cascade is initiated to prevent excessive bleeding. During this process, Factor V is activated by thrombin, another protein involved in coagulation, and then forms a complex with activated Factor X and calcium ions on the surface of platelets or other cells. This complex converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Deficiency or dysfunction of Factor V can lead to bleeding disorders such as hemophilia B or factor V deficiency, while mutations in the gene encoding Factor V can increase the risk of thrombosis, as seen in the Factor V Leiden mutation.

Factor IXa is a protein that plays a crucial role in the coagulation cascade, which is a series of biochemical reactions involved in blood clotting. It is an activated form of Factor IX, which is one of the coagulation factors that help convert prothrombin to thrombin, leading to the formation of a fibrin clot and stopping bleeding at the site of injury.

Factor IXa works by activating Factor X in the presence of calcium ions, phospholipids, and Factor VIIIa, which is another activated coagulation factor. This complex is called the tenase complex. The activation of Factor X leads to the formation of thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Deficiencies or dysfunctions in Factor IXa can lead to bleeding disorders such as hemophilia B, also known as Christmas disease, which is characterized by prolonged bleeding times and spontaneous bleeding episodes.

Hydroxyethyl starch derivatives are modified starches that are used as plasma expanders in medicine. They are created by chemically treating corn, potato, or wheat starch with hydroxylethyl groups, which makes the starch more soluble and less likely to be broken down by enzymes in the body. This results in a large molecule that can remain in the bloodstream for an extended period, increasing intravascular volume and improving circulation.

These derivatives are available in different molecular weights and substitution patterns, which affect their pharmacokinetics and pharmacodynamics. They are used to treat or prevent hypovolemia (low blood volume) due to various causes such as bleeding, burns, or dehydration. Common brand names include Hetastarch, Pentastarch, and Voluven.

It's important to note that the use of hydroxyethyl starch derivatives has been associated with adverse effects, including kidney injury, coagulopathy, and pruritus (severe itching). Therefore, their use should be carefully monitored and restricted to specific clinical situations.

Thrombin time (TT) is a medical laboratory test that measures the time it takes for a clot to form after thrombin, an enzyme that converts fibrinogen to fibrin in the final step of the coagulation cascade, is added to a plasma sample. This test is used to evaluate the efficiency of the conversion of fibrinogen to fibrin and can be used to detect the presence of abnormalities in the coagulation system, such as the presence of heparin or dysfibrinogenemia. Increased thrombin time may indicate the presence of a systemic anticoagulant or a deficiency in fibrinogen.

Factor XIIa is a protease enzyme that plays a role in the coagulation cascade, which is the series of events that leads to blood clotting. It is formed when Factor XII, also known as Hageman factor, is activated by contact with negatively charged surfaces such as damaged endothelial cells or artificial surfaces like medical devices.

Once activated, Factor XIIa can activate other components of the coagulation cascade, including Factor XI, which ultimately leads to the formation of a fibrin clot. While Factor XIIa is an important part of the coagulation system, it is not essential for normal hemostasis (the process that stops bleeding) in humans, as people with deficiencies in Factor XII do not have an increased risk of bleeding. However, excessive activation of Factor XIIa has been implicated in several pathological conditions, including thrombosis and inflammation.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Fibrin is defined as a protein that is formed from fibrinogen during the clotting of blood. It plays an essential role in the formation of blood clots, also known as a clotting or coagulation cascade. When an injury occurs and bleeding starts, fibrin threads form a net-like structure that entraps platelets and red blood cells to create a stable clot, preventing further loss of blood.

The process of forming fibrin from fibrinogen is initiated by thrombin, another protein involved in the coagulation cascade. Thrombin cleaves fibrinogen into fibrin monomers, which then polymerize to form long strands of fibrin. These strands cross-link with each other through a process catalyzed by factor XIIIa, forming a stable clot that protects the wound and promotes healing.

It is important to note that abnormalities in fibrin formation or breakdown can lead to bleeding disorders or thrombotic conditions, respectively. Proper regulation of fibrin production and degradation is crucial for maintaining healthy hemostasis and preventing excessive clotting or bleeding.

Plasma substitutes are fluids that are used to replace the plasma volume in conditions such as hypovolemia (low blood volume) or plasma loss, for example due to severe burns, trauma, or major surgery. They do not contain cells or clotting factors, but they help to maintain intravascular volume and tissue perfusion. Plasma substitutes can be divided into two main categories: crystalloids and colloids.

Crystalloid solutions contain small molecules that can easily move between intracellular and extracellular spaces. Examples include normal saline (0.9% sodium chloride) and lactated Ringer's solution. They are less expensive and have a lower risk of allergic reactions compared to colloids, but they may require larger volumes to achieve the same effect due to their rapid distribution in the body.

Colloid solutions contain larger molecules that tend to stay within the intravascular space for longer periods, thus increasing the oncotic pressure and helping to maintain fluid balance. Examples include albumin, fresh frozen plasma, and synthetic colloids such as hydroxyethyl starch (HES) and gelatin. Colloids may be more effective in restoring intravascular volume, but they carry a higher risk of allergic reactions and anaphylaxis, and some types have been associated with adverse effects such as kidney injury and coagulopathy.

The choice of plasma substitute depends on various factors, including the patient's clinical condition, the underlying cause of plasma loss, and any contraindications or potential side effects of the available products. It is important to monitor the patient's hemodynamic status, electrolyte balance, and coagulation profile during and after the administration of plasma substitutes to ensure appropriate resuscitation and avoid complications.

Factor XII, also known as Hageman factor, is a protein that plays a role in the coagulation cascade, which is the series of events that leads to the formation of a blood clot. It is one of the zymogens, or inactive precursor proteins, that becomes activated and helps to trigger the coagulation process.

When Factor XII comes into contact with negatively charged surfaces, such as damaged endothelial cells or artificial surfaces like those found on medical devices, it undergoes a conformational change and becomes activated. Activated Factor XII then activates other proteins in the coagulation cascade, including Factor XI, which ultimately leads to the formation of a fibrin clot.

Deficiencies in Factor XII are generally not associated with bleeding disorders, as the coagulation cascade can still proceed through other pathways. However, excessive activation of Factor XII has been implicated in certain thrombotic disorders, such as deep vein thrombosis and disseminated intravascular coagulation (DIC).

Factor XI, also known as plasma thromboplastin antecedent (PTA) or antihemophilic factor C, is a protein involved in blood coagulation. It is one of the factors in the intrinsic pathway of coagulation, which is activated when blood comes into contact with negatively charged surfaces, such as damaged blood vessels.

When Factor XI is activated (usually by thrombin or activated Factor XII), it activates more Factor XI and also activates Factor IX, leading to the formation of a complex that converts Factor X to its active form, Factor Xa. This ultimately leads to the formation of a fibrin clot and helps to stop bleeding.

Deficiencies in Factor XI can lead to an increased risk of bleeding, although the severity of the bleeding disorder can vary widely among individuals with Factor XI deficiency. Treatment for Factor XI deficiency typically involves replacement therapy with fresh frozen plasma or recombinant Factor XI concentrate.

Vitamin K is a fat-soluble vitamin that plays a crucial role in blood clotting and bone metabolism. It is essential for the production of several proteins involved in blood clotting, including factor II (prothrombin), factor VII, factor IX, and factor X. Additionally, Vitamin K is necessary for the synthesis of osteocalcin, a protein that contributes to bone health by regulating the deposition of calcium in bones.

There are two main forms of Vitamin K: Vitamin K1 (phylloquinone), which is found primarily in green leafy vegetables and some vegetable oils, and Vitamin K2 (menaquinones), which is produced by bacteria in the intestines and is also found in some fermented foods.

Vitamin K deficiency can lead to bleeding disorders such as hemorrhage and excessive bruising. While Vitamin K deficiency is rare in adults, it can occur in newborns who have not yet developed sufficient levels of the vitamin. Therefore, newborns are often given a Vitamin K injection shortly after birth to prevent bleeding problems.

Factor XI deficiency, also known as Hemophilia C or Rosenthal syndrome, is a rare bleeding disorder caused by a deficiency or dysfunction of coagulation factor XI. This protease plays an important role in the intrinsic pathway of blood coagulation. Factor XI deficiency can lead to prolonged bleeding after surgery, trauma, or menstruation, but it typically does not cause spontaneous bleeding like Hemophilia A and B. The severity of the condition varies widely among affected individuals. Inheritance is autosomal recessive, meaning that two defective copies of the gene (one from each parent) are necessary to have the disease.

Antithrombins are substances that prevent the formation or promote the dissolution of blood clots (thrombi). They include:

1. Anticoagulants: These are medications that reduce the ability of the blood to clot. Examples include heparin, warfarin, and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran.
2. Thrombolytic agents: These are medications that break down existing blood clots. Examples include alteplase, reteplase, and tenecteplase.
3. Fibrinolytics: These are a type of thrombolytic agent that specifically target fibrin, a protein involved in the formation of blood clots.
4. Natural anticoagulants: These are substances produced by the body to regulate blood clotting. Examples include antithrombin III, protein C, and protein S.

Antithrombins are used in the prevention and treatment of various thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). It is important to note that while antithrombins can help prevent or dissolve blood clots, they also increase the risk of bleeding, so their use must be carefully monitored.

Factor XII deficiency, also known as Hageman factor deficiency, is a rare genetic disorder characterized by a lack or dysfunction of coagulation factor XII. This protein is involved in the initiation of the coagulation cascade, which leads to the formation of a blood clot. People with Factor XII deficiency may have an increased risk of bleeding, but it is typically mild and not life-threatening. The diagnosis is usually made through blood tests that measure the level and function of Factor XII. Treatment is generally not necessary unless there is significant bleeding, in which case fresh frozen plasma or cryoprecipitate may be given to provide temporary correction of the deficiency. It's important to note that Factor XII deficiency is not a common cause of bleeding disorders and it doesn't increase the risk of thrombosis.

Fibrin(ogen) degradation products (FDPs) are a group of proteins that result from the breakdown of fibrinogen and fibrin, which are key components of blood clots. This process occurs during the normal physiological process of fibrinolysis, where clots are dissolved to maintain blood flow.

FDPs can be measured in the blood as a marker for the activation of the coagulation and fibrinolytic systems. Elevated levels of FDPs may indicate the presence of a disorder that causes abnormal clotting or bleeding, such as disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of cancer.

It is important to note that FDPs are not specific to any particular disorder and their measurement should be interpreted in conjunction with other clinical and laboratory findings.

Factor VIIIa is a protein that plays a crucial role in the coagulation cascade, which is the series of biochemical reactions involved in blood clotting. Specifically, Factor VIIIa is an activated form of Factor VIII, which is one of the essential clotting factors required for normal hemostasis (the process that stops bleeding).

Factor VIIIa functions as a cofactor for another protein called Factor IXa, and together they form the "tenase complex." This complex activates Factor X to Factor Xa, which ultimately leads to the formation of a fibrin clot.

Deficiencies or dysfunctions in Factor VIII or Factor VIIIa can result in bleeding disorders such as hemophilia A, a genetic condition characterized by prolonged bleeding and spontaneous hemorrhages.

Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a clot forms in an artery, it can cut off the supply of oxygen and nutrients to the tissues served by that artery, leading to damage or tissue death. If a thrombus forms in the heart, it can cause a heart attack. If a thrombus breaks off and travels through the bloodstream, it can lodge in a smaller vessel, causing blockage and potentially leading to damage in the organ that the vessel supplies. This is known as an embolism.

Thrombosis can occur due to various factors such as injury to the blood vessel wall, abnormalities in blood flow, or changes in the composition of the blood. Certain medical conditions, medications, and lifestyle factors can increase the risk of thrombosis. Treatment typically involves anticoagulant or thrombolytic therapy to dissolve or prevent further growth of the clot, as well as addressing any underlying causes.

Blood platelets, also known as thrombocytes, are small, colorless cell fragments in our blood that play an essential role in normal blood clotting. They are formed in the bone marrow from large cells called megakaryocytes and circulate in the blood in an inactive state until they are needed to help stop bleeding. When a blood vessel is damaged, platelets become activated and change shape, releasing chemicals that attract more platelets to the site of injury. These activated platelets then stick together to form a plug, or clot, that seals the wound and prevents further blood loss. In addition to their role in clotting, platelets also help to promote healing by releasing growth factors that stimulate the growth of new tissue.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the conversion of prothrombin to thrombin, which is a critical step in the coagulation process.

Inherited deficiencies or abnormalities in Factor V can lead to bleeding disorders. For example, Factor V Leiden is a genetic mutation that causes an increased risk of blood clots, while Factor V deficiency can cause a bleeding disorder.

It's worth noting that "Factor Va" is not a standard medical term. Factor V becomes activated and turns into Factor Va during the coagulation cascade. Therefore, it is possible that you are looking for the definition of "Factor Va" in the context of its role as an activated form of Factor V in the coagulation process.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Thrombomodulin is a protein that is found on the surface of endothelial cells, which line the interior surface of blood vessels. It plays an important role in the regulation of blood coagulation (clotting) and the activation of natural anticoagulant pathways. Thrombomodulin binds to thrombin, a protein involved in blood clotting, and changes its function from promoting coagulation to inhibiting it. This interaction also activates protein C, an important anticoagulant protein, which helps to prevent the excessive formation of blood clots. Thrombomodulin also has anti-inflammatory properties and is involved in the maintenance of the integrity of the endothelial cell lining.

Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. This results in impaired blood clotting and prolonged bleeding, particularly after injuries or surgeries. Symptoms can range from mild to severe, with the most severe form resulting in spontaneous bleeding into joints and muscles, leading to pain, swelling, and potential joint damage over time. Hemophilia A primarily affects males, as it is an X-linked recessive disorder, and is usually inherited from a carrier mother. However, about one third of cases result from a spontaneous mutation in the gene for factor VIII. Treatment typically involves replacement therapy with infusions of factor VIII concentrates to prevent or control bleeding episodes.

1-Carboxyglutamic acid, also known as γ-carboxyglutamic acid, is a post-translational modification found on certain blood clotting factors and other calcium-binding proteins. It is formed by the carboxylation of glutamic acid residues in these proteins, which enhances their ability to bind to calcium ions. This modification is essential for the proper functioning of many physiological processes, including blood coagulation, bone metabolism, and wound healing.

Kaolin is not a medical term per se, but it is a mineral that has various applications in the medical field. Medically, kaolin is used as an ingredient in some over-the-counter (OTC) medications and clinical products, particularly in oral and topical formulations.

Medical definition: Kaolin is a natural hydrated aluminum silicate clay mineral (with the chemical formula Al2Si2O5(OH)4) used in medical applications as an antidiarrheal agent and as a component in various dermatological products for its absorbent, protective, and soothing properties.

Protein S is a vitamin K-dependent protein found in the blood that functions as a natural anticoagulant. It plays a crucial role in regulating the body's clotting system by inhibiting the activation of coagulation factors, thereby preventing excessive blood clotting. Protein S also acts as a cofactor for activated protein C, which is another important anticoagulant protein.

Protein S exists in two forms: free and bound to a protein called C4b-binding protein (C4BP). Only the free form of Protein S has biological activity in inhibiting coagulation. Inherited or acquired deficiencies in Protein S can lead to an increased risk of thrombosis, or abnormal blood clot formation, which can cause various medical conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Regular monitoring of Protein S levels is essential for patients with a history of thrombotic events or those who have a family history of thrombophilia.

Argon Plasma Coagulation (APC) is a medical procedure that uses ionized argon gas to deliver electrical current and heat to tissue, resulting in coagulation. It is commonly used in the treatment of gastrointestinal bleeding, as well as for cutting and coagulating during surgical procedures. The argon plasma is created by passing argon gas through a high-voltage electrical field, which ionizes the gas and creates a highly precise and controllable plasma beam. This beam can be directed at the tissue to achieve hemostasis (stopping bleeding) or to cut tissue with minimal thermal damage to surrounding structures. The procedure is often performed under endoscopic guidance.

Hemophilia B is a genetic disorder that affects the body's ability to control blood clotting, also known as coagulation. This condition is caused by a deficiency or dysfunction in Factor IX, one of the proteins essential for normal blood clotting. As a result, people with Hemophilia B experience prolonged bleeding and bruising after injuries, surgeries, or spontaneously, particularly in joints and muscles.

There are different degrees of severity, depending on how much Factor IX is missing or not functioning properly. Mild cases may only become apparent after significant trauma, surgery, or tooth extraction, while severe cases can lead to spontaneous bleeding into joints and muscles, causing pain, swelling, and potential long-term damage. Hemophilia B primarily affects males, as it is an X-linked recessive disorder, but females can be carriers of the condition and may experience mild symptoms.

Blood coagulation disorders, inherited, also known as coagulopathies, are genetic conditions that affect the body's ability to form blood clots in response to injury or damage to blood vessels. These disorders can lead to excessive bleeding or hemorrhage, and in some cases, abnormal clotting.

There are several types of inherited blood coagulation disorders, including:

1. Hemophilia A and B: These are X-linked recessive disorders that affect the production of factors VIII and IX, respectively, which are essential for normal blood clotting. People with hemophilia may experience prolonged bleeding after injury or surgery, and spontaneous bleeding into joints and muscles.
2. Von Willebrand disease: This is the most common inherited coagulation disorder, affecting both men and women. It results from a deficiency or abnormality of von Willebrand factor, a protein that helps platelets stick to damaged blood vessels and assists in the activation of factor VIII. People with von Willebrand disease may experience excessive bleeding after injury, surgery, or dental work.
3. Factor XI deficiency: This is an autosomal recessive disorder that affects the production of factor XI, a protein involved in the intrinsic pathway of blood coagulation. People with factor XI deficiency may have a mild to moderate bleeding tendency, particularly after surgery or trauma.
4. Rare coagulation factor deficiencies: There are several other rare inherited coagulation disorders that affect the production of other clotting factors, such as factors II, V, VII, X, and XIII. These conditions can lead to a range of bleeding symptoms, from mild to severe.

Inherited blood coagulation disorders are usually diagnosed through a combination of medical history, physical examination, and laboratory tests that measure the levels and function of clotting factors in the blood. Treatment may include replacement therapy with purified clotting factor concentrates, medications to control bleeding, and management of bleeding symptoms as they arise.

Hypoprothrombinemia is a medical condition characterized by a decreased level of prothrombin (coagulation factor II) in the blood, which can lead to an increased bleeding tendency. Prothrombin is a protein involved in the coagulation cascade that helps to form blood clots and stop bleeding.

Hypoprothrombinemia can be caused by various factors, including vitamin K deficiency, liver disease, inherited or acquired disorders of prothrombin synthesis, or the use of certain medications such as warfarin. Symptoms may include easy bruising, prolonged bleeding from cuts or injuries, nosebleeds, and in severe cases, internal bleeding. Treatment typically involves addressing the underlying cause and may include vitamin K supplementation, fresh frozen plasma transfusions, or other specific therapies depending on the etiology of the condition.

Coagulation protein disorders are a group of medical conditions that affect the body's ability to form blood clots properly. These disorders can be caused by genetic defects or acquired factors, such as liver disease or vitamin K deficiency.

The coagulation system is a complex process that involves various proteins called clotting factors. When there is an injury to a blood vessel, these clotting factors work together in a specific order to form a clot and prevent excessive bleeding. In coagulation protein disorders, one or more of these clotting factors are missing or not functioning properly, leading to abnormal bleeding or clotting.

There are several types of coagulation protein disorders, including:

1. Hemophilia: This is a genetic disorder that affects the clotting factor VIII or IX. People with hemophilia may experience prolonged bleeding after injuries, surgery, or dental work.
2. Von Willebrand disease: This is another genetic disorder that affects the von Willebrand factor, a protein that helps platelets stick together and form a clot. People with this condition may have nosebleeds, easy bruising, and excessive bleeding during menstruation or after surgery.
3. Factor XI deficiency: This is a rare genetic disorder that affects the clotting factor XI. People with this condition may experience prolonged bleeding after surgery or trauma.
4. Factor VII deficiency: This is a rare genetic disorder that affects the clotting factor VII. People with this condition may have nosebleeds, easy bruising, and excessive bleeding during menstruation or after surgery.
5. Acquired coagulation protein disorders: These are conditions that develop due to other medical factors, such as liver disease, vitamin K deficiency, or the use of certain medications. These disorders can affect one or more clotting factors and may cause abnormal bleeding or clotting.

Treatment for coagulation protein disorders depends on the specific condition and severity of symptoms. In some cases, replacement therapy with the missing clotting factor may be necessary to prevent excessive bleeding. Other treatments may include medications to control bleeding, such as desmopressin or antifibrinolytic agents, and lifestyle changes to reduce the risk of injury and bleeding.

Prekallikrein is a zymogen, or inactive precursor, of the serine protease kallikrein. It is a protein that plays a role in the coagulation cascade and the kinin-kallikrein system. Prekallikrein is primarily produced in the liver and circulates in the bloodstream. When activated, prekallikrein is converted to kallikrein, which then participates in various physiological processes such as blood pressure regulation, inflammation, and fibrinolysis (the breakdown of blood clots). The activation of prekallikrein is facilitated by the surface of negatively charged activators like kininogen or collagen, in conjunction with factor XII (Hageman factor) in a positive feedback loop.

In summary, Prekallikrein is a crucial protein in the coagulation and kinin-kallikrein systems that becomes activated to kallikrein upon contact with negatively charged surfaces and factor XII, contributing to various physiological processes.

Fibrinopeptide A is a small protein molecule that is cleaved and released from the larger fibrinogen protein during the blood clotting process. Specifically, it is removed by the enzyme thrombin as part of the conversion of fibrinogen to fibrin, which is the main structural component of a blood clot. The measurement of Fibrinopeptide A in the blood can be used as a marker for ongoing thrombin activation and fibrin formation, which are key events in coagulation and hemostasis. Increased levels of Fibrinopeptide A may indicate abnormal or excessive blood clotting, such as in disseminated intravascular coagulation (DIC) or deep vein thrombosis (DVT).

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Vitamin K deficiency is a condition that occurs when the body lacks adequate amounts of Vitamin K, a fat-soluble vitamin essential for blood clotting and bone metabolism. This can lead to an increased risk of excessive bleeding (hemorrhage) and calcification of tissues.

Vitamin K is required for the activation of several proteins involved in blood clotting, known as coagulation factors II, VII, IX, and X. A deficiency in Vitamin K can result in these factors remaining in their inactive forms, leading to impaired blood clotting and an increased risk of bleeding.

Vitamin K deficiency can occur due to several reasons, including malnutrition, malabsorption disorders (such as cystic fibrosis or celiac disease), liver diseases, use of certain medications (such as antibiotics or anticoagulants), and prolonged use of warfarin therapy.

In newborns, Vitamin K deficiency can lead to a serious bleeding disorder known as hemorrhagic disease of the newborn. This is because newborns have low levels of Vitamin K at birth, and their gut bacteria, which are responsible for producing Vitamin K, are not yet fully developed. Therefore, it is recommended that newborns receive a dose of Vitamin K within the first few days of life to prevent this condition.

Symptoms of Vitamin K deficiency can include easy bruising, nosebleeds, bleeding gums, blood in urine or stools, and excessive menstrual bleeding. In severe cases, it can lead to life-threatening hemorrhage. Treatment typically involves administering Vitamin K supplements or injections to replenish the body's levels of this essential nutrient.

Platelet activation is the process by which platelets (also known as thrombocytes) become biologically active and change from their inactive discoid shape to a spherical shape with pseudopodia, resulting in the release of chemical mediators that are involved in hemostasis and thrombosis. This process is initiated by various stimuli such as exposure to subendothelial collagen, von Willebrand factor, or thrombin during vascular injury, leading to platelet aggregation and the formation of a platelet plug to stop bleeding. Platelet activation also plays a role in inflammation, immune response, and wound healing.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Serine proteinase inhibitors, also known as serine protease inhibitors or serpins, are a group of proteins that inhibit serine proteases, which are enzymes that cut other proteins in a process called proteolysis. Serine proteinases are important in many biological processes such as blood coagulation, fibrinolysis, inflammation and cell death. The inhibition of these enzymes by serpin proteins is an essential regulatory mechanism to maintain the balance and prevent uncontrolled proteolytic activity that can lead to diseases.

Serpins work by forming a covalent complex with their target serine proteinases, irreversibly inactivating them. The active site of serpins contains a reactive center loop (RCL) that mimics the protease's target protein sequence and acts as a bait for the enzyme. When the protease cleaves the RCL, it gets trapped within the serpin structure, leading to its inactivation.

Serpin proteinase inhibitors play crucial roles in various physiological processes, including:

1. Blood coagulation and fibrinolysis regulation: Serpins such as antithrombin, heparin cofactor II, and protease nexin-2 control the activity of enzymes involved in blood clotting and dissolution to prevent excessive or insufficient clot formation.
2. Inflammation modulation: Serpins like α1-antitrypsin, α2-macroglobulin, and C1 inhibitor regulate the activity of proteases released during inflammation, protecting tissues from damage.
3. Cell death regulation: Some serpins, such as PI-9/SERPINB9, control apoptosis (programmed cell death) by inhibiting granzyme B, a protease involved in this process.
4. Embryonic development and tissue remodeling: Serpins like plasminogen activator inhibitor-1 (PAI-1) and PAI-2 regulate the activity of enzymes involved in extracellular matrix degradation during embryonic development and tissue remodeling.
5. Neuroprotection: Serpins such as neuroserpin protect neurons from damage by inhibiting proteases released during neuroinflammation or neurodegenerative diseases.

Dysregulation of serpins has been implicated in various pathological conditions, including thrombosis, emphysema, Alzheimer's disease, and cancer. Understanding the roles of serpins in these processes may provide insights into potential therapeutic strategies for treating these diseases.

Platelet aggregation is the clumping together of platelets (thrombocytes) in the blood, which is an essential step in the process of hemostasis (the stopping of bleeding) after injury to a blood vessel. When the inner lining of a blood vessel is damaged, exposure of subendothelial collagen and tissue factor triggers platelet activation. Activated platelets change shape, become sticky, and release the contents of their granules, which include ADP (adenosine diphosphate).

ADP then acts as a chemical mediator to attract and bind additional platelets to the site of injury, leading to platelet aggregation. This forms a plug that seals the damaged vessel and prevents further blood loss. Platelet aggregation is also a crucial component in the formation of blood clots (thrombosis) within blood vessels, which can have pathological consequences such as heart attacks and strokes if they obstruct blood flow to vital organs.

Factor X deficiency, also known as Stuart-Prower factor deficiency, is a rare bleeding disorder that affects the body's ability to form blood clots. It is caused by a mutation in the gene that provides instructions for making coagulation factor X, a protein involved in the coagulation cascade, which is a series of chemical reactions that lead to the formation of a blood clot.

People with factor X deficiency may experience excessive bleeding after injury or surgery, and they may also have an increased risk of spontaneous bleeding, such as nosebleeds, heavy menstrual periods, and joint bleeds. The severity of the condition can vary widely, from mild to severe, depending on the level of factor X activity in the blood.

Factor X deficiency can be inherited or acquired. Inherited forms of the disorder are caused by mutations in the F10 gene and are usually present at birth. Acquired forms of the disorder can develop later in life due to conditions such as liver disease, vitamin K deficiency, or the use of certain medications that interfere with coagulation.

Treatment for factor X deficiency typically involves replacement therapy with fresh frozen plasma or recombinant factor X concentrates to help restore normal clotting function. In some cases, other treatments such as antifibrinolytic agents or desmopressin may also be used to manage bleeding symptoms.

Viperidae is not a term that has a medical definition per se, but it is a term used in the field of biology and zoology. Viperidae is the family name for a group of venomous snakes commonly known as vipers. This family includes various types of pit vipers, adders, and rattlesnakes.

While Viperidae itself may not have direct medical relevance, understanding the biology and behavior of these creatures is important in the context of medical fields such as toxicology and emergency medicine. Knowledge about the venomous properties of viper snakes and their potential to cause harm to humans is crucial for appropriate treatment and management of snakebites.

Transglutaminases are a family of enzymes that catalyze the post-translational modification of proteins by forming isopeptide bonds between the carboxamide group of peptide-bound glutamine residues and the ε-amino group of lysine residues. This process is known as transamidation or cross-linking. Transglutaminases play important roles in various biological processes, including cell signaling, differentiation, apoptosis, and tissue repair. There are several types of transglutaminases, such as tissue transglutaminase (TG2), factor XIII, and blood coagulation factor XIIIA. Abnormal activity or expression of these enzymes has been implicated in various diseases, such as celiac disease, neurodegenerative disorders, and cancer.

Laser coagulation, also known as laser photocoagulation, is a medical procedure that uses a laser to seal or destroy abnormal blood vessels or tissue. The laser produces a concentrated beam of light that can be precisely focused on the target area. When the laser energy is absorbed by the tissue, it causes the temperature to rise, which leads to coagulation (the formation of a clot) or destruction of the tissue.

In ophthalmology, laser coagulation is commonly used to treat conditions such as diabetic retinopathy, age-related macular degeneration, and retinal tears or holes. The procedure can help to seal leaking blood vessels, reduce fluid leakage, and prevent further vision loss. It is usually performed as an outpatient procedure and may be repeated if necessary.

In other medical specialties, laser coagulation may be used to control bleeding, destroy tumors, or remove unwanted tissue. The specific technique and parameters of the laser treatment will depend on the individual patient's needs and the condition being treated.

Hemostatics are substances or agents that promote bleeding cessation or prevent the spread of bleeding. They can act in various ways, such as by stimulating the body's natural clotting mechanisms, constricting blood vessels to reduce blood flow, or forming a physical barrier to block the bleeding site.

Hemostatics are often used in medical settings to manage wounds, injuries, and surgical procedures. They can be applied directly to the wound as a powder, paste, or gauze, or they can be administered systemically through intravenous injection. Examples of hemostatic agents include fibrin sealants, collagen-based products, thrombin, and oxidized regenerated cellulose.

It's important to note that while hemostatics can be effective in controlling bleeding, they should be used with caution and only under the guidance of a healthcare professional. Inappropriate use or overuse of hemostatic agents can lead to complications such as excessive clotting, thrombosis, or tissue damage.

In the context of medical and biological sciences, a "binding site" refers to a specific location on a protein, molecule, or cell where another molecule can attach or bind. This binding interaction can lead to various functional changes in the original protein or molecule. The other molecule that binds to the binding site is often referred to as a ligand, which can be a small molecule, ion, or even another protein.

The binding between a ligand and its target binding site can be specific and selective, meaning that only certain ligands can bind to particular binding sites with high affinity. This specificity plays a crucial role in various biological processes, such as signal transduction, enzyme catalysis, or drug action.

In the case of drug development, understanding the location and properties of binding sites on target proteins is essential for designing drugs that can selectively bind to these sites and modulate protein function. This knowledge can help create more effective and safer therapeutic options for various diseases.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

Polygeline is a colloidal plasma expander, which is a type of intravenous fluid used to increase blood volume in hypovolemia or shock. It is made up of polyvinylpyrrolidone (PVP) molecules that are cross-linked with divinyl sulfone and then suspended in an electrolyte solution. Polygeline works by drawing water into the circulation, thereby increasing the volume of the plasma.

It is important to note that polygeline has been associated with anaphylactic reactions and therefore should be used with caution. It is also not recommended for use in patients with renal impairment or those who are allergic to PVP. As with any medical treatment, it should only be administered under the direction of a qualified healthcare professional.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

Electrocoagulation is a medical procedure that uses heat generated from an electrical current to cause coagulation (clotting) of tissue. This procedure is often used to treat a variety of medical conditions, such as:

* Gastrointestinal bleeding: Electrocoagulation can be used to control bleeding in the stomach or intestines by applying an electrical current to the affected blood vessels, causing them to shrink and clot.
* Skin lesions: Electrocoagulation can be used to remove benign or malignant skin lesions, such as warts, moles, or skin tags, by applying an electrical current to the growth, which causes it to dehydrate and eventually fall off.
* Vascular malformations: Electrocoagulation can be used to treat vascular malformations (abnormal blood vessels) by applying an electrical current to the affected area, causing the abnormal vessels to shrink and clot.

The procedure is typically performed using a specialized device that delivers an electrical current through a needle or probe. The intensity and duration of the electrical current can be adjusted to achieve the desired effect. Electrocoagulation may be used alone or in combination with other treatments, such as surgery or medication.

It's important to note that electrocoagulation is not without risks, including burns, infection, and scarring. It should only be performed by a qualified medical professional who has experience with the procedure.

Arcidae is a family of marine bivalves, commonly known as ark clams or angel wings. These bivalves are characterized by their triangular or elongated shells, which are often sculptured with radial ribs and concentric growth lines. They are filter feeders, living buried in the sand or mud and feeding on plankton and organic matter in the water. Arcidae species can be found in both shallow and deep waters, ranging from tropical to polar regions. Some examples of genera within this family include Barbatia, Arca, and Anadara.

Kallikreins are a group of serine proteases, which are enzymes that help to break down other proteins. They are found in various tissues and body fluids, including the pancreas, kidneys, and saliva. In the body, kallikreins play important roles in several physiological processes, such as blood pressure regulation, inflammation, and fibrinolysis (the breakdown of blood clots).

There are two main types of kallikreins: tissue kallikreins and plasma kallikreins. Tissue kallikreins are primarily involved in the activation of kininogen, a protein that leads to the production of bradykinin, a potent vasodilator that helps regulate blood pressure. Plasma kallikreins, on the other hand, play a key role in the coagulation cascade by activating factors XI and XII, which ultimately lead to the formation of a blood clot.

Abnormal levels or activity of kallikreins have been implicated in various diseases, including cancer, cardiovascular disease, and inflammatory disorders. For example, some studies suggest that certain tissue kallikreins may promote tumor growth and metastasis, while others indicate that they may have protective effects against cancer. Plasma kallikreins have also been linked to the development of thrombosis (blood clots) and inflammation in cardiovascular disease.

Overall, kallikreins are important enzymes with diverse functions in the body, and their dysregulation has been associated with various pathological conditions.

Alpha-2-antiplasmin (α2AP) is a protein found in the blood plasma that inhibits fibrinolysis, the process by which blood clots are broken down. It does this by irreversibly binding to and inhibiting plasmin, an enzyme that degrades fibrin clots.

Alpha-2-antiplasmin is one of the most important regulators of fibrinolysis, helping to maintain a balance between clot formation and breakdown. Deficiencies or dysfunction in alpha-2-antiplasmin can lead to an increased risk of bleeding due to uncontrolled plasmin activity.

Factor VII deficiency is a bleeding disorder that is caused by a deficiency or dysfunction of coagulation factor VII, which is a protein involved in the coagulation cascade and is necessary for the initiation of blood clotting. This condition can lead to prolonged bleeding after injury or surgery, easy bruising, and spontaneous bleeding. The severity of the disorder varies widely, depending on the level of factor VII activity. In severe cases, factor VII activity may be less than 1% of normal, leading to a high risk of bleeding. In milder cases, factor VII activity may be between 5-40% of normal, leading to a lower risk of bleeding. Treatment typically involves replacement therapy with fresh frozen plasma or recombinant factor VIIa to control bleeding episodes and prevent complications.

Thrombophilia is a medical condition characterized by an increased tendency to form blood clots (thrombi) due to various genetic or acquired abnormalities in the coagulation system. These abnormalities can lead to a hypercoagulable state, which can cause thrombosis in both veins and arteries. Commonly identified thrombophilias include factor V Leiden mutation, prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, and protein S deficiency.

Acquired thrombophilias can be caused by various factors such as antiphospholipid antibody syndrome (APS), malignancies, pregnancy, oral contraceptive use, hormone replacement therapy, and certain medical conditions like inflammatory bowel disease or nephrotic syndrome.

It is essential to diagnose thrombophilia accurately, as it may influence the management of venous thromboembolism (VTE) events and guide decisions regarding prophylactic anticoagulation in high-risk situations.

A platelet count is a laboratory test that measures the number of platelets, also known as thrombocytes, in a sample of blood. Platelets are small, colorless cell fragments that circulate in the blood and play a crucial role in blood clotting. They help to stop bleeding by sticking together to form a plug at the site of an injured blood vessel.

A normal platelet count ranges from 150,000 to 450,000 platelets per microliter (µL) of blood. A lower than normal platelet count is called thrombocytopenia, while a higher than normal platelet count is known as thrombocytosis.

Abnormal platelet counts can be a sign of various medical conditions, including bleeding disorders, infections, certain medications, and some types of cancer. It is important to consult with a healthcare provider if you have any concerns about your platelet count or if you experience symptoms such as easy bruising, prolonged bleeding, or excessive menstrual flow.

Enzyme precursors are typically referred to as zymogens or proenzymes. These are inactive forms of enzymes that can be activated under specific conditions. When the need for the enzyme's function arises, the proenzyme is converted into its active form through a process called proteolysis, where it is cleaved by another enzyme. This mechanism helps control and regulate the activation of certain enzymes in the body, preventing unwanted or premature reactions. A well-known example of an enzyme precursor is trypsinogen, which is converted into its active form, trypsin, in the digestive system.

Serine endopeptidases are a type of enzymes that cleave peptide bonds within proteins (endopeptidases) and utilize serine as the nucleophilic amino acid in their active site for catalysis. These enzymes play crucial roles in various biological processes, including digestion, blood coagulation, and programmed cell death (apoptosis). Examples of serine endopeptidases include trypsin, chymotrypsin, thrombin, and elastase.

Kininogens are a group of proteins found in the blood plasma that play a crucial role in the inflammatory response and blood coagulation. They are precursors to bradykinin, a potent vasodilator and inflammatory mediator. There are two types of kininogens: high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is involved in the intrinsic pathway of blood coagulation, while LMWK is responsible for the release of bradykinin. Both kininogens are important targets in the regulation of inflammation and hemostasis.

Lipoproteins are complex particles composed of multiple proteins and lipids (fats) that play a crucial role in the transport and metabolism of fat molecules in the body. They consist of an outer shell of phospholipids, free cholesterols, and apolipoproteins, enclosing a core of triglycerides and cholesteryl esters.

There are several types of lipoproteins, including:

1. Chylomicrons: These are the largest lipoproteins and are responsible for transporting dietary lipids from the intestines to other parts of the body.
2. Very-low-density lipoproteins (VLDL): Produced by the liver, VLDL particles carry triglycerides to peripheral tissues for energy storage or use.
3. Low-density lipoproteins (LDL): Often referred to as "bad cholesterol," LDL particles transport cholesterol from the liver to cells throughout the body. High levels of LDL in the blood can lead to plaque buildup in artery walls and increase the risk of heart disease.
4. High-density lipoproteins (HDL): Known as "good cholesterol," HDL particles help remove excess cholesterol from cells and transport it back to the liver for excretion or recycling. Higher levels of HDL are associated with a lower risk of heart disease.

Understanding lipoproteins and their roles in the body is essential for assessing cardiovascular health and managing risks related to heart disease and stroke.

Antifibrinolytic agents are a class of medications that inhibit the breakdown of blood clots. They work by blocking the action of enzymes called plasminogen activators, which convert plasminogen to plasmin, the main enzyme responsible for breaking down fibrin, a protein that forms the framework of a blood clot.

By preventing the conversion of plasminogen to plasmin, antifibrinolytic agents help to stabilize existing blood clots and prevent their premature dissolution. These medications are often used in clinical settings where excessive bleeding is a concern, such as during or after surgery, childbirth, or trauma.

Examples of antifibrinolytic agents include tranexamic acid, aminocaproic acid, and epsilon-aminocaproic acid. While these medications can be effective in reducing bleeding, they also carry the risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, due to their pro-coagulant effects. Therefore, they should be used with caution and only under the close supervision of a healthcare provider.

Plasma Kallikrein is a serine protease enzyme that plays a crucial role in the coagulation cascade and kinin-kallikrein system. It's produced as an inactive precursor, known as prekallikrein, which is activated when cleaved by factor XIIa (Hageman factor) into its active form, kallikrein.

Once activated, plasma kallikrein can cleave several substrates, including high-molecular-weight kininogen (HK). This results in the release of bradykinin, a potent vasodilator that contributes to increased vascular permeability and inflammation. Plasma kallikrein also activates factor XII, creating a positive feedback loop that amplifies the coagulation cascade and the kinin-kallikrein system.

Plasma kallikrein is involved in several physiological processes, such as blood pressure regulation, inflammation, and fibrinolysis (the breakdown of blood clots). Dysregulation of plasma kallikrein activity has been implicated in various pathological conditions, including hereditary angioedema, thrombosis, and sepsis.

I'm sorry for any confusion, but "snakes" is not a medical term. It refers to a group of legless reptiles that can be found on every continent except Antarctica. If you have any questions about snakes in a different context, please provide more information and I'll do my best to help!

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

Carbon-carbon ligases are a type of enzyme that catalyze the formation of carbon-carbon bonds between two molecules. These enzymes play important roles in various biological processes, including the biosynthesis of natural products and the metabolism of carbohydrates and lipids.

Carbon-carbon ligases can be classified into several categories based on the type of reaction they catalyze. For example, aldolases catalyze the condensation of an aldehyde or ketone with another molecule to form a new carbon-carbon bond and a new carbonyl group. Other examples include the polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs), which are large multienzyme complexes that catalyze the sequential addition of activated carbon units to form complex natural products.

Carbon-carbon ligases are important targets for drug discovery and development, as they play critical roles in the biosynthesis of many disease-relevant molecules. Inhibitors of these enzymes have shown promise as potential therapeutic agents for a variety of diseases, including cancer, infectious diseases, and metabolic disorders.

Protein binding, in the context of medical and biological sciences, refers to the interaction between a protein and another molecule (known as the ligand) that results in a stable complex. This process is often reversible and can be influenced by various factors such as pH, temperature, and concentration of the involved molecules.

In clinical chemistry, protein binding is particularly important when it comes to drugs, as many of them bind to proteins (especially albumin) in the bloodstream. The degree of protein binding can affect a drug's distribution, metabolism, and excretion, which in turn influence its therapeutic effectiveness and potential side effects.

Protein-bound drugs may be less available for interaction with their target tissues, as only the unbound or "free" fraction of the drug is active. Therefore, understanding protein binding can help optimize dosing regimens and minimize adverse reactions.

Protease-activated receptor 1 (PAR-1) is a type of G protein-coupled receptor that is activated by proteolytic cleavage rather than by binding to a ligand in the traditional sense. PAR-1 is expressed on the surface of various cell types, including endothelial cells, smooth muscle cells, and platelets.

When activated by proteases such as thrombin or trypsin, PAR-1 undergoes a conformational change that allows it to interact with G proteins and initiate intracellular signaling pathways. These pathways can lead to a variety of cellular responses, including platelet activation, smooth muscle contraction, and inflammation.

PAR-1 has been implicated in several physiological processes, including hemostasis, thrombosis, and vascular remodeling, as well as in the pathophysiology of various diseases, such as atherosclerosis, cancer, and Alzheimer's disease. Therefore, PAR-1 is an important target for the development of therapeutic agents for these conditions.

'Artocarpus' is a genus of trees in the mulberry family (Moraceae). It includes several tropical species that are native to Southeast Asia, such as the jackfruit (*Artocarpus heterophyllus*) and the breadfruit (*Artocarpus altilis*). These trees are known for their large, edible fruits and hard, woody trunks.

The wood of Artocarpus trees is often used for timber, and some species have medicinal properties. For example, the bark of *Artocarpus incisa* has been used in traditional medicine to treat skin diseases and diarrhea. The leaves and fruits of *Artocarpus communis* are also used in traditional medicine in some parts of Asia.

It is important to note that while Artocarpus species have various uses, they should only be used under the guidance of a healthcare professional, as improper use can lead to adverse effects.

Hemodilution is a medical term that refers to the reduction in the concentration of certain components in the blood, usually referring to red blood cells (RBCs) or hemoglobin. This occurs when an individual's plasma volume expands due to the infusion of intravenous fluids or the body's own production of fluid, such as during severe infection or inflammation. As a result, the number of RBCs per unit of blood decreases, leading to a lower hematocrit and hemoglobin level. It is important to note that while hemodilution reduces the concentration of RBCs in the blood, it does not necessarily indicate anemia or blood loss.

Phosphatidylserines are a type of phospholipids that are essential components of the cell membrane, particularly in the brain. They play a crucial role in maintaining the fluidity and permeability of the cell membrane, and are involved in various cellular processes such as signal transduction, protein anchorage, and apoptosis (programmed cell death). Phosphatidylserines contain a polar head group made up of serine amino acids and two non-polar fatty acid tails. They are abundant in the inner layer of the cell membrane but can be externalized to the outer layer during apoptosis, where they serve as signals for recognition and removal of dying cells by the immune system. Phosphatidylserines have been studied for their potential benefits in various medical conditions, including cognitive decline, Alzheimer's disease, and depression.

Sulfoglycosphingolipids are a type of glycosphingolipid that contain a sulfate ester group in their carbohydrate moiety. They are important components of animal cell membranes and play a role in various biological processes, including cell recognition, signal transduction, and cell adhesion.

The most well-known sulfoglycosphingolipids are the sulfatides, which contain a 3'-sulfate ester on the galactose residue of the glycosphingolipid GalCer (galactosylceramide). Sulfatides are abundant in the nervous system and have been implicated in various neurological disorders.

Other sulfoglycosphingolipids include the seminolipids, which contain a 3'-sulfate ester on the galactose residue of lactosylceramide (Galβ1-4Glcβ1-Cer), and are found in high concentrations in the testis.

Abnormalities in sulfoglycosphingolipid metabolism have been associated with several genetic disorders, such as metachromatic leukodystrophy (MLD) and globoid cell leukodystrophy (GLD), which are characterized by progressive neurological deterioration.

Plasminogen is a glycoprotein that is present in human plasma, and it is the inactive precursor of the enzyme plasmin. Plasmin is a serine protease that plays a crucial role in the dissolution of blood clots by degrading fibrin, one of the major components of a blood clot.

Plasminogen can be activated to form plasmin through the action of various activators, such as tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Once activated, plasmin can break down fibrin and other proteins, helping to prevent excessive clotting and promoting the normal turnover of extracellular matrix components.

Abnormalities in plasminogen activation have been implicated in various diseases, including thrombosis, fibrosis, and cancer. Therefore, understanding the regulation and function of plasminogen is important for developing therapies to treat these conditions.

Factor XIIIa is a protein involved in the blood clotting process. It is a activated form of Factor XIII, which is a protransglutaminase enzyme that plays a role in stabilizing blood clots. Factor XIIIa cross-links fibrin molecules in the clot to form a more stable and insoluble clot. This action helps prevent further bleeding from the site of injury.

Factor XIIIa is formed when thrombin, another protein involved in blood clotting, cleaves and activates Factor XIII. Once activated, Factor XIIIa catalyzes the formation of covalent bonds between fibrin molecules, creating a mesh-like structure that strengthens the clot.

Deficiencies or dysfunctions in Factor XIIIa can lead to bleeding disorders, including factor XIII deficiency, which is a rare but serious condition characterized by prolonged bleeding and an increased risk of spontaneous hemorrhage.

Phospholipids are a major class of lipids that consist of a hydrophilic (water-attracting) head and two hydrophobic (water-repelling) tails. The head is composed of a phosphate group, which is often bound to an organic molecule such as choline, ethanolamine, serine or inositol. The tails are made up of two fatty acid chains.

Phospholipids are a key component of cell membranes and play a crucial role in maintaining the structural integrity and function of the cell. They form a lipid bilayer, with the hydrophilic heads facing outwards and the hydrophobic tails facing inwards, creating a barrier that separates the interior of the cell from the outside environment.

Phospholipids are also involved in various cellular processes such as signal transduction, intracellular trafficking, and protein function regulation. Additionally, they serve as emulsifiers in the digestive system, helping to break down fats in the diet.

Von Willebrand factor (vWF) is a large multimeric glycoprotein that plays a crucial role in hemostasis, the process which leads to the cessation of bleeding and the formation of a blood clot. It was named after Erik Adolf von Willebrand, a Finnish physician who first described the disorder associated with its deficiency, known as von Willebrand disease (vWD).

The primary functions of vWF include:

1. Platelet adhesion and aggregation: vWF mediates the initial attachment of platelets to damaged blood vessel walls by binding to exposed collagen fibers and then interacting with glycoprotein Ib (GPIb) receptors on the surface of platelets, facilitating platelet adhesion. Subsequently, vWF also promotes platelet-platelet interactions (aggregation) through its interaction with platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptors under high shear stress conditions found in areas of turbulent blood flow, such as arterioles and the capillary bed.

2. Transport and stabilization of coagulation factor VIII: vWF serves as a carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation and maintaining its stability in circulation. This interaction between vWF and FVIII is essential for the proper functioning of the coagulation cascade, particularly in the context of vWD, where impaired FVIII function can lead to bleeding disorders.

3. Wound healing: vWF contributes to wound healing by promoting platelet adhesion and aggregation at the site of injury, which facilitates the formation of a provisional fibrin-based clot that serves as a scaffold for tissue repair and regeneration.

In summary, von Willebrand factor is a vital hemostatic protein involved in platelet adhesion, aggregation, coagulation factor VIII stabilization, and wound healing. Deficiencies or dysfunctions in vWF can lead to bleeding disorders such as von Willebrand disease.

Complement C1 Inactivator proteins are a part of the complement system, which is a group of proteins in the blood that play a crucial role in the body's immune defense system. Specifically, Complement C1 Inactivator proteins are responsible for regulating the activation of the first component of the complement system, C1.

The complement system is activated in response to the presence of foreign substances such as bacteria or viruses in the body. The activation of C1 leads to a cascade of reactions that result in the destruction of the foreign substance. However, if this process is not properly regulated, it can lead to damage to the body's own cells and tissues.

Complement C1 Inactivator proteins help to prevent this by regulating the activation of C1. They do this by binding to and inhibiting the activity of C1, preventing it from initiating the complement cascade. A deficiency in Complement C1 Inactivator proteins can lead to a condition called hereditary angioedema, which is characterized by recurrent episodes of swelling in various parts of the body.

Benzamidines are a group of organic compounds that contain a benzene ring linked to an amidine functional group. They are commonly used as antimicrobial agents, particularly in the treatment of various gram-negative bacterial infections. Benzamidines work by inhibiting the enzyme bacterial dehydrogenases, which are essential for the bacteria's survival.

Some examples of benzamidine derivatives include:

* Tempanamine hydrochloride (Tembaglanil): used to treat urinary tract infections caused by susceptible strains of Escherichia coli and Klebsiella pneumoniae.
* Chlorhexidine: a broad-spectrum antimicrobial agent used as a disinfectant and preservative in various medical and dental applications.
* Prothiobenzamide: an anti-inflammatory and analgesic drug used to treat gout and rheumatoid arthritis.

It is important to note that benzamidines have a narrow therapeutic index, which means that the difference between an effective dose and a toxic dose is small. Therefore, they should be used with caution and under the supervision of a healthcare professional.

I'm sorry for any confusion, but "Horseshoe Crabs" are not a medical term or a medical condition. They are actually marine arthropods that have survived for over 450 million years, and are found primarily in the Atlantic Ocean, especially around the Gulf of Mexico and the eastern seaboard of the United States.

However, Horseshoe Crabs do have a significant role in the medical field, particularly in the production of Limulus amebocyte lysate (LAL), which is used to test for bacterial endotoxins in medical equipment and injectable drugs. The blood of Horseshoe Crabs contains amebocytes, which can clot in response to endotoxins found in gram-negative bacteria. This reaction forms a gel-like clot that can be detected and measured, providing a crucial tool for ensuring the sterility of medical products.

So while "Horseshoe Crabs" are not a medical term per se, they do have an important place in medical research and production.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Hemorrhagic disorders are medical conditions characterized by abnormal bleeding due to impaired blood clotting. This can result from deficiencies in coagulation factors, platelet dysfunction, or the use of medications that interfere with normal clotting processes. Examples include hemophilia, von Willebrand disease, and disseminated intravascular coagulation (DIC). Treatment often involves replacing the missing clotting factor or administering medications to help control bleeding.

Thrombin receptors are a type of G protein-coupled receptor (GPCR) that play a crucial role in hemostasis and thrombosis. They are activated by the protease thrombin, which is generated during the coagulation cascade. There are two main types of thrombin receptors: protease-activated receptor 1 (PAR-1) and PAR-4.

PAR-1 is expressed on various cell types including platelets, endothelial cells, and smooth muscle cells, while PAR-4 is primarily expressed on platelets. Activation of these receptors triggers a variety of intracellular signaling pathways that lead to diverse cellular responses such as platelet activation, aggregation, and secretion; vasoconstriction; and inflammation.

Dysregulation of thrombin receptor signaling has been implicated in several pathological conditions, including arterial and venous thrombosis, atherosclerosis, and cancer. Therefore, thrombin receptors are considered important therapeutic targets for the treatment of these disorders.

Hirudin is not a medical term itself, but it is a specific substance with medical relevance. Hirudin is a naturally occurring anticoagulant that is found in the saliva of certain species of leeches (such as Hirudo medicinalis). This compound works by inhibiting the activity of thrombin, a key enzyme in the coagulation cascade, which ultimately results in preventing blood clot formation.

Medically, hirudin has been used in some research and therapeutic settings for its anticoagulant properties. For instance, recombinant hirudin (also known as lepirudin) is available for clinical use as an injectable anticoagulant to treat or prevent blood clots in specific medical conditions, such as heparin-induced thrombocytopenia (HIT).

In summary, Hirudins are a group of anticoagulant substances, primarily derived from leeches, that inhibit the activity of thrombin and have potential medical applications in preventing or treating blood clots.

Peptide hydrolases, also known as proteases or peptidases, are a group of enzymes that catalyze the hydrolysis of peptide bonds in proteins and peptides. They play a crucial role in various biological processes such as protein degradation, digestion, cell signaling, and regulation of various physiological functions. Based on their catalytic mechanism and the specificity for the peptide bond, they are classified into several types, including serine proteases, cysteine proteases, aspartic proteases, and metalloproteases. These enzymes have important clinical applications in the diagnosis and treatment of various diseases, such as cancer, viral infections, and inflammatory disorders.

Crotalid venoms are the toxic secretions produced by the members of the Crotalinae subfamily, also known as pit vipers. This group includes rattlesnakes, cottonmouths (or water moccasins), and copperheads, which are native to the Americas, as well as Old World vipers found in Asia and Europe, such as gaboon vipers and saw-scaled vipers.

Crotalid venoms are complex mixtures of various bioactive molecules, including enzymes, proteins, peptides, and other low molecular weight components. They typically contain a variety of pharmacologically active components, such as hemotoxic and neurotoxic agents, which can cause extensive local tissue damage, coagulopathy, cardiovascular dysfunction, and neuromuscular disorders in the victim.

The composition of crotalid venoms can vary significantly between different species and even among individual specimens within the same species. This variability is influenced by factors such as geographic location, age, sex, diet, and environmental conditions. As a result, the clinical manifestations of crotalid envenomation can be highly variable, ranging from mild local reactions to severe systemic effects that may require intensive medical treatment and supportive care.

Crotalid venoms have been the subject of extensive research in recent years due to their potential therapeutic applications. For example, certain components of crotalid venoms have shown promise as drugs for treating various medical conditions, such as cardiovascular diseases, pain, and inflammation. However, further studies are needed to fully understand the mechanisms of action of these venom components and to develop safe and effective therapies based on them.

Arthropods are a phylum of animals that includes insects, spiders, crustaceans, and other creatures with jointed appendages. Arthropod proteins, therefore, refer to the proteins that are found in these organisms. These proteins play various roles in the structure, function, and regulation of arthropod cells, tissues, and organs.

Arthropod proteins can be classified into several categories based on their functions, such as structural proteins, enzymes, signaling proteins, and defense proteins. Structural proteins provide support and protection to the arthropod exoskeleton, which is composed mainly of chitin and proteins. Enzymes are proteins that catalyze chemical reactions in arthropod metabolism, while signaling proteins regulate various physiological processes, including growth, development, and reproduction. Defense proteins protect arthropods from pathogens, parasites, and environmental stressors.

Arthropod proteins have attracted significant interest in biomedical research due to their potential applications in drug discovery, vaccine development, and diagnostic tools. For example, some arthropod proteins have been identified as promising targets for the development of new insecticides and antiparasitic drugs. Additionally, arthropod-derived proteins have been used in the production of recombinant vaccines against infectious diseases such as Lyme disease and malaria.

Understanding the structure and function of arthropod proteins is essential for advancing our knowledge of arthropod biology, evolution, and ecology. It also has important implications for human health, agriculture, and environmental conservation.

Molecular models are three-dimensional representations of molecular structures that are used in the field of molecular biology and chemistry to visualize and understand the spatial arrangement of atoms and bonds within a molecule. These models can be physical or computer-generated and allow researchers to study the shape, size, and behavior of molecules, which is crucial for understanding their function and interactions with other molecules.

Physical molecular models are often made up of balls (representing atoms) connected by rods or sticks (representing bonds). These models can be constructed manually using materials such as plastic or wooden balls and rods, or they can be created using 3D printing technology.

Computer-generated molecular models, on the other hand, are created using specialized software that allows researchers to visualize and manipulate molecular structures in three dimensions. These models can be used to simulate molecular interactions, predict molecular behavior, and design new drugs or chemicals with specific properties. Overall, molecular models play a critical role in advancing our understanding of molecular structures and their functions.

Ellagic acid is a type of polyphenol, which is a class of organic compounds characterized by the presence of multiple phenol units. It is found in various fruits and vegetables, including raspberries, strawberries, pomegranates, and walnuts. Ellagic acid has been studied for its potential antioxidant, anti-inflammatory, and chemopreventive properties. However, more research is needed to confirm these effects and establish a clear medical definition of ellagic acid. It is not considered a medication or a treatment for any specific medical condition.

Thrombophlebitis is a medical condition characterized by the inflammation and clotting of blood in a vein, usually in the legs. The term thrombophlebitis comes from two words: "thrombo" which means blood clot, and "phlebitis" which refers to inflammation of the vein.

The condition can occur in superficial or deep veins. Superficial thrombophlebitis affects the veins just below the skin's surface, while deep vein thrombophlebitis (DVT) occurs in the deeper veins. DVT is a more serious condition as it can lead to complications such as pulmonary embolism if the blood clot breaks off and travels to the lungs.

Symptoms of thrombophlebitis may include redness, warmth, pain, swelling, or discomfort in the affected area. In some cases, there may be visible surface veins that are hard, tender, or ropy to touch. If left untreated, thrombophlebitis can lead to chronic venous insufficiency and other long-term complications. Treatment typically involves medications such as anticoagulants, antiplatelet agents, or thrombolytics, along with compression stockings and other supportive measures.

Cephapirin is a type of antibiotic that belongs to the class of cephalosporins. It is used to treat various bacterial infections, including respiratory tract infections, skin and soft tissue infections, bone and joint infections, and genitourinary tract infections. Cephapirin works by interfering with the bacteria's ability to form a cell wall, which results in bacterial death.

Like other cephalosporins, cephapirin is generally well-tolerated and has a broad spectrum of activity against many different types of bacteria. However, it may cause side effects such as nausea, diarrhea, vomiting, and allergic reactions in some people. It is important to take cephapirin exactly as directed by a healthcare provider, and to complete the full course of treatment even if symptoms improve before all of the medication has been taken.

It's worth noting that Cephapirin is not a commonly used antibiotic now a days, due to the availability of other cephalosporins which are more effective and have less side effects.

Invertebrate hormones refer to the chemical messengers that regulate various physiological processes in invertebrate animals, which include insects, mollusks, worms, and other animals without a backbone. These hormones are produced by specialized endocrine cells or glands and released into the bloodstream to target organs, where they elicit specific responses that help control growth, development, reproduction, metabolism, and behavior.

Examples of invertebrate hormones include:

1. Ecdysteroids: These are steroid hormones found in arthropods such as insects and crustaceans. They regulate molting (ecdysis) and metamorphosis by stimulating the growth and differentiation of new cuticle layers.
2. Juvenile hormone (JH): This is a sesquiterpenoid hormone produced by the corpora allata glands in insects. JH plays a crucial role in maintaining the juvenile stage, regulating reproduction, and controlling diapause (a period of suspended development during unfavorable conditions).
3. Neuropeptides: These are short chains of amino acids that act as hormones or neurotransmitters in invertebrates. They regulate various functions such as feeding behavior, growth, reproduction, and circadian rhythms. Examples include the neuropeptide F (NPF), which controls food intake and energy balance, and the insulin-like peptides (ILPs) that modulate metabolism and growth.
4. Molluscan cardioactive peptides: These are neuropeptides found in mollusks that regulate heart function by controlling heart rate and contractility. An example is FMRFamide, which has been identified in various mollusk species and influences several physiological processes, including feeding behavior, muscle contraction, and reproduction.
5. Vertebrate-like hormones: Some invertebrates produce hormones that are structurally and functionally similar to those found in vertebrates. For example, some annelids (segmented worms) and cephalopods (squid and octopus) have insulin-like peptides that regulate metabolism and growth, while certain echinoderms (starfish and sea urchins) produce steroid hormones that control reproduction.

In summary, invertebrates utilize various types of hormones to regulate their physiological functions, including neuropeptides, cardioactive peptides, insulin-like peptides, and vertebrate-like hormones. These hormones play crucial roles in controlling growth, development, reproduction, feeding behavior, and other essential processes that maintain homeostasis and ensure survival. Understanding the mechanisms of hormone action in invertebrates can provide valuable insights into the evolution of hormonal systems and their functions across different animal taxa.

Molecular weight, also known as molecular mass, is the mass of a molecule. It is expressed in units of atomic mass units (amu) or daltons (Da). Molecular weight is calculated by adding up the atomic weights of each atom in a molecule. It is a useful property in chemistry and biology, as it can be used to determine the concentration of a substance in a solution, or to calculate the amount of a substance that will react with another in a chemical reaction.

Blood proteins, also known as serum proteins, are a group of complex molecules present in the blood that are essential for various physiological functions. These proteins include albumin, globulins (alpha, beta, and gamma), and fibrinogen. They play crucial roles in maintaining oncotic pressure, transporting hormones, enzymes, vitamins, and minerals, providing immune defense, and contributing to blood clotting.

Albumin is the most abundant protein in the blood, accounting for about 60% of the total protein mass. It functions as a transporter of various substances, such as hormones, fatty acids, and drugs, and helps maintain oncotic pressure, which is essential for fluid balance between the blood vessels and surrounding tissues.

Globulins are divided into three main categories: alpha, beta, and gamma globulins. Alpha and beta globulins consist of transport proteins like lipoproteins, hormone-binding proteins, and enzymes. Gamma globulins, also known as immunoglobulins or antibodies, are essential for the immune system's defense against pathogens.

Fibrinogen is a protein involved in blood clotting. When an injury occurs, fibrinogen is converted into fibrin, which forms a mesh to trap platelets and form a clot, preventing excessive bleeding.

Abnormal levels of these proteins can indicate various medical conditions, such as liver or kidney disease, malnutrition, infections, inflammation, or autoimmune disorders. Blood protein levels are typically measured through laboratory tests like serum protein electrophoresis (SPE) and immunoelectrophoresis (IEP).

Snake venoms are complex mixtures of bioactive compounds produced by specialized glands in snakes. They primarily consist of proteins and peptides, including enzymes, neurotoxins, hemotoxins, cytotoxins, and cardiotoxins. These toxins can cause a variety of pharmacological effects on the victim's body, such as disruption of the nervous system, blood coagulation, muscle function, and cell membrane integrity, ultimately leading to tissue damage and potentially death. The composition of snake venoms varies widely among different species, making each species' venom unique in its toxicity profile.

Protein conformation refers to the specific three-dimensional shape that a protein molecule assumes due to the spatial arrangement of its constituent amino acid residues and their associated chemical groups. This complex structure is determined by several factors, including covalent bonds (disulfide bridges), hydrogen bonds, van der Waals forces, and ionic bonds, which help stabilize the protein's unique conformation.

Protein conformations can be broadly classified into two categories: primary, secondary, tertiary, and quaternary structures. The primary structure represents the linear sequence of amino acids in a polypeptide chain. The secondary structure arises from local interactions between adjacent amino acid residues, leading to the formation of recurring motifs such as α-helices and β-sheets. Tertiary structure refers to the overall three-dimensional folding pattern of a single polypeptide chain, while quaternary structure describes the spatial arrangement of multiple folded polypeptide chains (subunits) that interact to form a functional protein complex.

Understanding protein conformation is crucial for elucidating protein function, as the specific three-dimensional shape of a protein directly influences its ability to interact with other molecules, such as ligands, nucleic acids, or other proteins. Any alterations in protein conformation due to genetic mutations, environmental factors, or chemical modifications can lead to loss of function, misfolding, aggregation, and disease states like neurodegenerative disorders and cancer.

Streptomycetaceae is a family of bacteria belonging to the order Actinomycetales. These bacteria are gram-positive, aerobic, and have a filamentous morphology that can resemble fungi. They are known for their ability to produce a wide variety of antibiotics and other secondary metabolites, making them important sources of drugs used in medicine and agriculture. Streptomycetaceae species are commonly found in soil and decaying vegetation, where they play important roles in nutrient cycling and decomposition.

In the context of medicine, plasma refers to the clear, yellowish fluid that is the liquid component of blood. It's composed of water, enzymes, hormones, antibodies, clotting factors, and other proteins. Plasma serves as a transport medium for cells, nutrients, waste products, gases, and other substances throughout the body. Additionally, it plays a crucial role in the immune response and helps regulate various bodily functions.

Plasma can be collected from blood donors and processed into various therapeutic products, such as clotting factors for people with hemophilia or immunoglobulins for patients with immune deficiencies. This process is called plasma fractionation.

"Cattle" is a term used in the agricultural and veterinary fields to refer to domesticated animals of the genus *Bos*, primarily *Bos taurus* (European cattle) and *Bos indicus* (Zebu). These animals are often raised for meat, milk, leather, and labor. They are also known as bovines or cows (for females), bulls (intact males), and steers/bullocks (castrated males). However, in a strict medical definition, "cattle" does not apply to humans or other animals.

Platelet adhesiveness refers to the ability of platelets, which are small blood cells that help your body form clots to prevent excessive bleeding, to stick to other cells or surfaces. This process is crucial in hemostasis, the process of stopping bleeding after injury to a blood vessel.

When the endothelium (the lining of blood vessels) is damaged, subendothelial structures are exposed, which can trigger platelet adhesion. Platelets then change shape and release chemical signals that cause other platelets to clump together, forming a platelet plug. This plug helps to seal the damaged vessel and prevent further bleeding.

Platelet adhesiveness is influenced by several factors, including the presence of von Willebrand factor (vWF), a protein in the blood that helps platelets bind to damaged vessels, and the expression of glycoprotein receptors on the surface of platelets. Abnormalities in platelet adhesiveness can lead to bleeding disorders or thrombotic conditions.

Surface Plasmon Resonance (SPR) is a physical phenomenon that occurs at the interface between a metal and a dielectric material, when electromagnetic radiation (usually light) is shone on it. It involves the collective oscillation of free electrons in the metal, known as surface plasmons, which are excited by the incident light. The resonance condition is met when the momentum and energy of the photons match those of the surface plasmons, leading to a strong absorption of light and an evanescent wave that extends into the dielectric material.

In the context of medical diagnostics and research, SPR is often used as a sensitive and label-free detection technique for biomolecular interactions. By immobilizing one binding partner (e.g., a receptor or antibody) onto the metal surface and flowing the other partner (e.g., a ligand or antigen) over it, changes in the refractive index at the interface can be measured in real-time as the plasmons are disturbed by the presence of bound molecules. This allows for the quantification of binding affinities, kinetics, and specificity with high sensitivity and selectivity.

Tosylarginine Methyl Ester (TAME) is not a medication or a therapeutic agent, but it is a research compound used in scientific studies. It is a synthetic molecule that is often used as a control or a reference standard in enzyme inhibition assays. TAME is an esterified form of the amino acid arginine, with a tosyl group (p-toluenesulfonyl) attached to the nitrogen atom.

TAME is specifically used as a selective and reversible inhibitor of the enzyme called butyrylcholinesterase (BChE), which is involved in the breakdown of certain neurotransmitters in the body. By inhibiting BChE, TAME can help to increase the levels of these neurotransmitters in the brain, making it a useful tool for studying the mechanisms of this enzyme and its role in various physiological processes.

It's important to note that while TAME is used in research settings, it is not approved for use as a drug or therapeutic agent in humans or animals.

Proteinase-activated receptors (PARs) are a subfamily of G protein-coupled receptors that are activated by proteolytic cleavage of their extracellular N-terminal domain. This process exposes a new tethered ligand domain that binds to the receptor and activates it.

There are four known PARs (PAR-1, PAR-2, PAR-3, and PAR-4) that play important roles in various physiological and pathophysiological processes, including inflammation, hemostasis, wound healing, and cancer. Proteinases such as thrombin, trypsin, and matrix metalloproteinases can activate PARs, leading to the activation of downstream signaling pathways that regulate cellular responses such as proliferation, migration, and gene expression.

Proteinase-activated receptors have been identified as important drug targets for various diseases, including thrombosis, inflammation, and cancer. Inhibitors or antagonists of PARs have shown promise in preclinical and clinical studies for the treatment of these conditions.

"Viper venoms" refer to the toxic secretions produced by members of the Viperidae family of snakes, which include pit vipers (such as rattlesnakes, copperheads, and cottonmouths) and true vipers (like adders, vipers, and gaboon vipers). These venoms are complex mixtures of proteins, enzymes, and other bioactive molecules that can cause a wide range of symptoms in prey or predators, including local tissue damage, pain, swelling, bleeding, and potentially life-threatening systemic effects such as coagulopathy, cardiovascular shock, and respiratory failure.

The composition of viper venoms varies widely between different species and even among individuals within the same species. However, many viper venoms contain a variety of enzymes (such as phospholipases A2, metalloproteinases, and serine proteases) that can cause tissue damage and disrupt vital physiological processes in the victim. Additionally, some viper venoms contain neurotoxins that can affect the nervous system and cause paralysis or other neurological symptoms.

Understanding the composition and mechanisms of action of viper venoms is important for developing effective treatments for venomous snakebites, as well as for gaining insights into the evolution and ecology of these fascinating and diverse creatures.

Warfarin is a anticoagulant medication that works by inhibiting the vitamin K-dependent activation of several coagulation factors (factors II, VII, IX, and X). This results in prolonged clotting times and reduced thrombus formation. It is commonly used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Warfarin is also known by its brand names Coumadin and Jantoven.

It's important to note that warfarin has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic one is small. Therefore, it requires careful monitoring of the patient's coagulation status through regular blood tests (INR) to ensure that the dosage is appropriate and to minimize the risk of bleeding complications.

A postmature infant is a newborn who is delivered at or after 42 weeks (294 days) of gestation. These infants are also known as "post-term" or "post-dates." At this stage, the placenta may not function optimally, leading to potential issues such as decreased fetal movement, meconium staining of amniotic fluid, and low birth weight. Postmature infants may require close monitoring and evaluation after delivery to ensure their well-being.

The endothelium is a thin layer of simple squamous epithelial cells that lines the interior surface of blood vessels, lymphatic vessels, and heart chambers. The vascular endothelium, specifically, refers to the endothelial cells that line the blood vessels. These cells play a crucial role in maintaining vascular homeostasis by regulating vasomotor tone, coagulation, platelet activation, inflammation, and permeability of the vessel wall. They also contribute to the growth and repair of the vascular system and are involved in various pathological processes such as atherosclerosis, hypertension, and diabetes.

Russell's Viper is not a medical condition or term. It is a type of venomous snake, scientifically known as Daboia russelii, found in parts of Asia. The bite of this viper can cause severe symptoms such as pain, swelling, bleeding, tissue damage, and potentially life-threatening systemic effects like kidney failure, blood clotting problems, and cardiac arrest. Medical personnel should be notified immediately in case of a snakebite, and appropriate antivenom therapy should be initiated as soon as possible to reduce the risk of complications or mortality.

Venom is a complex mixture of toxic compounds produced by certain animals, such as snakes, spiders, scorpions, and marine creatures like cone snails and stonefish. These toxic substances are specifically designed to cause damage to the tissues or interfere with the normal physiological processes of other organisms, which can lead to harmful or even lethal effects.

Venoms typically contain a variety of components, including enzymes, peptides, proteins, and small molecules, each with specific functions that contribute to the overall toxicity of the mixture. Some of these components may cause localized damage, such as tissue necrosis or inflammation, while others can have systemic effects, impacting various organs and bodily functions.

The study of venoms, known as toxinology, has important implications for understanding the evolution of animal behavior, developing new therapeutics, and advancing medical treatments for envenomation (the process of being poisoned by venom). Additionally, venoms have been used in traditional medicine for centuries, and ongoing research continues to uncover novel compounds with potential applications in modern pharmacology.

Viscoelastic substances are materials that exhibit both viscous and elastic properties when undergoing deformation. In the context of medicine, viscoelastic substances are often used to describe certain biological fluids, such as synovial fluid found in joints, or the vitreous humor in the eye. These fluids have a complex structure that allows them to behave as a liquid and a solid simultaneously, providing resistance to sudden force while also allowing for smooth movement over time.

Artificial viscoelastic substances are also used in medical applications, such as in surgical sealants and hemostatic agents, which are designed to control bleeding by forming a gel-like substance that fills wounds and helps to promote clotting. These materials have unique properties that allow them to conform to the shape of the wound and provide sustained pressure to help stop bleeding.

Fibrinolytic agents are medications that dissolve or break down blood clots by activating plasminogen, which is converted into plasmin. Plasmin is a proteolytic enzyme that degrades fibrin, the structural protein in blood clots. Fibrinolytic agents are used medically to treat conditions such as acute ischemic stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction (heart attack) by restoring blood flow in occluded vessels. Examples of fibrinolytic agents include alteplase, reteplase, and tenecteplase. It is important to note that these medications carry a risk of bleeding complications and should be administered with caution.

Venous thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) in the deep veins, often in the legs (deep vein thrombosis or DVT), but it can also occur in other parts of the body such as the arms, pelvis, or lungs (pulmonary embolism).

The formation of a venous thrombus can be caused by various factors, including injury to the blood vessel wall, changes in blood flow, and alterations in the composition of the blood. These factors can lead to the activation of clotting factors and platelets, which can result in the formation of a clot that blocks the vein.

Symptoms of venous thrombosis may include swelling, pain, warmth, and redness in the affected area. In some cases, the clot can dislodge and travel to other parts of the body, causing potentially life-threatening complications such as pulmonary embolism.

Risk factors for venous thrombosis include advanced age, obesity, smoking, pregnancy, use of hormonal contraceptives or hormone replacement therapy, cancer, recent surgery or trauma, prolonged immobility, and a history of previous venous thromboembolism. Treatment typically involves the use of anticoagulant medications to prevent further clotting and dissolve existing clots.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Tertiary protein structure refers to the three-dimensional arrangement of all the elements (polypeptide chains) of a single protein molecule. It is the highest level of structural organization and results from interactions between various side chains (R groups) of the amino acids that make up the protein. These interactions, which include hydrogen bonds, ionic bonds, van der Waals forces, and disulfide bridges, give the protein its unique shape and stability, which in turn determines its function. The tertiary structure of a protein can be stabilized by various factors such as temperature, pH, and the presence of certain ions. Any changes in these factors can lead to denaturation, where the protein loses its tertiary structure and thus its function.

Electrophoresis, polyacrylamide gel (EPG) is a laboratory technique used to separate and analyze complex mixtures of proteins or nucleic acids (DNA or RNA) based on their size and electrical charge. This technique utilizes a matrix made of cross-linked polyacrylamide, a type of gel, which provides a stable and uniform environment for the separation of molecules.

In this process:

1. The polyacrylamide gel is prepared by mixing acrylamide monomers with a cross-linking agent (bis-acrylamide) and a catalyst (ammonium persulfate) in the presence of a buffer solution.
2. The gel is then poured into a mold and allowed to polymerize, forming a solid matrix with uniform pore sizes that depend on the concentration of acrylamide used. Higher concentrations result in smaller pores, providing better resolution for separating smaller molecules.
3. Once the gel has set, it is placed in an electrophoresis apparatus containing a buffer solution. Samples containing the mixture of proteins or nucleic acids are loaded into wells on the top of the gel.
4. An electric field is applied across the gel, causing the negatively charged molecules to migrate towards the positive electrode (anode) while positively charged molecules move toward the negative electrode (cathode). The rate of migration depends on the size, charge, and shape of the molecules.
5. Smaller molecules move faster through the gel matrix and will migrate farther from the origin compared to larger molecules, resulting in separation based on size. Proteins and nucleic acids can be selectively stained after electrophoresis to visualize the separated bands.

EPG is widely used in various research fields, including molecular biology, genetics, proteomics, and forensic science, for applications such as protein characterization, DNA fragment analysis, cloning, mutation detection, and quality control of nucleic acid or protein samples.

Polyphosphates are compounds consisting of many phosphate groups linked together in the form of chains or rings. They are often used in various medical and healthcare applications, such as:

* Dental care products: Polyphosphates can help prevent the formation of dental plaque and calculus by binding to calcium ions in saliva and inhibiting the growth of bacteria that cause tooth decay.
* Nutritional supplements: Polyphosphates are sometimes used as a source of phosphorus in nutritional supplements, particularly for people who have kidney disease or other medical conditions that require them to limit their intake of phosphorus from food sources.
* Medical devices: Polyphosphates may be used in the manufacture of medical devices, such as contact lenses and catheters, to improve their biocompatibility and resistance to bacterial growth.

It's worth noting that while polyphosphates have various medical uses, they can also be found in many non-medical products, such as food additives, water treatment chemicals, and cleaning agents.

'Agkistrodon' is a genus of venomous snakes commonly known as pit vipers, found predominantly in North America and parts of Asia. This genus includes several species, among them the copperhead (A. contortrix), cottonmouth or water moccasin (A. piscivorus), and the cantil (A. bilineatus). These snakes are characterized by their triangular heads, heat-sensing pits between the eyes and nostrils, and elliptical pupils. They deliver venom through hollow fangs and can cause significant harm to humans if they bite.

It is important to note that 'Agkistrodon' species are often misidentified due to their similarities with other pit vipers. Accurate identification of a snakebite victim is crucial for proper medical treatment, so seeking professional help from herpetologists or medical professionals is highly recommended in such situations.

Battered Child Syndrome is a medical condition in which a child has been physically abused and harmed, often over a period of time. It is also known as Non-accidental Injury (NAI) or Inflicted Traumatic Injury. The syndrome is characterized by a pattern of injuries, including bruises, fractures, burns, and internal injuries, which are not consistent with the history provided by the caregiver.

The symptoms of Battered Child Syndrome may include:

1. Unexplained or inconsistent explanations for injuries
2. Multiple injuries in various stages of healing
3. Injuries to different parts of the body, such as the ears, mouth, and genitals
4. Frequent visits to the emergency department or doctor's office for treatment of injuries
5. Delayed seeking of medical attention for serious injuries
6. Behavioral changes, such as fearfulness, regression, or aggression
7. Developmental delays or learning difficulties
8. Failure to thrive (poor growth and weight gain)

The diagnosis of Battered Child Syndrome is made by a healthcare professional based on the history, physical examination, and any diagnostic tests that may be necessary. The syndrome is a serious form of child abuse that requires immediate intervention and protection for the child. Treatment typically involves medical care for injuries, counseling and support for the child and family, and reporting the abuse to child protective services or law enforcement agencies.

Cell-derived microparticles (CDMs), also known as microvesicles or microparticles, are small membrane-bound particles that are released from the cell surface upon activation or apoptosis of various cell types, including platelets, leukocytes, endothelial cells, and red blood cells. CDMs range in size from 0.1 to 1.0 micrometers in diameter and contain a variety of bioactive molecules, such as lipids, proteins, and nucleic acids, which can be transferred to neighboring or distant cells, thereby modulating their function.

CDMs have been implicated in various physiological and pathological processes, including coagulation, inflammation, immune response, angiogenesis, and cancer progression. They have also emerged as potential biomarkers for various diseases, such as cardiovascular disease, sepsis, and cancer, due to their distinct molecular signature and abundance in body fluids, such as blood, urine, and cerebrospinal fluid.

The mechanisms of CDM formation and release are complex and involve several cellular processes, including cytoskeletal rearrangement, membrane budding, and vesicle shedding. The molecular composition of CDMs reflects their cellular origin and activation state, and can be analyzed by various techniques, such as flow cytometry, proteomics, and transcriptomics, to gain insights into their biological functions and clinical relevance.

Plasminogen inactivators are substances that inhibit the activity of plasminogen, a proenzyme that is converted into the active enzyme plasmin. Plasmin plays a crucial role in the breakdown of blood clots by cleaving fibrin, the protein that forms the structural framework of a clot.

There are two main types of plasminogen activators: tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). These enzymes convert plasminogen into plasmin, thereby promoting fibrinolysis, or the dissolution of blood clots. Plasminogen inactivators, on the other hand, inhibit this process by blocking the conversion of plasminogen to plasmin.

Plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) are two main types of plasminogen inactivators. PAI-1 is a serine protease inhibitor that inactivates tPA and uPA by forming covalent complexes with them. PAI-1 is produced by various cells, including endothelial cells, hepatocytes, and adipocytes. Elevated levels of PAI-1 have been associated with an increased risk of thrombosis and cardiovascular disease.

PAI-2 is another serine protease inhibitor that primarily inhibits uPA. It is produced by various cells, including monocytes, macrophages, and trophoblasts. PAI-2 has been shown to play a role in pregnancy, immune response, and cancer.

Overall, plasminogen inactivators are important regulators of the fibrinolytic system, which helps maintain blood flow and prevent excessive clotting or bleeding. Dysregulation of this system can lead to various pathological conditions, such as thrombosis, hemorrhage, and cancer.

Fibrinolysin is defined as a proteolytic enzyme that dissolves or breaks down fibrin, a protein involved in the clotting of blood. This enzyme is produced by certain cells, such as endothelial cells that line the interior surface of blood vessels, and is an important component of the body's natural mechanism for preventing excessive blood clotting and maintaining blood flow.

Fibrinolysin works by cleaving specific bonds in the fibrin molecule, converting it into soluble degradation products that can be safely removed from the body. This process is known as fibrinolysis, and it helps to maintain the balance between clotting and bleeding in the body.

In medical contexts, fibrinolysin may be used as a therapeutic agent to dissolve blood clots that have formed in the blood vessels, such as those that can occur in deep vein thrombosis or pulmonary embolism. It is often administered in combination with other medications that help to enhance its activity and specificity for fibrin.

Enzyme activation refers to the process by which an enzyme becomes biologically active and capable of carrying out its specific chemical or biological reaction. This is often achieved through various post-translational modifications, such as proteolytic cleavage, phosphorylation, or addition of cofactors or prosthetic groups to the enzyme molecule. These modifications can change the conformation or structure of the enzyme, exposing or creating a binding site for the substrate and allowing the enzymatic reaction to occur.

For example, in the case of proteolytic cleavage, an inactive precursor enzyme, known as a zymogen, is cleaved into its active form by a specific protease. This is seen in enzymes such as trypsin and chymotrypsin, which are initially produced in the pancreas as inactive precursors called trypsinogen and chymotrypsinogen, respectively. Once they reach the small intestine, they are activated by enteropeptidase, a protease that cleaves a specific peptide bond, releasing the active enzyme.

Phosphorylation is another common mechanism of enzyme activation, where a phosphate group is added to a specific serine, threonine, or tyrosine residue on the enzyme by a protein kinase. This modification can alter the conformation of the enzyme and create a binding site for the substrate, allowing the enzymatic reaction to occur.

Enzyme activation is a crucial process in many biological pathways, as it allows for precise control over when and where specific reactions take place. It also provides a mechanism for regulating enzyme activity in response to various signals and stimuli, such as hormones, neurotransmitters, or changes in the intracellular environment.

"Bothrops" is a genus of venomous snakes commonly known as lancehead vipers, found primarily in Central and South America. The name "Bothrops" comes from the Greek words "bothros," meaning pit, and "ops," meaning face, referring to the deep pits on the sides of their heads that help them detect heat and locate prey. These snakes are known for their aggressive behavior and potent venom, which can cause severe pain, swelling, tissue damage, and potentially life-threatening systemic effects if left untreated.

The genus "Bothrops" includes over 30 species of pit vipers, many of which are considered medically important due to their ability to inflict serious envenomations in humans. Some notable examples include Bothrops asper (the terciopelo or fer-de-lance), Bothrops atrox (the common lancehead), and Bothrops jararaca (the jararaca).

If you encounter a snake of this genus, it is essential to seek medical attention immediately if bitten, as the venom can cause significant harm if not treated promptly.

Salivary proteins and peptides refer to the diverse group of molecules that are present in saliva, which is the clear, slightly alkaline fluid produced by the salivary glands in the mouth. These proteins and peptides play a crucial role in maintaining oral health and contributing to various physiological functions.

Some common types of salivary proteins and peptides include:

1. **Mucins**: These are large, heavily glycosylated proteins that give saliva its viscous quality. They help to lubricate the oral cavity, protect the mucosal surfaces, and aid in food bolus formation.
2. **Amylases**: These enzymes break down carbohydrates into simpler sugars, initiating the digestive process even before food reaches the stomach.
3. **Proline-rich proteins (PRPs)**: PRPs contribute to the buffering capacity of saliva and help protect against tooth erosion by forming a protective layer on tooth enamel.
4. **Histatins**: These are small cationic peptides with antimicrobial properties, playing a significant role in maintaining oral microbial homeostasis and preventing dental caries.
5. **Lactoferrin**: An iron-binding protein that exhibits antibacterial, antifungal, and anti-inflammatory activities, contributing to the overall oral health.
6. **Statherin and Cystatins**: These proteins regulate calcium phosphate precipitation, preventing dental calculus formation and maintaining tooth mineral homeostasis.

Salivary proteins and peptides have attracted significant interest in recent years due to their potential diagnostic and therapeutic applications. Alterations in the composition of these molecules can provide valuable insights into various oral and systemic diseases, making them promising biomarkers for disease detection and monitoring.

Plasminogen Activator Inhibitor 1 (PAI-1) is a protein involved in the regulation of fibrinolysis, which is the body's natural process of breaking down blood clots. PAI-1 inhibits tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), two enzymes that convert plasminogen to plasmin, which degrades fibrin clots. Therefore, PAI-1 acts as a natural antagonist of the fibrinolytic system, promoting clot formation and stability. Increased levels of PAI-1 have been associated with thrombotic disorders, such as deep vein thrombosis and pulmonary embolism.

Thromboembolism is a medical condition that refers to the obstruction of a blood vessel by a thrombus (blood clot) that has formed elsewhere in the body and then been transported by the bloodstream to a narrower vessel, where it becomes lodged. This process can occur in various parts of the body, leading to different types of thromboembolisms:

1. Deep Vein Thrombosis (DVT): A thrombus forms in the deep veins, usually in the legs or pelvis, and then breaks off and travels to the lungs, causing a pulmonary embolism.
2. Pulmonary Embolism (PE): A thrombus formed elsewhere, often in the deep veins of the legs, dislodges and travels to the lungs, blocking one or more pulmonary arteries. This can lead to shortness of breath, chest pain, and potentially life-threatening complications if not treated promptly.
3. Cerebral Embolism: A thrombus formed in another part of the body, such as the heart or carotid artery, dislodges and travels to the brain, causing a stroke or transient ischemic attack (TIA).
4. Arterial Thromboembolism: A thrombus forms in an artery and breaks off, traveling to another part of the body and blocking blood flow to an organ or tissue, leading to potential damage or loss of function. Examples include mesenteric ischemia (intestinal damage due to blocked blood flow) and retinal artery occlusion (vision loss due to blocked blood flow in the eye).

Prevention, early detection, and appropriate treatment are crucial for managing thromboembolism and reducing the risk of severe complications.

Glycoproteins are complex proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. These glycans are linked to the protein through asparagine residues (N-linked) or serine/threonine residues (O-linked). Glycoproteins play crucial roles in various biological processes, including cell recognition, cell-cell interactions, cell adhesion, and signal transduction. They are widely distributed in nature and can be found on the outer surface of cell membranes, in extracellular fluids, and as components of the extracellular matrix. The structure and composition of glycoproteins can vary significantly depending on their function and location within an organism.

"Light coagulation," also known as "laser coagulation," is a medical term that refers to the use of laser technology to cauterize (seal or close) tissue. This procedure uses heat generated by a laser to cut, coagulate, or destroy tissue. In light coagulation, the laser beam is focused on the blood vessels in question, causing the blood within them to clot and the vessels to seal. This can be used for various medical purposes, such as stopping bleeding during surgery, destroying abnormal tissues (like tumors), or treating eye conditions like diabetic retinopathy and age-related macular degeneration.

It's important to note that this is a general definition, and the specific use of light coagulation may vary depending on the medical specialty and the individual patient's needs. As always, it's best to consult with a healthcare professional for more detailed information about any medical procedure or treatment.

'Erythrina' is a botanical term, not a medical one. It refers to a genus of plants in the family Fabaceae, also known as the pea or legume family. These plants are commonly called coral trees due to their bright red flowers. While some parts of certain species can have medicinal uses, such as anti-inflammatory and analgesic properties, 'Erythrina' itself is not a medical term or condition.

Blood viscosity is a measure of the thickness or flow resistance of blood. It is defined as the ratio of shear stress to shear rate within the flowing blood, which reflects the internal friction or resistance to flow. Blood viscosity is primarily determined by the concentration and size of red blood cells (hematocrit), plasma proteins, and other blood constituents. An increase in any of these components can raise blood viscosity, leading to impaired blood flow, reduced oxygen delivery to tissues, and potential cardiovascular complications if not managed appropriately.

Annexin A5 is a protein that belongs to the annexin family, which are calcium-dependent phospholipid-binding proteins. Annexin A5 has high affinity for phosphatidylserine, a type of phospholipid that is usually located on the inner leaflet of the plasma membrane in healthy cells. However, when cells undergo apoptosis (programmed cell death), phosphatidylserine is exposed on the outer leaflet of the plasma membrane.

Annexin A5 can bind to exposed phosphatidylserine on the surface of apoptotic cells and is commonly used as a marker for detecting apoptosis in various experimental settings, including flow cytometry, immunohistochemistry, and imaging techniques. Annexin A5-based assays are widely used in research and clinical settings to study the mechanisms of apoptosis and to develop diagnostic tools for various diseases, such as cancer, neurodegenerative disorders, and cardiovascular diseases.

I believe there may be some confusion in your question. "Rabbits" is a common name used to refer to the Lagomorpha species, particularly members of the family Leporidae. They are small mammals known for their long ears, strong legs, and quick reproduction.

However, if you're referring to "rabbits" in a medical context, there is a term called "rabbit syndrome," which is a rare movement disorder characterized by repetitive, involuntary movements of the fingers, resembling those of a rabbit chewing. It is also known as "finger-chewing chorea." This condition is usually associated with certain medications, particularly antipsychotics, and typically resolves when the medication is stopped or adjusted.

Aprotinin is a medication that belongs to a class of drugs called serine protease inhibitors. It works by inhibiting the activity of certain enzymes in the body that can cause tissue damage and bleeding. Aprotinin is used in medical procedures such as heart bypass surgery to reduce blood loss and the need for blood transfusions. It is administered intravenously and its use is typically stopped a few days after the surgical procedure.

Aprotinin was first approved for use in the United States in 1993, but its use has been restricted or withdrawn in many countries due to concerns about its safety. In 2006, a study found an increased risk of kidney damage and death associated with the use of aprotinin during heart bypass surgery, leading to its withdrawal from the market in Europe and Canada. However, it is still available for use in the United States under a restricted access program.

It's important to note that the use of aprotinin should be carefully considered and discussed with the healthcare provider, taking into account the potential benefits and risks of the medication.

A Structure-Activity Relationship (SAR) in the context of medicinal chemistry and pharmacology refers to the relationship between the chemical structure of a drug or molecule and its biological activity or effect on a target protein, cell, or organism. SAR studies aim to identify patterns and correlations between structural features of a compound and its ability to interact with a specific biological target, leading to a desired therapeutic response or undesired side effects.

By analyzing the SAR, researchers can optimize the chemical structure of lead compounds to enhance their potency, selectivity, safety, and pharmacokinetic properties, ultimately guiding the design and development of novel drugs with improved efficacy and reduced toxicity.

Tissue Plasminogen Activator (tPA) is a thrombolytic enzyme, which means it dissolves blood clots. It is naturally produced by the endothelial cells that line the interior surface of blood vessels. tPA activates plasminogen, a zymogen, to convert it into plasmin, a protease that breaks down fibrin, the structural protein in blood clots. This enzyme is used medically as a thrombolytic drug under various brand names, such as Activase and Alteplase, to treat conditions like acute ischemic stroke, pulmonary embolism, and deep vein thrombosis by dissolving the clots and restoring blood flow.

Microfluidics is a multidisciplinary field that involves the study, manipulation, and control of fluids that are geometrically constrained to a small, typically sub-millimeter scale. It combines elements from physics, chemistry, biology, materials science, and engineering to design and fabricate microscale devices that can handle and analyze small volumes of fluids, often in the range of picoliters to microliters.

In medical contexts, microfluidics has numerous applications, including diagnostic testing, drug discovery, and personalized medicine. For example, microfluidic devices can be used to perform rapid and sensitive molecular assays for detecting pathogens or biomarkers in patient samples, as well as to screen drugs and evaluate their efficacy and toxicity in vitro.

Microfluidics also enables the development of organ-on-a-chip platforms that mimic the structure and function of human tissues and organs, allowing researchers to study disease mechanisms and test new therapies in a more physiologically relevant context than traditional cell culture models. Overall, microfluidics offers significant potential for improving healthcare outcomes by enabling faster, more accurate, and more cost-effective diagnostic and therapeutic strategies.

Biological models, also known as physiological models or organismal models, are simplified representations of biological systems, processes, or mechanisms that are used to understand and explain the underlying principles and relationships. These models can be theoretical (conceptual or mathematical) or physical (such as anatomical models, cell cultures, or animal models). They are widely used in biomedical research to study various phenomena, including disease pathophysiology, drug action, and therapeutic interventions.

Examples of biological models include:

1. Mathematical models: These use mathematical equations and formulas to describe complex biological systems or processes, such as population dynamics, metabolic pathways, or gene regulation networks. They can help predict the behavior of these systems under different conditions and test hypotheses about their underlying mechanisms.
2. Cell cultures: These are collections of cells grown in a controlled environment, typically in a laboratory dish or flask. They can be used to study cellular processes, such as signal transduction, gene expression, or metabolism, and to test the effects of drugs or other treatments on these processes.
3. Animal models: These are living organisms, usually vertebrates like mice, rats, or non-human primates, that are used to study various aspects of human biology and disease. They can provide valuable insights into the pathophysiology of diseases, the mechanisms of drug action, and the safety and efficacy of new therapies.
4. Anatomical models: These are physical representations of biological structures or systems, such as plastic models of organs or tissues, that can be used for educational purposes or to plan surgical procedures. They can also serve as a basis for developing more sophisticated models, such as computer simulations or 3D-printed replicas.

Overall, biological models play a crucial role in advancing our understanding of biology and medicine, helping to identify new targets for therapeutic intervention, develop novel drugs and treatments, and improve human health.

Afibrinogenemia is a rare genetic disorder characterized by the complete absence or severely decreased levels of fibrinogen, a protein involved in blood clotting. This condition leads to an increased risk of excessive bleeding due to the inability to form proper blood clots. It is caused by mutations in the genes that provide instructions for making the three chains (Aα, Bβ, and γ) that make up the fibrinogen protein. Inheritance is autosomal recessive, meaning an individual must inherit two copies of the defective gene, one from each parent, to have the condition.

Inflammation is a complex biological response of tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is characterized by the following signs: rubor (redness), tumor (swelling), calor (heat), dolor (pain), and functio laesa (loss of function). The process involves the activation of the immune system, recruitment of white blood cells, and release of inflammatory mediators, which contribute to the elimination of the injurious stimuli and initiation of the healing process. However, uncontrolled or chronic inflammation can also lead to tissue damage and diseases.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

SERPINs are an acronym for "serine protease inhibitors." They are a group of proteins that inhibit serine proteases, which are enzymes that cut other proteins. SERPINs are found in various tissues and body fluids, including blood, and play important roles in regulating biological processes such as inflammation, blood clotting, and cell death. They do this by forming covalent complexes with their target proteases, thereby preventing them from carrying out their proteolytic activities. Mutations in SERPIN genes have been associated with several genetic disorders, including emphysema, cirrhosis, and dementia.

I'm sorry for any confusion, but "Pentosan Sulfuric Polyester" is not a recognized medical term or a substance used in medicine. It seems to be a non-existent term. You might have made a mistake while typing or it could be a specific chemical compound not related to medical field. If you meant "Pentosan Polysulfate," I can provide its definition:

Pentosan Polysulfate is a semi-synthetic drug with properties similar to heparin. It is used in the treatment of osteoarthritis and interstitial cystitis due to its anti-inflammatory and analgesic effects. The chemical structure consists of a polyanionic, polydisperse molecule made up of repeating pentosan units linked by sulfuric ester bonds.

Gelatin is not strictly a medical term, but it is often used in medical contexts. Medically, gelatin is recognized as a protein-rich substance that is derived from collagen, which is found in the skin, bones, and connective tissue of animals. It is commonly used in the production of various medical and pharmaceutical products such as capsules, wound dressings, and drug delivery systems due to its biocompatibility and ability to form gels.

In a broader sense, gelatin is a translucent, colorless, flavorless food ingredient that is derived from collagen through a process called hydrolysis. It is widely used in the food industry as a gelling agent, thickener, stabilizer, and texturizer in various foods such as candies, desserts, marshmallows, and yogurts.

It's worth noting that while gelatin has many uses, it may not be suitable for vegetarians or those with dietary restrictions since it is derived from animal products.

Vitamin K epoxide reductases (VKORs) are enzymes that play a crucial role in the vitamin K cycle, which is essential for the post-translational modification of certain proteins involved in blood coagulation and bone metabolism. Specifically, VKORs reduce vitamin K epoxide back to its active form, vitamin K hydroquinone, allowing it to participate in the carboxylation of these proteins.

The most well-known member of this enzyme family is VKORC1 (Vitamin K Epoxide Reductase Complex Subunit 1), which is the target of the anticoagulant drug warfarin. Warfarin inhibits VKORC1, preventing the reduction of vitamin K epoxide and thereby interfering with the carboxylation of coagulation factors II, VII, IX, and X, as well as proteins C and S. This leads to the production of functionally inactive forms of these proteins and results in the anticoagulant effect of warfarin.

I'm sorry for any confusion, but "Isoflurophate" does not appear to be a recognized term in medical or scientific literature. It is possible that there may be a spelling error or typo in the term you are looking for. If you meant "Isoflurane," which is a commonly used anesthetic in medical and surgical procedures, I can provide a definition for that.

Isoflurane: A volatile halogenated ether liquid used as an inhalational general anesthetic agent. It has a rapid onset and offset of action, making it useful for both induction and maintenance of anesthesia. Isoflurane is also known to have bronchodilatory properties, which can be beneficial in patients with reactive airway disease or asthma.

Calcium is an essential mineral that is vital for various physiological processes in the human body. The medical definition of calcium is as follows:

Calcium (Ca2+) is a crucial cation and the most abundant mineral in the human body, with approximately 99% of it found in bones and teeth. It plays a vital role in maintaining structural integrity, nerve impulse transmission, muscle contraction, hormonal secretion, blood coagulation, and enzyme activation.

Calcium homeostasis is tightly regulated through the interplay of several hormones, including parathyroid hormone (PTH), calcitonin, and vitamin D. Dietary calcium intake, absorption, and excretion are also critical factors in maintaining optimal calcium levels in the body.

Hypocalcemia refers to low serum calcium levels, while hypercalcemia indicates high serum calcium levels. Both conditions can have detrimental effects on various organ systems and require medical intervention to correct.

Point-of-care (POC) systems refer to medical diagnostic tests or tools that are performed at or near the site where a patient receives care, such as in a doctor's office, clinic, or hospital room. These systems provide rapid and convenient results, allowing healthcare professionals to make immediate decisions regarding diagnosis, treatment, and management of a patient's condition.

POC systems can include various types of diagnostic tests, such as:

1. Lateral flow assays (LFAs): These are paper-based devices that use capillary action to detect the presence or absence of a target analyte in a sample. Examples include pregnancy tests and rapid strep throat tests.
2. Portable analyzers: These are compact devices used for measuring various parameters, such as blood glucose levels, coagulation status, or electrolytes, using small volumes of samples.
3. Imaging systems: Handheld ultrasound machines and portable X-ray devices fall under this category, providing real-time imaging at the point of care.
4. Monitoring devices: These include continuous glucose monitors, pulse oximeters, and blood pressure cuffs that provide real-time data to help manage patient conditions.

POC systems offer several advantages, such as reduced turnaround time for test results, decreased need for sample transportation, and increased patient satisfaction due to faster decision-making and treatment initiation. However, it is essential to ensure the accuracy and reliability of these tests by following proper testing procedures and interpreting results correctly.

Protamines are small, arginine-rich proteins that are found in the sperm cells of many organisms. They play a crucial role in the process of sperm maturation, also known as spermiogenesis. During this process, the DNA in the sperm cell is tightly packed and compacted by the protamines, which helps to protect the genetic material during its journey to fertilize an egg.

Protamines are typically composed of around 50-100 amino acids and have a high proportion of positively charged arginine residues, which allow them to interact strongly with the negatively charged DNA molecule. This interaction results in the formation of highly condensed chromatin structures that are resistant to enzymatic digestion and other forms of damage.

In addition to their role in sperm maturation, protamines have also been studied for their potential use in drug delivery and gene therapy applications. Their ability to bind strongly to DNA makes them attractive candidates for delivering drugs or genetic material directly to the nucleus of a cell. However, more research is needed to fully understand the potential benefits and risks associated with these applications.

Trypsin inhibitors are substances that inhibit the activity of trypsin, an enzyme that helps digest proteins in the small intestine. Trypsin inhibitors can be found in various foods such as soybeans, corn, and raw egg whites. In the case of soybeans, trypsin inhibitors are denatured and inactivated during cooking and processing.

In a medical context, trypsin inhibitors may be used therapeutically to regulate excessive trypsin activity in certain conditions such as pancreatitis, where there is inflammation of the pancreas leading to the release of activated digestive enzymes, including trypsin, into the pancreas and surrounding tissues. By inhibiting trypsin activity, these inhibitors can help reduce tissue damage and inflammation.

The liver is a large, solid organ located in the upper right portion of the abdomen, beneath the diaphragm and above the stomach. It plays a vital role in several bodily functions, including:

1. Metabolism: The liver helps to metabolize carbohydrates, fats, and proteins from the food we eat into energy and nutrients that our bodies can use.
2. Detoxification: The liver detoxifies harmful substances in the body by breaking them down into less toxic forms or excreting them through bile.
3. Synthesis: The liver synthesizes important proteins, such as albumin and clotting factors, that are necessary for proper bodily function.
4. Storage: The liver stores glucose, vitamins, and minerals that can be released when the body needs them.
5. Bile production: The liver produces bile, a digestive juice that helps to break down fats in the small intestine.
6. Immune function: The liver plays a role in the immune system by filtering out bacteria and other harmful substances from the blood.

Overall, the liver is an essential organ that plays a critical role in maintaining overall health and well-being.

Sequence homology, amino acid, refers to the similarity in the order of amino acids in a protein or a portion of a protein between two or more species. This similarity can be used to infer evolutionary relationships and functional similarities between proteins. The higher the degree of sequence homology, the more likely it is that the proteins are related and have similar functions. Sequence homology can be determined through various methods such as pairwise alignment or multiple sequence alignment, which compare the sequences and calculate a score based on the number and type of matching amino acids.

X-ray crystallography is a technique used in structural biology to determine the three-dimensional arrangement of atoms in a crystal lattice. In this method, a beam of X-rays is directed at a crystal and diffracts, or spreads out, into a pattern of spots called reflections. The intensity and angle of each reflection are measured and used to create an electron density map, which reveals the position and type of atoms in the crystal. This information can be used to determine the molecular structure of a compound, including its shape, size, and chemical bonds. X-ray crystallography is a powerful tool for understanding the structure and function of biological macromolecules such as proteins and nucleic acids.

Vitamin K2, also known as menaquinone, is a fat-soluble vitamin that plays a crucial role in the blood clotting process and bone metabolism. It is one of the two main forms of Vitamin K (the other being Vitamin K1 or phylloquinone), and it is found in animal-based foods and fermented foods.

Vitamin K2 is a collective name for a group of vitamin K compounds characterized by the presence of a long-chain fatty acid attached to the molecule. The most common forms of Vitamin K2 are MK-4 and MK-7, which differ in the length of their side chains.

Vitamin K2 is absorbed more efficiently than Vitamin K1 and has a longer half-life, which means it stays in the body for a longer period. It is stored in various tissues, including bones, where it plays an essential role in maintaining bone health by assisting in the regulation of calcium deposition and helping to prevent the calcification of blood vessels and other soft tissues.

Deficiency in Vitamin K2 is rare but can lead to bleeding disorders and weakened bones. Food sources of Vitamin K2 include animal-based foods such as liver, egg yolks, and fermented dairy products like cheese and natto (a Japanese food made from fermented soybeans). Some studies suggest that supplementing with Vitamin K2 may have benefits for bone health, heart health, and cognitive function. However, more research is needed to confirm these potential benefits.

"Competitive binding" is a term used in pharmacology and biochemistry to describe the behavior of two or more molecules (ligands) competing for the same binding site on a target protein or receptor. In this context, "binding" refers to the physical interaction between a ligand and its target.

When a ligand binds to a receptor, it can alter the receptor's function, either activating or inhibiting it. If multiple ligands compete for the same binding site, they will compete to bind to the receptor. The ability of each ligand to bind to the receptor is influenced by its affinity for the receptor, which is a measure of how strongly and specifically the ligand binds to the receptor.

In competitive binding, if one ligand is present in high concentrations, it can prevent other ligands with lower affinity from binding to the receptor. This is because the higher-affinity ligand will have a greater probability of occupying the binding site and blocking access to the other ligands. The competition between ligands can be described mathematically using equations such as the Langmuir isotherm, which describes the relationship between the concentration of ligand and the fraction of receptors that are occupied by the ligand.

Competitive binding is an important concept in drug development, as it can be used to predict how different drugs will interact with their targets and how they may affect each other's activity. By understanding the competitive binding properties of a drug, researchers can optimize its dosage and delivery to maximize its therapeutic effect while minimizing unwanted side effects.

Cadaverine is a foul-smelling organic compound that is produced by the breakdown of certain amino acids in dead bodies. It is formed through the decarboxylation of lysine, an essential amino acid, and is characterized by its strong, unpleasant odor. Cadaverine is often used as a forensic indicator of decomposition and is also being studied for its potential role in various physiological processes, such as inflammation and cancer.

"Swine" is a common term used to refer to even-toed ungulates of the family Suidae, including domestic pigs and wild boars. However, in a medical context, "swine" often appears in the phrase "swine flu," which is a strain of influenza virus that typically infects pigs but can also cause illness in humans. The 2009 H1N1 pandemic was caused by a new strain of swine-origin influenza A virus, which was commonly referred to as "swine flu." It's important to note that this virus is not transmitted through eating cooked pork products; it spreads from person to person, mainly through respiratory droplets produced when an infected person coughs or sneezes.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

Calcium chloride is an inorganic compound with the chemical formula CaCl2. It is a white, odorless, and tasteless solid that is highly soluble in water. Calcium chloride is commonly used as a de-icing agent, a desiccant (drying agent), and a food additive to enhance texture and flavor.

In medical terms, calcium chloride can be used as a medication to treat hypocalcemia (low levels of calcium in the blood) or hyperkalemia (high levels of potassium in the blood). It is administered intravenously and works by increasing the concentration of calcium ions in the blood, which helps to regulate various physiological processes such as muscle contraction, nerve impulse transmission, and blood clotting.

However, it is important to note that calcium chloride can have adverse effects if not used properly or in excessive amounts. It can cause tissue irritation, cardiac arrhythmias, and other serious complications. Therefore, its use should be monitored carefully by healthcare professionals.

Substrate specificity in the context of medical biochemistry and enzymology refers to the ability of an enzyme to selectively bind and catalyze a chemical reaction with a particular substrate (or a group of similar substrates) while discriminating against other molecules that are not substrates. This specificity arises from the three-dimensional structure of the enzyme, which has evolved to match the shape, charge distribution, and functional groups of its physiological substrate(s).

Substrate specificity is a fundamental property of enzymes that enables them to carry out highly selective chemical transformations in the complex cellular environment. The active site of an enzyme, where the catalysis takes place, has a unique conformation that complements the shape and charge distribution of its substrate(s). This ensures efficient recognition, binding, and conversion of the substrate into the desired product while minimizing unwanted side reactions with other molecules.

Substrate specificity can be categorized as:

1. Absolute specificity: An enzyme that can only act on a single substrate or a very narrow group of structurally related substrates, showing no activity towards any other molecule.
2. Group specificity: An enzyme that prefers to act on a particular functional group or class of compounds but can still accommodate minor structural variations within the substrate.
3. Broad or promiscuous specificity: An enzyme that can act on a wide range of structurally diverse substrates, albeit with varying catalytic efficiencies.

Understanding substrate specificity is crucial for elucidating enzymatic mechanisms, designing drugs that target specific enzymes or pathways, and developing biotechnological applications that rely on the controlled manipulation of enzyme activities.

Annexins are a family of calcium-dependent phospholipid-binding proteins that are found in various organisms, including humans. They are involved in several cellular processes, such as membrane organization, signal transduction, and regulation of ion channels. Some annexins also have roles in inflammation, blood coagulation, and apoptosis (programmed cell death).

Annexins have a conserved structure, consisting of a core domain that binds to calcium ions and a variable number of domains that bind to phospholipids. This allows annexins to interact with membranes in a calcium-dependent manner, which is important for their functions.

There are several different annexin proteins, each with its own specific functions and expression patterns. For example, annexin A1 is involved in the regulation of inflammation and has been studied as a potential target for anti-inflammatory therapies. Annexin A2 is involved in the regulation of coagulation and has been studied as a potential target for anticoagulant therapies. Other annexins have roles in cell division, differentiation, and survival.

Overall, annexins are important regulators of various cellular processes and have potential as targets for therapeutic intervention in a variety of diseases.

Hematocrit is a medical term that refers to the percentage of total blood volume that is made up of red blood cells. It is typically measured as part of a complete blood count (CBC) test. A high hematocrit may indicate conditions such as dehydration, polycythemia, or living at high altitudes, while a low hematocrit may be a sign of anemia, bleeding, or overhydration. It is important to note that hematocrit values can vary depending on factors such as age, gender, and pregnancy status.

Factor XIII deficiency, also known as fibrin stabilizing factor deficiency, is a rare bleeding disorder caused by a lack or dysfunction of Factor XIII, a protein involved in the final stage of blood clotting. This deficiency results in impaired clot stability and increased risk of bleeding. Symptoms can include umbilical cord bleeding at birth, prolonged bleeding after circumcision, easy bruising, nosebleeds, muscle bleeds, gastrointestinal bleeds, and excessive menstrual bleeding. Treatment typically involves replacement of the missing Factor XIII through injections, either prophylactically or on-demand to manage bleeding episodes.

Colloids are a type of mixture that contains particles that are intermediate in size between those found in solutions and suspensions. These particles range in size from about 1 to 1000 nanometers in diameter, which is smaller than what can be seen with the naked eye, but larger than the molecules in a solution.

Colloids are created when one substance, called the dispersed phase, is dispersed in another substance, called the continuous phase. The dispersed phase can consist of particles such as proteins, emulsified fats, or finely divided solids, while the continuous phase is usually a liquid, but can also be a gas or a solid.

Colloids are important in many areas of medicine and biology, including drug delivery, diagnostic imaging, and tissue engineering. They are also found in nature, such as in milk, blood, and fog. The properties of colloids can be affected by factors such as pH, temperature, and the presence of other substances, which can influence their stability and behavior.

The umbilical veins are blood vessels in the umbilical cord that carry oxygenated and nutrient-rich blood from the mother to the developing fetus during pregnancy. There are typically two umbilical veins, one of which usually degenerates and becomes obliterated, leaving a single functional vein. This remaining vein is known as the larger umbilical vein or the venous duct. It enters the fetal abdomen through the umbilicus and passes through the liver, where it branches off to form the portal sinus. Ultimately, the blood from the umbilical vein mixes with the blood from the inferior vena cava and is pumped to the heart through the right atrium.

It's important to note that after birth, the umbilical veins are no longer needed and undergo involution, becoming the ligamentum teres in the adult.

Monocytes are a type of white blood cell that are part of the immune system. They are large cells with a round or oval shape and a nucleus that is typically indented or horseshoe-shaped. Monocytes are produced in the bone marrow and then circulate in the bloodstream, where they can differentiate into other types of immune cells such as macrophages and dendritic cells.

Monocytes play an important role in the body's defense against infection and tissue damage. They are able to engulf and digest foreign particles, microorganisms, and dead or damaged cells, which helps to clear them from the body. Monocytes also produce cytokines, which are signaling molecules that help to coordinate the immune response.

Elevated levels of monocytes in the bloodstream can be a sign of an ongoing infection, inflammation, or other medical conditions such as cancer or autoimmune disorders.

Cricetinae is a subfamily of rodents that includes hamsters, gerbils, and relatives. These small mammals are characterized by having short limbs, compact bodies, and cheek pouches for storing food. They are native to various parts of the world, particularly in Europe, Asia, and Africa. Some species are popular pets due to their small size, easy care, and friendly nature. In a medical context, understanding the biology and behavior of Cricetinae species can be important for individuals who keep them as pets or for researchers studying their physiology.

The complement system is a group of proteins found in the blood and on the surface of cells that when activated, work together to help eliminate pathogens such as bacteria, viruses, and fungi from the body. The proteins are normally inactive in the bloodstream. When they encounter an invading microorganism or foreign substance, a series of reactions take place leading to the activation of the complement system. Activation results in the production of effector molecules that can punch holes in the cell membranes of pathogens, recruit and activate immune cells, and help remove debris and dead cells from the body.

There are three main pathways that can lead to complement activation: the classical pathway, the lectin pathway, and the alternative pathway. Each pathway involves a series of proteins that work together in a cascade-like manner to amplify the response and generate effector molecules. The three main effector molecules produced by the complement system are C3b, C4b, and C5b. These molecules can bind to the surface of pathogens, marking them for destruction by other immune cells.

Complement proteins also play a role in the regulation of the immune response. They help to prevent excessive activation of the complement system, which could damage host tissues. Dysregulation of the complement system has been implicated in a number of diseases, including autoimmune disorders and inflammatory conditions.

In summary, Complement System Proteins are a group of proteins that play a crucial role in the immune response by helping to eliminate pathogens and regulate the immune response. They can be activated through three different pathways, leading to the production of effector molecules that mark pathogens for destruction. Dysregulation of the complement system has been linked to various diseases.

Oligopeptides are defined in medicine and biochemistry as short chains of amino acids, typically containing fewer than 20 amino acid residues. These small peptides are important components in various biological processes, such as serving as signaling molecules, enzyme inhibitors, or structural elements in some proteins. They can be found naturally in foods and may also be synthesized for use in medical research and therapeutic applications.

Surgical hemostasis refers to the methods and techniques used during surgical procedures to stop bleeding or prevent hemorrhage. This can be achieved through various means, including the use of surgical instruments such as clamps, ligatures, or staples to physically compress blood vessels and stop the flow of blood. Electrosurgical tools like cautery may also be used to coagulate and seal off bleeding vessels using heat. Additionally, topical hemostatic agents can be applied to promote clotting and control bleeding in wounded tissues. Effective surgical hemostasis is crucial for ensuring a successful surgical outcome and minimizing the risk of complications such as excessive blood loss, infection, or delayed healing.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

I'm sorry for any confusion, but "Lupus Coagulation Inhibitor" is not a recognized medical term or concept in hematology or immunology.

Systemic Lupus Erythematosus (SLE), often referred to simply as lupus, is an autoimmune disease where the body's immune system mistakenly attacks healthy tissue. However, this does not result in a specific coagulation inhibitor.

If you're asking about lupus anticoagulants, these are antibodies that can interfere with clotting tests but paradoxically increase the risk of blood clots in vivo. They are sometimes seen in patients with SLE and other autoimmune diseases.

Please provide more context if you meant something else, so I can give a more accurate response.

In genetics, sequence alignment is the process of arranging two or more DNA, RNA, or protein sequences to identify regions of similarity or homology between them. This is often done using computational methods to compare the nucleotide or amino acid sequences and identify matching patterns, which can provide insight into evolutionary relationships, functional domains, or potential genetic disorders. The alignment process typically involves adjusting gaps and mismatches in the sequences to maximize the similarity between them, resulting in an aligned sequence that can be visually represented and analyzed.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

Disulfides are a type of organic compound that contains a sulfur-sulfur bond. In the context of biochemistry and medicine, disulfide bonds are often found in proteins, where they play a crucial role in maintaining their three-dimensional structure and function. These bonds form when two sulfhydryl groups (-SH) on cysteine residues within a protein molecule react with each other, releasing a molecule of water and creating a disulfide bond (-S-S-) between the two cysteines. Disulfide bonds can be reduced back to sulfhydryl groups by various reducing agents, which is an important process in many biological reactions. The formation and reduction of disulfide bonds are critical for the proper folding, stability, and activity of many proteins, including those involved in various physiological processes and diseases.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

'Gene expression regulation' refers to the processes that control whether, when, and where a particular gene is expressed, meaning the production of a specific protein or functional RNA encoded by that gene. This complex mechanism can be influenced by various factors such as transcription factors, chromatin remodeling, DNA methylation, non-coding RNAs, and post-transcriptional modifications, among others. Proper regulation of gene expression is crucial for normal cellular function, development, and maintaining homeostasis in living organisms. Dysregulation of gene expression can lead to various diseases, including cancer and genetic disorders.

Protease inhibitors are a class of antiviral drugs that are used to treat infections caused by retroviruses, such as the human immunodeficiency virus (HIV), which is responsible for causing AIDS. These drugs work by blocking the activity of protease enzymes, which are necessary for the replication and multiplication of the virus within infected cells.

Protease enzymes play a crucial role in the life cycle of retroviruses by cleaving viral polyproteins into functional units that are required for the assembly of new viral particles. By inhibiting the activity of these enzymes, protease inhibitors prevent the virus from replicating and spreading to other cells, thereby slowing down the progression of the infection.

Protease inhibitors are often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS. Common examples of protease inhibitors include saquinavir, ritonavir, indinavir, and atazanavir. While these drugs have been successful in improving the outcomes of people living with HIV/AIDS, they can also cause side effects such as nausea, diarrhea, headaches, and lipodystrophy (changes in body fat distribution).

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Factor V deficiency is a rare bleeding disorder that is caused by a mutation in the gene that produces coagulation factor V, a protein involved in the clotting process. This condition can lead to excessive bleeding following injury or surgery, and may also cause menorrhagia (heavy menstrual periods) in women.

Factor V deficiency is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) in order to develop the condition. People who inherit only one copy of the mutated gene are carriers and may have a milder form of the disorder or no symptoms at all.

Treatment for factor V deficiency typically involves replacement therapy with fresh frozen plasma or clotting factor concentrates, which can help to reduce bleeding episodes and prevent complications. In some cases, medications such as desmopressin or antifibrinolytics may also be used to manage the condition.

Trypsin is a proteolytic enzyme, specifically a serine protease, that is secreted by the pancreas as an inactive precursor, trypsinogen. Trypsinogen is converted into its active form, trypsin, in the small intestine by enterokinase, which is produced by the intestinal mucosa.

Trypsin plays a crucial role in digestion by cleaving proteins into smaller peptides at specific arginine and lysine residues. This enzyme helps to break down dietary proteins into amino acids, allowing for their absorption and utilization by the body. Additionally, trypsin can activate other zymogenic pancreatic enzymes, such as chymotrypsinogen and procarboxypeptidases, thereby contributing to overall protein digestion.

A "Blood Cell Count" is a medical laboratory test that measures the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in a sample of blood. This test is often used as a part of a routine check-up or to help diagnose various medical conditions, such as anemia, infection, inflammation, and many others.

The RBC count measures the number of oxygen-carrying cells in the blood, while the WBC count measures the number of immune cells that help fight infections. The platelet count measures the number of cells involved in clotting. Abnormal results in any of these counts may indicate an underlying medical condition and further testing may be required for diagnosis and treatment.

Amino acids are organic compounds that serve as the building blocks of proteins. They consist of a central carbon atom, also known as the alpha carbon, which is bonded to an amino group (-NH2), a carboxyl group (-COOH), a hydrogen atom (H), and a variable side chain (R group). The R group can be composed of various combinations of atoms such as hydrogen, oxygen, sulfur, nitrogen, and carbon, which determine the unique properties of each amino acid.

There are 20 standard amino acids that are encoded by the genetic code and incorporated into proteins during translation. These include:

1. Alanine (Ala)
2. Arginine (Arg)
3. Asparagine (Asn)
4. Aspartic acid (Asp)
5. Cysteine (Cys)
6. Glutamine (Gln)
7. Glutamic acid (Glu)
8. Glycine (Gly)
9. Histidine (His)
10. Isoleucine (Ile)
11. Leucine (Leu)
12. Lysine (Lys)
13. Methionine (Met)
14. Phenylalanine (Phe)
15. Proline (Pro)
16. Serine (Ser)
17. Threonine (Thr)
18. Tryptophan (Trp)
19. Tyrosine (Tyr)
20. Valine (Val)

Additionally, there are several non-standard or modified amino acids that can be incorporated into proteins through post-translational modifications, such as hydroxylation, methylation, and phosphorylation. These modifications expand the functional diversity of proteins and play crucial roles in various cellular processes.

Amino acids are essential for numerous biological functions, including protein synthesis, enzyme catalysis, neurotransmitter production, energy metabolism, and immune response regulation. Some amino acids can be synthesized by the human body (non-essential), while others must be obtained through dietary sources (essential).

Caseins are a group of phosphoproteins found in the milk of mammals, including cows and humans. They are the major proteins in milk, making up about 80% of the total protein content. Caseins are characterized by their ability to form micelles, or tiny particles, in milk when it is mixed with calcium. This property allows caseins to help transport calcium and other minerals throughout the body.

Caseins are also known for their nutritional value, as they provide essential amino acids and are easily digestible. They are often used as ingredients in infant formula and other food products. Additionally, caseins have been studied for their potential health benefits, such as reducing the risk of cardiovascular disease and improving bone health. However, more research is needed to confirm these potential benefits.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Peptides are short chains of amino acid residues linked by covalent bonds, known as peptide bonds. They are formed when two or more amino acids are joined together through a condensation reaction, which results in the elimination of a water molecule and the formation of an amide bond between the carboxyl group of one amino acid and the amino group of another.

Peptides can vary in length from two to about fifty amino acids, and they are often classified based on their size. For example, dipeptides contain two amino acids, tripeptides contain three, and so on. Oligopeptides typically contain up to ten amino acids, while polypeptides can contain dozens or even hundreds of amino acids.

Peptides play many important roles in the body, including serving as hormones, neurotransmitters, enzymes, and antibiotics. They are also used in medical research and therapeutic applications, such as drug delivery and tissue engineering.

Hemoglobin (Hb or Hgb) is the main oxygen-carrying protein in the red blood cells, which are responsible for delivering oxygen throughout the body. It is a complex molecule made up of four globin proteins and four heme groups. Each heme group contains an iron atom that binds to one molecule of oxygen. Hemoglobin plays a crucial role in the transport of oxygen from the lungs to the body's tissues, and also helps to carry carbon dioxide back to the lungs for exhalation.

There are several types of hemoglobin present in the human body, including:

* Hemoglobin A (HbA): This is the most common type of hemoglobin, making up about 95-98% of total hemoglobin in adults. It consists of two alpha and two beta globin chains.
* Hemoglobin A2 (HbA2): This makes up about 1.5-3.5% of total hemoglobin in adults. It consists of two alpha and two delta globin chains.
* Hemoglobin F (HbF): This is the main type of hemoglobin present in fetal life, but it persists at low levels in adults. It consists of two alpha and two gamma globin chains.
* Hemoglobin S (HbS): This is an abnormal form of hemoglobin that can cause sickle cell disease when it occurs in the homozygous state (i.e., both copies of the gene are affected). It results from a single amino acid substitution in the beta globin chain.
* Hemoglobin C (HbC): This is another abnormal form of hemoglobin that can cause mild to moderate hemolytic anemia when it occurs in the homozygous state. It results from a different single amino acid substitution in the beta globin chain than HbS.

Abnormal forms of hemoglobin, such as HbS and HbC, can lead to various clinical disorders, including sickle cell disease, thalassemia, and other hemoglobinopathies.

Affinity chromatography is a type of chromatography technique used in biochemistry and molecular biology to separate and purify proteins based on their biological characteristics, such as their ability to bind specifically to certain ligands or molecules. This method utilizes a stationary phase that is coated with a specific ligand (e.g., an antibody, antigen, receptor, or enzyme) that selectively interacts with the target protein in a sample.

The process typically involves the following steps:

1. Preparation of the affinity chromatography column: The stationary phase, usually a solid matrix such as agarose beads or magnetic beads, is modified by covalently attaching the ligand to its surface.
2. Application of the sample: The protein mixture is applied to the top of the affinity chromatography column, allowing it to flow through the stationary phase under gravity or pressure.
3. Binding and washing: As the sample flows through the column, the target protein selectively binds to the ligand on the stationary phase, while other proteins and impurities pass through. The column is then washed with a suitable buffer to remove any unbound proteins and contaminants.
4. Elution of the bound protein: The target protein can be eluted from the column using various methods, such as changing the pH, ionic strength, or polarity of the buffer, or by introducing a competitive ligand that displaces the bound protein.
5. Collection and analysis: The eluted protein fraction is collected and analyzed for purity and identity, often through techniques like SDS-PAGE or mass spectrometry.

Affinity chromatography is a powerful tool in biochemistry and molecular biology due to its high selectivity and specificity, enabling the efficient isolation of target proteins from complex mixtures. However, it requires careful consideration of the binding affinity between the ligand and the protein, as well as optimization of the elution conditions to minimize potential damage or denaturation of the purified protein.

Endopeptidases are a type of enzyme that breaks down proteins by cleaving peptide bonds inside the polypeptide chain. They are also known as proteinases or endoproteinases. These enzymes work within the interior of the protein molecule, cutting it at specific points along its length, as opposed to exopeptidases, which remove individual amino acids from the ends of the protein chain.

Endopeptidases play a crucial role in various biological processes, such as digestion, blood coagulation, and programmed cell death (apoptosis). They are classified based on their catalytic mechanism and the structure of their active site. Some examples of endopeptidase families include serine proteases, cysteine proteases, aspartic proteases, and metalloproteases.

It is important to note that while endopeptidases are essential for normal physiological functions, they can also contribute to disease processes when their activity is unregulated or misdirected. For instance, excessive endopeptidase activity has been implicated in the pathogenesis of neurodegenerative disorders, cancer, and inflammatory conditions.

Platelet aggregation inhibitors are a class of medications that prevent platelets (small blood cells involved in clotting) from sticking together and forming a clot. These drugs work by interfering with the ability of platelets to adhere to each other and to the damaged vessel wall, thereby reducing the risk of thrombosis (blood clot formation).

Platelet aggregation inhibitors are often prescribed for people who have an increased risk of developing blood clots due to various medical conditions such as atrial fibrillation, coronary artery disease, peripheral artery disease, stroke, or a history of heart attack. They may also be used in patients undergoing certain medical procedures, such as angioplasty and stenting, to prevent blood clot formation in the stents.

Examples of platelet aggregation inhibitors include:

1. Aspirin: A nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase, which is involved in platelet activation and aggregation.
2. Clopidogrel (Plavix): A P2Y12 receptor antagonist that selectively blocks ADP-induced platelet activation and aggregation.
3. Prasugrel (Effient): A third-generation thienopyridine P2Y12 receptor antagonist, similar to clopidogrel but with faster onset and greater potency.
4. Ticagrelor (Brilinta): A direct-acting P2Y12 receptor antagonist that does not require metabolic activation and has a reversible binding profile.
5. Dipyridamole (Persantine): An antiplatelet agent that inhibits platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels in platelets, which leads to decreased platelet reactivity.
6. Iloprost (Ventavis): A prostacyclin analogue that inhibits platelet aggregation and causes vasodilation, often used in the treatment of pulmonary arterial hypertension.
7. Cilostazol (Pletal): A phosphodiesterase III inhibitor that increases cAMP levels in platelets, leading to decreased platelet activation and aggregation, as well as vasodilation.
8. Ticlopidine (Ticlid): An older P2Y12 receptor antagonist with a slower onset of action and more frequent side effects compared to clopidogrel or prasugrel.

Protein precursors, also known as proproteins or prohormones, are inactive forms of proteins that undergo post-translational modification to become active. These modifications typically include cleavage of the precursor protein by specific enzymes, resulting in the release of the active protein. This process allows for the regulation and control of protein activity within the body. Protein precursors can be found in various biological processes, including the endocrine system where they serve as inactive hormones that can be converted into their active forms when needed.

The placenta is an organ that develops in the uterus during pregnancy and provides oxygen and nutrients to the growing baby through the umbilical cord. It also removes waste products from the baby's blood. The placenta attaches to the wall of the uterus, and the baby's side of the placenta contains many tiny blood vessels that connect to the baby's circulatory system. This allows for the exchange of oxygen, nutrients, and waste between the mother's and baby's blood. After the baby is born, the placenta is usually expelled from the uterus in a process called afterbirth.

Protein C deficiency is a genetic disorder that affects the body's ability to control blood clotting. Protein C is a protein in the blood that helps regulate the formation of blood clots. When blood clots form too easily or do not dissolve properly, they can block blood vessels and lead to serious medical conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

People with protein C deficiency have lower than normal levels of this protein in their blood, which can increase their risk of developing abnormal blood clots. The condition is usually inherited and present from birth, but it may not cause any symptoms until later in life, such as during pregnancy, after surgery, or due to other factors that increase the risk of blood clots.

Protein C deficiency can be classified into two types: type I and type II. Type I deficiency is characterized by lower than normal levels of both functional and immunoreactive protein C in the blood. Type II deficiency is characterized by normal or near-normal levels of immunoreactive protein C, but reduced functional activity.

Protein C deficiency can be diagnosed through blood tests that measure the level and function of protein C in the blood. Treatment may include anticoagulant medications to prevent blood clots from forming or dissolve existing ones. Regular monitoring of protein C levels and careful management of risk factors for blood clots are also important parts of managing this condition.

Electrochemical techniques are a group of analytical methods used in chemistry and biochemistry that involve the study of chemical processes that cause electrons to move. These techniques use an electrochemical cell, which consists of two electrodes (a working electrode and a counter electrode) immersed in an electrolyte solution. An electrical potential is applied between the electrodes, which drives redox reactions to occur at the electrode surfaces. The resulting current that flows through the cell can be measured and related to the concentration of analytes in the solution.

There are several types of electrochemical techniques, including:

1. Voltammetry: This technique measures the current that flows through the cell as a function of the applied potential. There are several types of voltammetry, including cyclic voltammetry, differential pulse voltammetry, and square wave voltammetry.
2. Amperometry: This technique measures the current that flows through the cell at a constant potential.
3. Potentiometry: This technique measures the potential difference between the working electrode and a reference electrode at zero current flow.
4. Impedance spectroscopy: This technique measures the impedance of the electrical circuit formed by the electrochemical cell as a function of frequency.

Electrochemical techniques are widely used in various fields, such as environmental monitoring, pharmaceuticals, food analysis, and biomedical research. They offer several advantages, including high sensitivity, selectivity, and simplicity, making them a powerful tool for chemical analysis.

Fetoscopy is a minimally invasive surgical procedure that allows direct visualization of the fetus and the intrauterine environment through the use of a fiber-optic scope. It is typically performed during the second trimester of pregnancy to diagnose or treat various fetal conditions, such as twin-to-twin transfusion syndrome, congenital diaphragmatic hernia, or spina bifida. The procedure involves inserting a thin tube called a fetoscope through the mother's abdomen and uterus to access the fetus. Fetoscopy can also be used for taking fetal tissue samples for genetic testing.

It is important to note that while fetoscopy can provide valuable information and treatment options, it does carry some risks, including preterm labor, premature rupture of membranes, infection, and bleeding. Therefore, the decision to undergo fetoscopy should be made carefully, in consultation with a medical professional, and based on a thorough evaluation of the potential benefits and risks.

Sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs. It is characterized by a whole-body inflammatory state (systemic inflammation) that can lead to blood clotting issues, tissue damage, and multiple organ failure.

Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Infections that lead to sepsis most often start in the lungs, urinary tract, skin, or gastrointestinal tract.

Sepsis is a medical emergency. If you suspect sepsis, seek immediate medical attention. Early recognition and treatment of sepsis are crucial to improve outcomes. Treatment usually involves antibiotics, intravenous fluids, and may require oxygen, medication to raise blood pressure, and corticosteroids. In severe cases, surgery may be required to clear the infection.

Deoxyribonucleic acid (DNA) is the genetic material present in the cells of organisms where it is responsible for the storage and transmission of hereditary information. DNA is a long molecule that consists of two strands coiled together to form a double helix. Each strand is made up of a series of four nucleotide bases - adenine (A), guanine (G), cytosine (C), and thymine (T) - that are linked together by phosphate and sugar groups. The sequence of these bases along the length of the molecule encodes genetic information, with A always pairing with T and C always pairing with G. This base-pairing allows for the replication and transcription of DNA, which are essential processes in the functioning and reproduction of all living organisms.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Lipids are a broad group of organic compounds that are insoluble in water but soluble in nonpolar organic solvents. They include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, diglycerides, triglycerides, and phospholipids. Lipids serve many important functions in the body, including energy storage, acting as structural components of cell membranes, and serving as signaling molecules. High levels of certain lipids, particularly cholesterol and triglycerides, in the blood are associated with an increased risk of cardiovascular disease.

A cell membrane, also known as the plasma membrane, is a thin semi-permeable phospholipid bilayer that surrounds all cells in animals, plants, and microorganisms. It functions as a barrier to control the movement of substances in and out of the cell, allowing necessary molecules such as nutrients, oxygen, and signaling molecules to enter while keeping out harmful substances and waste products. The cell membrane is composed mainly of phospholipids, which have hydrophilic (water-loving) heads and hydrophobic (water-fearing) tails. This unique structure allows the membrane to be flexible and fluid, yet selectively permeable. Additionally, various proteins are embedded in the membrane that serve as channels, pumps, receptors, and enzymes, contributing to the cell's overall functionality and communication with its environment.

Site-directed mutagenesis is a molecular biology technique used to introduce specific and targeted changes to a specific DNA sequence. This process involves creating a new variant of a gene or a specific region of interest within a DNA molecule by introducing a planned, deliberate change, or mutation, at a predetermined site within the DNA sequence.

The methodology typically involves the use of molecular tools such as PCR (polymerase chain reaction), restriction enzymes, and/or ligases to introduce the desired mutation(s) into a plasmid or other vector containing the target DNA sequence. The resulting modified DNA molecule can then be used to transform host cells, allowing for the production of large quantities of the mutated gene or protein for further study.

Site-directed mutagenesis is a valuable tool in basic research, drug discovery, and biotechnology applications where specific changes to a DNA sequence are required to understand gene function, investigate protein structure/function relationships, or engineer novel biological properties into existing genes or proteins.

Heparin sulfate is not exactly referred to as "heparitin sulfate" in medical terminology. The correct term is heparan sulfate, which is a type of glycosaminoglycan (GAG), a long unbranched chain of repeating disaccharide units composed of a hexuronic acid and a hexosamine.

Heparan sulfate is found on the cell surface and in the extracellular matrix, where it plays crucial roles in various biological processes, including cell signaling, regulation of growth factor activity, and control of blood coagulation. It is also an important component of the proteoglycans, which are complex molecules that help to maintain the structural integrity and function of tissues and organs.

Like heparin, heparan sulfate has a high negative charge due to the presence of sulfate groups, which allows it to bind to and interact with various proteins and growth factors. However, heparan sulfate has a more diverse structure than heparin, with variations in the pattern of sulfation along the chain, which leads to specificity in its interactions with different proteins.

Defects in heparan sulfate biosynthesis or function have been implicated in various human diseases, including certain forms of cancer, developmental disorders, and infectious diseases.

Hydrolysis is a chemical process, not a medical one. However, it is relevant to medicine and biology.

Hydrolysis is the breakdown of a chemical compound due to its reaction with water, often resulting in the formation of two or more simpler compounds. In the context of physiology and medicine, hydrolysis is a crucial process in various biological reactions, such as the digestion of food molecules like proteins, carbohydrates, and fats. Enzymes called hydrolases catalyze these hydrolysis reactions to speed up the breakdown process in the body.

... may refer to: Coagulation factor IXa, an enzyme Coagulation factor XIa, an enzyme This ... disambiguation page lists articles associated with the title Activated blood coagulation factor XI. If an internal link led you ...
... , also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. It ... Coagulation begins almost instantly after an injury to the endothelium lining a blood vessel. Exposure of blood to the ... Coagulation can physically trap invading microbes in blood clots. Also, some products of the coagulation system can contribute ... Physiology of blood coagulation is based on hemostasis, the normal bodily process that stops bleeding. Coagulation is a part of ...
Look up coagulation in Wiktionary, the free dictionary. Coagulation is the process by which blood forms clots. Coagulation may ... the coagulation of milk into curd by rennet or acid Coagulation, the loss of solubility as a result of denaturation Blood Gulch ... a multiplayer map called "Coagulation" in the video game Halo 2 Mixing of two particles in an aerosol to form a third particle ... a possible early stage of planet formation This disambiguation page lists articles associated with the title Coagulation. If an ...
Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a ... Coagulation factor XIII A chain is a protein that in humans is encoded by the F13A1 gene. This gene encodes the coagulation ... Hilgenfeld R, Liesum A, Storm R, Metzner HJ, Karges HE (1990). "Crystallization of blood coagulation factor XIII by an ... Takahashi N, Takahashi Y, Putnam FW (1986). "Primary structure of blood coagulation factor XIIIa (fibrinoligase, ...
v t e (Blood, Coagulation system, All stub articles, Hematology stubs). ... Coagulation activation markers are biomarkers of net activation of coagulation and fibrinolysis. Examples include prothrombin ... Levels of coagulation activation markers are increased with pregnancy, with estrogen-containing birth control pills, with ... Birth control pills containing estradiol or estetrol also appear to have less influence on coagulation activation markers than ...
This also activates protein kinase C which stimulates platelet aggregation and therefore blood coagulation further down the ... Blood. 89 (6): 1944-53. doi:10.1182/blood.V89.6.1944. PMID 9058715. Overview of all the structural information available in the ... Blood. 82 (5): 1532-7. doi:10.1182/blood.V82.5.1532.1532. PMID 8395910. "José RJ, Williams AE, Chambers RC (February 2014). " ... Blood. 105 (8): 3178-84. doi:10.1182/blood-2004-10-3985. PMID 15626732. S2CID 24170814. Michelson AD (2013). Platelets (3rd ed ...
1 January 1986). Blood Coagulation. Elsevier. pp. 250-. ISBN 978-0-08-086072-5. OCLC 1058474585. Jun Teruya, ed. (5 January ... v t e v t e (CS1: long volume value, All stub articles, Biochemistry stubs, Hematology stubs, Coagulation system, Protein ...
Type II domains have also been found in a range of proteins including blood coagulation factor XII; bovine seminal plasma ... Fibronectins are involved in a number of important functions e.g., wound healing; cell adhesion; blood coagulation; cell ... Structural similarity of the protease precursor to blood coagulation factor XII". J. Biol. Chem. 268 (14): 10024-10028. doi: ...
doi:10.1182/blood-2008-01-077909. PMID 18574041. Dahlbäck, Björn (2000). "Blood coagulation". The Lancet. 355 (9215): 1627-1632 ... He is also the director of the blood coagulation unit at Malmö General Hospital. His research was important in showing that APC ... Dahlbäck, Björn (2000). "Blood coagulation". The Lancet. 355 (9215): 1627-1632. doi:10.1016/S0140-6736(00)02225-X. PMID ... specializing in hematology and the molecular mechanisms of blood coagulation. He determined that activated protein C (APC) ...
"Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency". Blood. 79 (6 ... Fujikawa K, Chung DW, Hendrickson LE, Davie EW (May 1986). "Amino acid sequence of human factor XI, a blood coagulation factor ... Fujikawa K, Chung DW, Hendrickson LE, Davie EW (May 1986). "Amino acid sequence of human factor XI, a blood coagulation factor ... Walsh PN (Jul 2001). "Roles of platelets and factor XI in the initiation of blood coagulation by thrombin". Thrombosis and ...
Davie studied the blood proteins involved in coagulation and was among the first scientists to describe the steps of the ... "1962: Blood Coagulation". UW Office of Research. November 1996. Archived from the original on August 25, 2015. Retrieved ... The Centre for Blood Research at the University of British Columbia established the Earl W. Davie Symposium in his honor. "Earl ... "Earl W. Davie Symposium". Centre for Blood Research. Retrieved November 12, 2015. (All articles with dead external links, ...
Blood Coagulation & Fibrinolysis. 23 (1): 45-50. doi:10.1097/mbc.0b013e32834d7ce3. PMID 22024796. S2CID 3327902. Keane C, ... Blood. 90 (3): 1109-14. doi:10.1182/blood.V90.3.1109. PMID 9242542. Nourse JP, Lea R, Crooks P, Wright G, Tran H, Catalano J, ...
de Boer JD, Majoor CJ, van 't Veer C, Bel EH, van der Poll T (April 2012). "Asthma and coagulation". Blood. 119 (14): 3236-44. ... doi:10.1182/blood-2011-11-391532. PMID 22262775. Middleton's Allergy Principles & Practice, N. F. Adkinson, B. S. Bochner, W. W ...
Budzynski, A. Z. (February 1991). "Interaction of hementin with fibrinogen and fibrin". Blood Coagulation & Fibrinolysis. 2 (1 ... which the Amazon leech inserts into the host to suck blood. Hementin dissolves platelet-rich blood clots and lets the blood ... Blood Coagulation & Fibrinolysis. DOI: 10.1097/00001721-199102000-00023 (1): 153-9. doi:10.1097/00001721-199102000-00023. PMID ... Hementin is able to dissolve a type of blood clots that cannot be dissolved by other compounds, such as streptokinase and ...
Blood Coagulation & Fibrinolysis. 16 (1): 1-7. doi:10.1097/00001721-200501000-00001. PMID 15650539. S2CID 44664652. Melzer C, ... It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, ...
Blood Coagulation & Fibrinolysis. 19 (7): 709-718. doi:10.1097/MBC.0b013e32830b2891. PMC 2713681. PMID 18832915. "Genomatix: ...
Blood Coagulation & Fibrinolysis. 19 (7): 709-18. doi:10.1097/MBC.0b013e32830b2891. PMC 2713681. PMID 18832915. Lee, J; Zheng, ... for DX-2400, a Matrix metalloproteinase-14 (MPP-14) targeted monoclonal antibody intended to inhibit tumor blood vessel ...
Franco, David; Everett, George; Manoucheri, Manoucher (2013). "I smell a rat". Blood Coagulation & Fibrinolysis. 24 (2): 202-4 ... the blood plasma and blood itself begin to leak from the smallest blood vessels. A poisoned animal suffers progressively ... Blood, 76 (12): 2555-2559, doi:10.1182/blood.V76.12.2555.2555, PMID 2265249 "COCA Clinical Action: Outbreak Alert Update: ... A complete blood count and complete metabolic panel were normal. Prothrombin time (PT) was above 100 s, partial thromboplastin ...
Marsh, NA (July 1998). "Use of snake venom fractions in the coagulation laboratory". Blood Coagulation & Fibrinolysis. 9 (5): ... Blood Coagulation & Fibrinolysis. 1 (3): 259-66. doi:10.1097/00001721-199008000-00002. PMID 2129412. Laboratory testing for the ... Blood. 68 (4): 869-74. doi:10.1182/blood.V68.4.869.869. PMID 3092888. Exner, T; Papadopoulos, G; Koutts, J (August 1990). "Use ... Exner, T; Rickard, KA; Kronenberg, H (October 1975). "Studies on phospholipids in the action of a lupus coagulation inhibitor ...
Coagulation, the formation of a blood clot or thrombus, occurs when the proteins of the coagulation cascade are activated, ... D-dimers are not normally present in human blood plasma, except when the coagulation system has been activated, for instance, ... D-dimer levels are used as a predictive biomarker for the blood disorder disseminated intravascular coagulation and in the ... Blood Coagulation & Fibrinolysis. 27 (5): 542-50. doi:10.1097/MBC.0000000000000453. PMC 4935535. PMID 26656897. Olson JD, ...
... inhibiting several blood coagulation enzymes counting thrombin and factor Xa. In the beginning, protein C inhibitor(PCI) was ... Blood Coagulation & Fibrinolysis. 4 (1): 153-8. doi:10.1097/00001721-199304010-00027. PMID 8384496. Moore A, Penfold LM, ... Blood Coagulation & Fibrinolysis. 6 (5): 382-7. doi:10.1097/00001721-199507000-00003. PMID 8589203. The MEROPS online database ... Blood Coagulation & Fibrinolysis. 4 (6): 921-6. doi:10.1097/00001721-199304060-00009. PMID 8148485. S2CID 33601129. Hayashi T, ...
... s, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood, ... Citrate is in liquid form in the tube and is used for coagulation tests, as well as in blood transfusion bags. It binds the ... A Bethesda unit (BU) is a measure of blood coagulation inhibitor activity. It is the amount of inhibitor that will inactivate ... Apixaban had no effect on mortality, recurrence of blood clots in blood vessels or major bleeding or minor bleeding, however ...
Blood Coagulation & Fibrinolysis. 25 (5): 507-511. doi:10.1097/MBC.0000000000000057. ISSN 1473-5733. PMID 24553060. S2CID ... Blood Coagulation & Fibrinolysis. 25 (5): 507-511. doi:10.1097/MBC.0000000000000057. ISSN 1473-5733. PMID 24553060. S2CID ... Blood Coagulation & Fibrinolysis. 25 (5): 507-511. doi:10.1097/MBC.0000000000000057. ISSN 1473-5733. PMID 24553060. S2CID ... It is characterized by progressive lower extremity edema distal to the thigh, tight shiny skin, cyanosis (inadequate blood ...
Blood Coagulation & Fibrinolysis. 19 (7): 709-18. doi:10.1097/MBC.0b013e32830b2891. PMC 2713681. PMID 18832915. Park J, Chun KH ... Blood. 127 (17): 2144-54. doi:10.1182/blood-2015-10-678706. PMC 4850869. PMID 26983850. Shanley M (6 October 2017). "Therapy to ... and high blood pressure. Belumosudil was approved for medical use in the United States in July 2021. The US Food and Drug ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. North ...
Blood Coagulation and Fibrinolysis. 22(2): 110-7 (2011). Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific ... The haemostatic (blood clotting) system involves the interaction of proteins in the blood, the blood vessel wall and the flow ... They form aggregates with white blood cells and in adults the platelets that are bound to white blood cells are usually ... There is more Antithrombin bound to Heparin in blood from newborns compared to blood from adults, suggesting different ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. ... and impaired coagulation. No definitive antidote for amatoxin poisoning is available, but some specific treatments have been ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. (CS1 ...
Activated blood coagulation factor XI may refer to: Coagulation factor IXa, an enzyme Coagulation factor XIa, an enzyme This ... disambiguation page lists articles associated with the title Activated blood coagulation factor XI. If an internal link led you ...
The journal is devoted to publishing significant developments worldwide in the field of blood coagulation, fibrinolysis, ... thrombosis, platelets and the kininogen-kinin system, as well as dealing with those aspects of blood rheology relevant to ... Blood Coagulation & Fibrinolysis is an international fully refereed journal that features review and original research articles ... Blood Coagulation & Fibrinolysis. You may be trying to access this site from a secured browser on the server. Please enable ...
Mathematical model of blood coagulation. Reused Wajima2009 model with modifications to reactions 27 (formation of Va:Xa complex ... SBML L2V4 representation of Hartmann2016 - Blood coagulation model for simulating anticoagulants. 281.13 KB. Preview , Download ... Predictions of individual coagulation factor time courses under steady-state warfarin, enoxaparin, and rivaroxaban treatment ... Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network ...
Researchers showed that dielectric blood coagulometry provided an easy to use method to detect changes in FXa activity in the ... which is associated with the occurrence of blood vessel-related diseases. Pathological enhancement of the clotting cascade ... Thrombosis occurs as a result of the generation of thrombi (blood clots) from platelets and red blood cells. These blood clots ... Stop that clot! Quantitative assessment of the blood coagulation cascade. Date:. December 17, 2018. Source:. Tokyo Medical and ...
Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits * Sections Miscarriages Caused by Blood Coagulation ... Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits) and Miscarriages Caused by Blood Coagulation Protein or ... Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits. Updated: Mar 30, 2022 ... Bick RL, Hoppensteadt D. Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a ...
Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX.. ... Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX.. ...
Fisher Scientific - Controls for heparin assay procedures. Shop Siemens Healthineers Ci-Trol™ Heparin Controls at Fishersci.com
It is exposed to flowing blood during injury or inflammation, binds FVIIa, and initiates the extrinsic coagulation pathway. ... The TF-FVIIa complex (extrinsic tenase) activates FX, triggering the intrinsic coagulation pathway (in vitro). ... including organ capsules and the adventitia of blood vessel walls. It is constitutively expressed on fibroblasts and, on ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
The sequential process by which the multiple coagulation factors of the blood interact, ultimately resulting in the formation ...
Effect on blood coagulation parameters in plasma isolated from hemophilia A patient assessed as clotting time at 40 nM by ...
What blood tests would I need to determine if my blood coagulation is normal? Or if it is thick from hereditary issues or ... Is it true that clotting of blood is same as coagulation of blood?. 1 doctor answer • 3 doctors weighed in ... If your blood is clotting too much, do you need to get surgery?. 2 doctor answers • 2 doctors weighed in ... What can I do if I have an unstable acute angina and my blood is not clotting?. 1 doctor answer • 2 doctors weighed in ...
Blood coagulation parameters in patients with severe COVID-19 from Kermanshah Province, Islamic Republic of Iran ... Eastern Mediterranean Health Journal , All issues , Volume 26 2020 , Volume 26 issue 9 , Blood coagulation parameters in ... More comparison of reports from various populations related to the clinical course, outcome of COVID-19 and blood coagulation ... Citation: Sayad B; Rahimi Z. Blood coagulation parameters in patients with Severe COVID-19 from Kermanshah Province, Islamic ...
We evaluated the effects of RIC on coagulation function in OPCAB patients.A total of 58 patients undergoing OPCAB were ... Effect of remote ischaemic conditioning on coagulation function as measured by whole blood impedance aggregometry and ... The trend towards a decrease in adenosine diphosphate-induced whole blood aggregation at the end of surgery was greater in the ... We evaluated the effects of RIC on coagulation function in OPCAB patients.. A total of 58 patients undergoing OPCAB were ...
The sequential process by which the multiple coagulation factors of the blood interact, ultimately resulting in the formation ... Human Gene Set: BLOOD_COAGULATION Standard name. BLOOD_COAGULATION. Systematic name. M11793. ...
Comparison of blood coagulation factors between patients with gastrointestinal or intracranial bleeding under vitamin K ...
... which are available for influencing or substituting the coagulation proteins: desmopressin (DDAVP), single coagulation factor ... I will address some biochemical characteristics and the physiological role of von Willebrand factor, the coagulation factors of ...
This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a ... involved_in blood coagulation IBA Inferred from Biological aspect of Ancestor. more info ... coagulation factor XII. Names. Hageman factor. Plasma coagulation Factor XIIa. beta-factor XIIa part 1. beta-factor XIIa part 2 ... involved_in blood coagulation, intrinsic pathway IC Inferred by Curator. more info ...
This study demonstrates that a 2-h hypoxic challenge in patients with COPD results in coagulation activation in conjunction ... Blood was sampled for thrombin-antithrombin complex (TAT), prothrombin activation fragments 1 + 2 (F(1 + 2)), von Willebrand ... The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD Chest. 2010 Jul;138(1):47-51. ... In the control group, there was no change in markers of coagulation or systemic inflammation over the 2-h study. In patients ...
These proteins help your blood to clot after injury. Learn more. ... A coagulation factor test checks the function of certain ... What are Coagulation Factor Tests?. Coagulation factors are proteins in your blood. They help form blood clots to stop bleeding ... Coagulation factor tests are blood tests that check one or more of your clotting factors to see if you:. *Have too much or too ... Why do I need a coagulation factor test?. You may need this test if you have:. *An abnormal result on a blood test that checks ...
Get up-to-date information on coagulation factor VIII side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn ... coagulation factor VIII is part of the drug class:. *. Blood coagulation factors. ... How was your experience with coagulation factor VIII?. First, a little about yourself. Male Female ... The coagulation factor VIII dose your doctor recommends will be based on the following (use any or all that apply): ...
This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which ... This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX ... Coagulation Factor XI / FXI / F11 Antibody, Rabbit PAb * Coagulation Factor XI / FXI / F11 Antibody, Rabbit PAb, Antigen ... Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality. [provided by RefSeq, Jul 2008]. Expression ...
This tests your pet s blood for coagulation issues. A small sample of blood is taken into a special tube which contains sodium ... VetScan VSPro: Coagulation:. The Complete Pet Animal Hospital. 5135 N Dysart Road Suite 4. Litchfield Park, AZ 85340 Phone: ( ... The amount of time it takes the blood to clot it recorded and displayed on the screen. This whole process takes less than 10 ... After the pet s information is inputted in the machine and the cartridge is room temperature, 2 drops of blood from the special ...
This condition is only temporary; in a few minutes the blood becomes viscid and sti... ... When blood is first drawn from the living body it is perfectly liquid, flowing in any direction as readily as water. ... The Coagulation Of Blood. When blood is first drawn from the living body it is perfectly liquid, flowing in any direction as ... Uses Of Coagulation. The living circulating blood in the healthy blood-vessels does not clot; it contains no solid fibrin, but ...
... is an international fully refereed journal that features review and original research articles ... The journal is devoted to publishing significant developments worldwide in the field of blood coagulation, fibrinolysis, ... thrombosis, platelets and the kininogen-kinin system, as well as dealing with those aspects of blood rheology relevant to ...
The thrombin generation potential, an in vitro blood coagulation test, which reflects an individual´s global coagulation status ... diagnosed by microscopic assessment of thick blood smear, were obtained. Biomarkers of blood coagulation (thrombin generation ... This study had the aim to investigate changes of blood coagulation under the standardized conditions of controlled human ... 191.5 nM (138.2-231.9); p = 0.026]. There were no significant changes of other coagulation parameters. ...
A low molecular weight platelet inhibitor of factor XIa: purification, characterization, and possible role in blood coagulation ... combined with the specificity of PIXI for factor XIa among serine proteases found in blood, suggest a role for PIXI in the ...
Whole Blood Coagulation System Provides Multipurpose Point-of-Care Solution. Feb 3, 2004 , Coagulation Testing, Hematology & ... By Lisa Fratt The Hemochron Response whole blood coagulation system is a future-oriented system based on International ... Roche to Expand Coagulation Testing Portfolio. Oct 4, 2011 , Coagulation Testing, Hematology & Serology, Miscellaneous ... Coagulation assays and test kits. Mar 19, 2003 , Coagulation Testing, Hematology & Serology, Miscellaneous ...
The blood coagulating factors are proteins or enzymes that prevent the bleeding. ... Europe Blood Coagulation Factor Market by Product Type. The study comprised of the European market of the blood coagulation ... Europe Blood Coagulation Factor Market Report, By Product Type (Blood Product, Non-Plasma Derived Coagulation Factor), End User ... Blood Coagulation Factor Market- Segmental Overview. The Europe blood coagulation factor market is segmented by product type, ...
Uncoagulable blood and life-threatening bleeding can result from the action of some snake venom toxins on haemostatic ... components of blood and vessel walls. Although envenoming by Micropechis ikaheka primarily affects neurones and muscle cells ... The inhibition of platelet aggregation and blood coagulation by Micropechis ikaheka venom. ... Anticoagulants, Aristolochic Acids, Bleeding Time, Blood Coagulation, Cell Adhesion, Cells, Cultured, Collagen, Dose-Response ...
  • The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. (nih.gov)
  • Blood Coagul Fibrinolysis, 2021 Dec 1. (nih.gov)
  • Blood Coagulation & Fibrinolysis is an international fully refereed journal that features review and original research articles on all clinical, laboratory and experimental aspects of haemostasis and thrombosis. (wkadcenter.com)
  • The journal is devoted to publishing significant developments worldwide in the field of blood coagulation, fibrinolysis, thrombosis, platelets and the kininogen-kinin system, as well as dealing with those aspects of blood rheology relevant to haemostasis and the effects of drugs on haemostatic components. (wkadcenter.com)
  • Mishchenko V.P., Gol'denberg Iu.M., Novosel'tseva T.V. (1980) Effect of the antioxidant ionol on blood coagulation and fibrinolysis. (msk.ru)
  • Natural oestrogen in the female climacteric--influence on blood coagulation and fibrinolysis. (herbal-organic.com)
  • The aim of the present study was to investigate the effect on blood coagulation and fibrinolysis of a natural oestrogen preparation, piperazine oestrone sulphate, prospectively in menopausal women. (herbal-organic.com)
  • Blood was sampled for thrombin-antithrombin complex (TAT), prothrombin activation fragments 1 + 2 (F(1 + 2)), von Willebrand factor antigen (VWF:Ag), D-dimer, and interleukin-6 (IL-6) at baseline and after 2 h. (nih.gov)
  • They found that the coagulation factor thrombin greatly amplifies the prothrombotic and proinflammatory function of endothelial cells, and they identified part of the molecular mechanism that is responsible for this effect. (versiti.org)
  • Proteine mit Einfluss auf die Blutgerinnung [Proteins influencing the blood coagulation]. (unil.ch)
  • Coagulation factors are proteins in your blood. (medlineplus.gov)
  • The blood coagulating factors are proteins or enzymes that prevent the bleeding. (axiommrc.com)
  • Plasma stored from EDTA-treated blood can also be used to measure most proteins, and genetic material can easily be stored from EDTA buffy coats (the interface between the red cells and the plasma after centrifugation, containing white cells and platelets). (bloodcollectingtube.com)
  • All the clotting factors are proteins that are circulating in the blood. (gleath.com)
  • Blood clotting requires platelets and several different kinds of proteins in order to be successful. (rockawaycancer.com)
  • Thrombosis occurs as a result of the generation of thrombi (blood clots) from platelets and red blood cells. (sciencedaily.com)
  • When you have an injury that causes bleeding, blood cells called platelets begin to make a soft blood clot to stop the bleeding. (medlineplus.gov)
  • The platelets release molecules into your blood that begin to turn on the clotting factors. (medlineplus.gov)
  • Fibrin and platelets form the blood clot to stop the bleeding. (labpedia.net)
  • Blood tests may show that the number of platelets in a blood sample has dropped (platelets are used up when blood clots) and that the blood is taking a long time to clot. (msdmanuals.com)
  • The reason for the thrombosis could be excessive activation of the coagulation factors and platelets. (thieme.co.uk)
  • According to Prof. Violi, these "reactive oxygen species" not only activate blood clotting and platelets but also cause the blood vessels to constrict (vasoconstriction). (thieme.co.uk)
  • Blood-borne transmission of pathogens has highlighted the crucial importance of effective policies, strategies, quality systems, and legislative and regulatory frameworks in the collection, testing, processing and supply of blood components, such as red cells, platelets and plasma, for clinical use. (who.int)
  • In March 2021, fol owing reports of rare blood coagulation disorders in a few individuals who had received the AZ vaccine in Europe, the WHO's Global Advisory Committee on Vaccine Safety (GACVS) and European Medicines Agency (EMA) reviewed al available information and data on thromboembolic events (blood clots) and thrombocytopenia (low platelets) after vaccination. (who.int)
  • This is your basic hematology tube (by which I mean identifying and counting blood cells, blood typing, etc). (bloodcollectingtube.com)
  • K2EDTA is recommended by the CLSI (CLSI guideline - Evacuated Tubes and Additives for Blood Specimen Collection-Fifth Edition H1-A5, 2003) and the ICSH (International Council for Standardization in Hematology). (bloodcollectingtube.com)
  • It is exposed to flowing blood during injury or inflammation, binds FVIIa, and initiates the extrinsic coagulation pathway. (merckvetmanual.com)
  • Tissue thromboplastin forms the complex with factor VII, Ca ++ , and stimulates the extrinsic coagulation pathway. (labpedia.net)
  • The TF-FVIIa complex (extrinsic tenase) activates FX, triggering the intrinsic coagulation pathway (in vitro). (merckvetmanual.com)
  • It activates coagulation factors VII and XI. (nih.gov)
  • Stuttgart/New York - Severe infections with the novel coronavirus SARS-CoV-2 activates the blood coagulation mechanism and increases the risk of life-threatening complications such as heart attack or stroke. (thieme.co.uk)
  • Factors 2, 7, 9 and 10 are essential for blood coagulation, and vitamin K activates them. (socratic.org)
  • Injury to body parts activates several systems, including the autonomic nervous system, the coagulation system, the fibrinolytic system, the complement system, and the systemic inflammatory response. (medscape.com)
  • These blood clots can block blood vessels, causing tissue damage and broader disease in affected patients. (sciencedaily.com)
  • They help form blood clots to stop bleeding when you have an injury. (medlineplus.gov)
  • You have several different types of clotting factors that are all important for making blood clots. (medlineplus.gov)
  • But normally, clotting factors are turned off, so you don't form abnormal blood clots. (medlineplus.gov)
  • Your blood clots too easily, even without an injury. (medlineplus.gov)
  • This condition may lead to clots that block your blood flow and cause serious conditions, such as heart attack , stroke , or clots in the lungs . (medlineplus.gov)
  • Coagulation factor tests are also used to monitor people who have a known problem with clotting factors or who take medicine called blood thinners to lower the risk of blood clots. (medlineplus.gov)
  • So too, when a surgeon ties an artery, the tight ligature crushes or tears its delicate inner surface, and the blood clots where this is injured. (bookdome.com)
  • Disseminated intravascular coagulation is a condition in which small blood clots develop throughout the bloodstream, blocking small blood vessels. (msdmanuals.com)
  • Overview of Blood Clotting Disorders Blood clots help stop bleeding. (msdmanuals.com)
  • Blood clotting (coagulation) disorders are dysfunctions in the body's ability to control the formation of blood clots. (msdmanuals.com)
  • How Blood Clots Hemostasis is the body's way of stopping injured blood vessels from bleeding. (msdmanuals.com)
  • Deep Vein Thrombosis (DVT) Deep vein thrombosis is the formation of blood clots (thrombi) in the deep veins, usually in the legs. (msdmanuals.com)
  • Blood clots may form in veins if the vein is injured, a disorder causes the blood to clot. (msdmanuals.com)
  • The diagnosis of DIC is confirmed if test results show abnormally increased quantities of plasma D-dimer (a substance that blood clots release when they break down. (msdmanuals.com)
  • More D-dimer indicates that more clots are being produced than usual) and often a low or decreasing level of fibrinogen (a protein that is consumed when blood clots). (msdmanuals.com)
  • Hyperactivity of the blood coagulation process (thrombophilia) could explain why many patients suffer a heart attack or stroke, which are caused by blood clots in the coronary or cerebral arteries. (thieme.co.uk)
  • The protein is increasingly produced when clots have already formed in the blood vessels. (thieme.co.uk)
  • Coagulation is the process by which our bodies form blood clots. (rockawaycancer.com)
  • In another type of coagulation disorders, blood clotting occurs in excess and blood clots form when they should not. (rockawaycancer.com)
  • Hyperfibrinolysis destroys stable blood clots, and antifibrinolytic agents may be required. (medscape.com)
  • The request stated that some of the about 200 affected employees were developing nodes on their vocal cords, that there were a number of unexplained blood clots, and suggestion of tumors. (cdc.gov)
  • RMS due to blood protein or platelet defects may come about through either of two mechanisms: (1) disorders associated with a hemorrhagic tendency or (2) defects associated with a thrombotic tendency. (medscape.com)
  • Bleeding disorders can lead to serious blood loss after an injury. (medlineplus.gov)
  • The factor influencing the growth in Europe are rising incidences of cardiovascular diseases and blood disorders. (axiommrc.com)
  • The internationally renowned expert has an assumption of why COVID-19 can so often lead to coagulation disorders. (thieme.co.uk)
  • In addition to Prof. Violi, several other scientists also point to coagulation disorders in their works published in the Thieme medical journal Thrombosis and Haemostasis and recommend appropriate treatment for these patients. (thieme.co.uk)
  • There are many different types of coagulation disorders, and each has its own cause. (rockawaycancer.com)
  • What are Coagulation Disorders? (rockawaycancer.com)
  • Bleeding disorders, a type of coagulation disorders, occur when our bodies cannot clot blood effectively, so excessive amounts of blood can leave the vessels, and there is less blood available in our body's circulation to carry nutrients, exchange carbon dioxide and oxygen with our tissues, and remove waste products of metabolism. (rockawaycancer.com)
  • How Are Coagulation Disorders Detected? (rockawaycancer.com)
  • The inhibition by PIXI of factor XIa-catalyzed activation of factor IX and its capacity to prevent factor XIa inactivation by alpha 1-protease inhibitor, combined with the specificity of PIXI for factor XIa among serine proteases found in blood, suggest a role for PIXI in the regulation of intrinsic coagulation. (qxmd.com)
  • Thrombosis is a harmful activation of the clotting process, which is associated with the occurrence of blood vessel-related diseases. (sciencedaily.com)
  • thrombosis is associated with the occurrence of strokes, ischemic heart disease, and other blood vessel-related diseases. (sciencedaily.com)
  • Blood Diseases and Thrombosis Clinic? (who.int)
  • For example, in thrombosis, a blood clot may form in a blood vessel that is not damaged and prevent blood circulation. (rockawaycancer.com)
  • Elevated circulatory levels of many blood coagulation factors are known to be a risk factor for deep vein thrombosis in humans. (elsevierpure.com)
  • This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. (nih.gov)
  • Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged. (nih.gov)
  • Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality. (nih.gov)
  • The clotting factors work together in a chain reaction to form a harder blood clot that will stay firmly in place. (medlineplus.gov)
  • Your blood doesn't clot enough after an injury or surgery. (medlineplus.gov)
  • An abnormal result on a blood test that checks how long it takes your blood to clot. (medlineplus.gov)
  • The cartridges contain calcium, which when mixed with sodium, will allow the blood to clot. (thecompletepetanimalhospital.com)
  • The amount of time it takes the blood to clot it recorded and displayed on the screen. (thecompletepetanimalhospital.com)
  • Ultimately we get a solid clot, colored red and smaller in size than the vessel in which the blood coagulated, but retaining its form, and floating in a quantity of pale yellow serum. (bookdome.com)
  • The essential point in coagulation being the formation of fibrin in the plasma, and blood only forming a certain amount of fibrin,* if this be removed as fast as it forms the remaining blood will not clot. (bookdome.com)
  • Mechanism for the blood clot is haemostasis which is controlled by the several factors such as the blood clotting factors. (axiommrc.com)
  • cell fragments that circulate in the bloodstream and help blood clot) are depleted, excessive bleeding occurs. (msdmanuals.com)
  • According to physiology experts, blood coagulation entails the entire process through which the formation of a blood clot takes place. (gleath.com)
  • The blood clot is formed to stop the process of blood loss from a ruptured vessel in your body. (gleath.com)
  • In the last part of this process, clot dissolution leads to blood flow friction as the liver eliminates the pro-clotting chemicals. (gleath.com)
  • This study showed that FXa activity, an important part of the coagulation cascade that is the target of drug treatments, could be quantitatively assessed by DBCM, a method that is easy to use and may be readily used in clinical treatment. (sciencedaily.com)
  • This gene encodes coagulation factor XI of the blood coagulation cascade. (nih.gov)
  • There is a cascade of coagulation factors needed for proper coagulation. (labpedia.net)
  • These clotting factors together interact and lead to the coagulation cascade. (gleath.com)
  • Predictions of individual coagulation factor time courses under steady-state warfarin, enoxaparin, and rivaroxaban treatment reflected the suppression of protein C and protein S under warfarin compared to rivaroxaban and enoxaparin. (ebi.ac.uk)
  • protein C, inactivator of coagulation fa. (gsea-msigdb.org)
  • This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. (nih.gov)
  • The unknown functions of a known protein: the case of coagulation factor XI. (nih.gov)
  • This collection concerns Kazal's work with blood plasma protein fraction. (upenn.edu)
  • Current work examines how activated protein C protects blood-forming stem cells in the bone marrow, how radiation alters the function of blood vessel endothelial cells, and how natural anticoagulant mechanisms alter this response. (versiti.org)
  • 1993. Malathion disposition in dermally and orally treated rats and its impact on the blood serum acetylcholine esterase and protein profile. (cdc.gov)
  • This detrimental effect might not occur during VTE treatment using other anticoagulants, such as rivaroxaban or enoxaparin, given their different mechanisms of action within the coagulation network. (ebi.ac.uk)
  • The complex reactions of blood coagulation are balanced by several natural anticoagulants resulting in tuned hemostasis. (lu.se)
  • A quantitative systems pharmacology model was developed describing the coagulation network to monitor clotting factor levels under warfarin, enoxaparin, and rivaroxaban treatment. (ebi.ac.uk)
  • I know they're basically all important but what would you say is the most important clotting factor to have in the blood? (healthtap.com)
  • The blood clotting factor market is seeing some positive impact of the COVID-19 pandemic as there is increase in the requirements of blood plasma for the treatment of the COVID-19. (axiommrc.com)
  • TF is a transmembrane glycoprotein receptor found in extravascular tissues, including organ capsules and the adventitia of blood vessel walls. (merckvetmanual.com)
  • the viscidity becomes more and more marked, until, after the lapse of five or six minutes, the whole mass sets into a jelly which adheres to the vessel containing it, so that this may be inverted without any blood whatever being spilled. (bookdome.com)
  • Uncoagulable blood and life-threatening bleeding can result from the action of some snake venom toxins on haemostatic components of blood and vessel walls. (ox.ac.uk)
  • If a blood vessel is damaged, blood may escape the vessel. (rockawaycancer.com)
  • Microscopy of mummified visceral tissue from a Medici family member in Italy identified a potential blood vessel containing erythrocytes. (cdc.gov)
  • n = 37) and discocyte shapes of cells within the blood vessel were characteristic of erythrocytes ( 2 ). (cdc.gov)
  • The Coagulation Analyzer survey is available as a downloadable pdf - you will need Adobe Acrobat reader to view this. (clpmag.com)
  • New applications and extended medication times drive the growing coagulation analyzer market. (clpmag.com)
  • Dade Behring Inc has announced that it has introduced the capability to connect the Sysmex® CA-7000 Coagulation Analyzer to the StreamLAB® Analytical Workcell, one of the company's customized automation solutions for the clinical laboratory. (clpmag.com)
  • Dade Behring Receives Marketing Clearance for Its Newest Coagulation Analyzer The Sysmex® CA-560 has received marketing clearance from the US Food and Drug Administration. (clpmag.com)
  • A: The nominal EDTA concentration is 1.8mg EDTA per milliliter of blood. (bloodcollectingtube.com)
  • 1981. Effect of oximes and atropine on the concentration of cerebral glycogen and blood glucose in malathion-treated rats. (cdc.gov)
  • It works to reinforce the platelet plug and captures the blood cells that are passing. (gleath.com)
  • Among the scientific community, it is now a well-recognized fact that activation of the blood coagulation system makes an important contribution to the body's defenses in a variety of conditions and diseases, in large part by regulating the functions of immune cells and of endothelial cells lining the inner surface of our blood vessels. (versiti.org)
  • Dr. Weiler's group investigates how activated blood coagulation factors alter the function of infected endothelial cells. (versiti.org)
  • [ 1 ] In addition, there was a significantly higher risk of receiving 5 or more units of red blood cells within 24 hours of surgery in the patients receiving N-acetylcysteine compared with the placebo group ( P = 0.005). (medscape.com)
  • The Coulter MAXM performs a complete blood count on blood specimens to provide a study of blood cells and coagulation for all participants. (cdc.gov)
  • This method directly measures lead (Pb), cadmium (Cd), total mercury (Hg), manganese (Mn), and selenium (Se) content of whole blood specimens using mass spectrometry after a simple dilution sample preparation step. (cdc.gov)
  • Blood and urine specimens are collected on participants aged one year and older at the mobile examination centers (MECs). (cdc.gov)
  • The laboratory component of NHANES includes the collection, processing, storage, and shipping of blood, urine and other biological and environmental specimens. (cdc.gov)
  • The blood collection procedure consists of administering a questionnaire to screen for conditions that excludes the participants from the blood draw and determines fasting status, a blood draw, and collecting specimens for special studies. (cdc.gov)
  • Understanding the physiology of massive hemorrhage, initiating massive transfusion, and preparing adequate blood inventories are fundamental components of management. (medscape.com)
  • If a drop of fresh drawn blood be spread out and watched with a powerful microscope, it will be seen that its coagulation is due to the separation of very fine solid threads which run in every direction through the plasma and form a close network entangling all the corpuscles. (bookdome.com)
  • Prothrombin is a glycoprotein with a molecular weight of 71,600 daltons in the blood and plasma. (labpedia.net)
  • The market is segmented by the product type like blood plasma and non-plasma derived factors. (axiommrc.com)
  • The study summarizes the dominating segments of the market like the product type segment is dominated by the blood products as they used for the supply of the plasma and the plasma contains the several coagulating factors in it and they help in the process of the haemostasis. (axiommrc.com)
  • 3 Blood products are defined as any therapeutic substances derived from human blood, including whole blood, labile blood components and plasma-derived medicinal products. (who.int)
  • Developed countries have implemented policies, strategies and procedures to ensure the availability, accessibility, safety and quality of all products derived from blood through effective blood and plasma programmes, permitting widespread access to a comprehensive range of blood products. (who.int)
  • The segment is dominated by the blood products in 2020. (axiommrc.com)
  • We investigated the effects of hypoxia on indices of coagulation and systemic inflammation in patients with COPD. (nih.gov)
  • In the control group, there was no change in markers of coagulation or systemic inflammation over the 2-h study. (nih.gov)
  • This study demonstrates that a 2-h hypoxic challenge in patients with COPD results in coagulation activation in conjunction with an increase in systemic inflammation. (nih.gov)
  • Activation of blood coagulation and endothelial inflammation are hallmarks of respiratory infections with RNA viruses that contribute significantly to the morbidity and mortality of patients with severe disease, such as COVID-19. (versiti.org)
  • What can cause excessive clotting of the blood? (healthtap.com)
  • The blood clotting is a procedure in which the blood gets converted into solid gel like at the site of injury for the prevention of the excessive bleeding. (axiommrc.com)
  • However, excessive cost of fully automated coagulation analyser and less availability of skilled professional is also hampering the market growth. (axiommrc.com)
  • The excessive clotting is usually stimulated by a substance that enters the blood as part of a disease (such as an infection or certain cancers) or as a complication of childbirth, retention of a dead fetus, or surgery. (msdmanuals.com)
  • As you know, it is only because of the process of coagulation that you remain protected from excessive blood loss. (gleath.com)
  • Morbidity from shock may be widespread and can include central nervous system (CNS) failure, respiratory failure (ie, from muscle fatigue or acute respiratory distress syndrome [ARDS]), renal failure, hepatic dysfunction, gastrointestinal ischemia, disseminated intravascular coagulation (DIC), metabolic derangements, and ultimately death. (medscape.com)
  • The pathophysiology of massive blood loss is complex, comprising a wide range of physiologic derangements arising from tissue injury, bleeding, and transfusion of blood or blood products. (medscape.com)
  • We found an abnormal pattern of coagulation parameters and association of advanced age and comorbidities with a high rate of mortality in severe COVID-19 patients, which should be taken into consideration in their hospital management. (who.int)
  • There is no available study related to the evaluation of coagulation parameters in COVID-19 patients from the Islamic Republic of Iran. (who.int)
  • The aims of the present study were to find the coagulation profile of 74 consecutive ICU-admitted patients with COVID-19 from Kermanshah Province, Islamic Republic of Iran, and to determine the influence of age and comorbidities on the level of these parameters. (who.int)
  • In addition, we aimed to compare coagulation parameters between survivors and non-survivors to detect their effects on the severity and outcome of the disease. (who.int)
  • Key physiologic parameters that affect metabolic homeostasis include tissue blood flow, the balance between oxygen delivery and demand, and the oxygen content. (medscape.com)
  • Abnormal coagulation factors in Chinese patients with COVID-19 were associated with poor prognosis (5). (who.int)
  • Activated blood coagulation factor XI may refer to: Coagulation factor IXa, an enzyme Coagulation factor XIa, an enzyme This disambiguation page lists articles associated with the title Activated blood coagulation factor XI. (wikipedia.org)
  • Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX. (jci.org)
  • It is only due to the stepwise activation of these clotting factors that you are able to experience the process of blood coagulation. (gleath.com)
  • DIC that develops slowly typically results from cancer, aneurysms, or cavernous hemangiomas (collections of dilated blood vessels). (msdmanuals.com)
  • Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). (sbir.gov)
  • Dr. Weiler is also researching how the blood coagulation system, as part of the immune system, affects patients who develop sepsis, or blood poisoning. (versiti.org)
  • The development of the human blood-CSF-brain barrier. (cdc.gov)
  • Blood transfusion in the last month will affect the result. (labpedia.net)
  • Wijeysundera et al sought to determine whether N-acetylcysteine is associated with increased blood loss and blood product transfusion in 89 patients with preexisting moderate renal insufficiency undergoing cardiac surgery. (medscape.com)
  • Transfusion of blood and blood products is usually necessary during a bleeding catastrophe. (medscape.com)
  • The process of ordering and checking blood may be cumbersome during massive blood transfusion. (medscape.com)
  • Transfusion of blood and blood products is not without negative consequences. (medscape.com)
  • Changing population demographics and more advanced surgical and medical procedures have increased the need for blood transfusion. (who.int)
  • This is not a complete list of coagulation factor VIIIdrug interactions. (rxwiki.com)
  • Throughout his career at Versiti Blood Research Institute (BRI), Senior Investigator Hartmut Weiler, PhD , has studied how the blood coagulation system and natural anticoagulant mechanisms affect the body's stress responses to challenges like pregnancy, injury and infections. (versiti.org)
  • You don't need any special preparations for a coagulation factor test. (medlineplus.gov)
  • How does consumption of these various preparations of pork affect the blood? (westonaprice.org)
  • Recent drug development has specifically targeted single parts of the coagulation process, such as FXa. (sciencedaily.com)
  • This process is the result of a series of coagulation factors that are also called clotting factors . (gleath.com)
  • As you know, all the 13 coagulation factors are essential for the clotting process to take place. (gleath.com)
  • After the needle is inserted, a small amount of blood will be collected into a test tube or vial. (medlineplus.gov)
  • In the study, the researchers tested whether time-based changes in the permittivity of blood could be used to assess profiles of FXa activity in blood from patients who had been treated with different FXa inhibitors. (sciencedaily.com)
  • The main aim of the present study was to find the coagulation profile of intensive care unit (ICU) admitted patients with COVID-19 from Kermanshah, Islamic Republic of Iran. (who.int)
  • More comparison of reports from various populations related to the clinical course, outcome of COVID-19 and blood coagulation profile in these patients are necessary to help the management and treatment of the disease. (who.int)
  • We evaluated the effects of RIC on coagulation function in OPCAB patients. (physiciansweekly.com)
  • RIC does not significantly affect perioperative platelet aggregability and coagulation in patients undergoing OPCAB. (physiciansweekly.com)
  • The investigators found patients in the N-acetylcysteine group had a 261-mL greater mean 24-hour chest-tube blood loss and received 1.6 units more of red blood cell transfusions than the placebo group. (medscape.com)
  • We used atomic force microscopy to identify the ring stage, an immature developmental stage of P. falciparum that is dominant in peripheral blood of infected patients and a diagnostic hallmark ( Figure , panel C). We verified the presence of P. falciparum by using immunohistochemistry with polyclonal mouse antiserum against Plasmodium spp. (cdc.gov)
  • The anticoagulant properties of FV were discovered during investigations of individual patients and follow the great tradition of bed-to-bench and bench-to-bed research in the coagulation field. (lu.se)
  • Blood products3 contribute to the saving of millions of lives every year, improve dramatically life expectancy and the quality of life of patients suffering from life-threatening conditions, and support complex medical and surgical procedures. (who.int)
  • What blood tests would I need to determine if my blood coagulation is normal? (healthtap.com)
  • This tests your pet s blood for coagulation issues. (thecompletepetanimalhospital.com)
  • The diagnostic assessment in idiopathic pulmonary artery hypertension (IPAH) includes a variety of blood studies, coagulation studies, tests for collagen-vascular disease, and imaging studies, as well as a variety of other tests and procedures. (medscape.com)
  • It is important blood remain in our blood vessels because, in addition to performing many other functions for our bodies, blood carries oxygen and nutrients to our tissues and carbon dioxide and waste products of metabolism away from our tissues. (rockawaycancer.com)